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Abstract 
 
Skeletal muscle dysfunction in COPD is associated with increased morbidity.  Novel agents might 
reverse skeletal muscle dysfunction through different mechanisms since the biopsy picture in COPD 
patients is heterogenous.  Thus there is a need for a biomarker of skeletal muscle dysfunction which 
could both be measured in blood and obviate the need for a biopsy. 
Previous work has found that muscle-specific microRNA (miR-1, miR-499, miR-206 and miR-133) are 
down-regulated in the quadriceps of COPD patients.  Tissue specific miRNA circulate in the blood at 
detectable levels and are currently under investigation as biomarkers of other diseases.  I therefore 
hypothesised that muscle-specific microRNA might be clinically viable biomarkers of skeletal muscle 
dysfunction. 
The studies in this thesis found that: 
1 Levels of circulating muscle-specific microRNA (miR-1, miR-133, miR-206 and miR-499) 
were increased in stable COPD patients.  The increase in muscle-specific microRNA in 
the stable COPD patients suggests that continual muscle turnover occurs outside of 
times of disease exacerbation.  
2 Plasma levels of muscle-specific miRNA were not different in COPD patients admitted 
to hospital for an exacerbation of their disease compared to stable COPD patients.  
3 Most muscle-specific microRNA did not change in muscle with acute exercise.  I 
demonstrated an increase in miR-181 (an miRNA not restricted to, but with known 
function in muscle) one hour after acute exercise in the quadriceps muscle of COPD 
patients. However when fold change was calculated for the COPD patients and 
controls, there was no statistical difference found. There were no detectable miR-181 
changes measured in blood.  
4 Finally, I used a microarray approach to investigate other circulating microRNA that 
might to be useful to separate patients based on their lean muscle-mass.  COPD 
patients with a reduced skeletal muscle mass had a reduced number of microRNA 
associated with growth and cell pluripotency, further studies are required to validate 
these findings.  
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Taken together, the results from this thesis suggest that the microRNA analysed were detectable in 
blood, but they could not be usefully used (based on current analysis) as biomarkers of quadriceps 
dysfunction.    
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1 .  Introduction 
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The need for a biomarker of skeletal muscle phenotype in COPD patients  
 
The theme underlying and uniting the four results chapters of this thesis is the search for potential 
biomarkers of skeletal muscle phenotype in patients suffering from Chronic Obstructive Pulmonary 
Disease (COPD). 
 
COPD is one of the most prevalent lung diseases in the UK and globally. The clinical picture is of 
airflow limitation resulting from the inflammation and re-modelling of small airways and often 
occurs together with parenchymal destruction (emphysema). Approximately one-third of COPD 
patients suffer quadriceps dysfunction comprising both a loss of muscle mass and an alteration in 
muscle phenotype. This not only impairs the patients’ ability to exercise with direct implications for 
weight-bearing activities of daily living, but also affects prognosis.  
 
There is no pharmacological curative treatment for COPD. However, exercise training has been 
shown to be the only treatment which can increase the exercise capacity of COPD patients, doing so 
by improving the main symptoms of skeletal muscle dysfunction. Long-term use of supplemental 
oxygen has also been shown to improve survival in patients with COPD and severe resting 
hypoxemia.  
 
The majority of COPD patients will experience an acute exacerbation of COPD (AECOPD) during the 
course of their disease. Patients typically experience deterioration in their lung function associated 
with worsening of their symptoms. Worsening muscle dysfunction occurs during an AECOPD, which 
is slow to recover. Similarly levels of physical activity also decline significantly during an exacerbation 
and remain low for weeks afterwards. 
 
Although one traditional method for assessing patients with COPD is to measure lung function 
(specifically using the measure of the volume of air expired in the first second of a forced expiratory 
manoeuvre (FEV1)), measurement of quadriceps strength and bulk have been shown to be superior 
predictors of mortality of those with more severe disease.   
 
At present the only method to assess quadriceps muscle composition, which is known to be 
heterogeneous amongst patients, is to perform a biopsy for analytical purposes. This is invasive and 
not practical for the majority of clinicians to perform. A better solution would be through the use of 
a blood-borne biomarker which would enable easy and rapid testing of COPD patients by clinicians.  
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A biomarker is defined by the National Institutes of Health Biomarkers Definitions Working Group as 
“a characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” 
(Atkinson, Colburn et al 2001). 
  
As clinical measurements of muscle strength relate poorly to muscle composition, to date no 
biomarker exists to assess muscle fibre phenotype in COPD patients. In addition to monitoring stable 
COPD patients, a circulating biomarker for quadriceps dysfunction would be useful for patients 
experiencing an acute deterioration in muscle function, for example before or during an AECOPD to 
be able to predict those at risk of significant morbidity and mortality.   
 
A biomarker of disease has to be reproducible, the result needs to be specific and sensitive for the 
purpose of the test/tissue and the results need to reflect the underlying pathology.  Importantly for 
a biomarker to have future clinical application, sampling needs to be easy and used to monitor 
disease progression. It is for these reasons circulating microRNA (miRNA) were explored for their 
biomarker potential in COPD in this thesis.    
 
Thus the formal aims of this thesis are: 
1. To investigate muscle-specific circulating miRNA in COPD during times of disease stability, an 
acute exacerbation of disease and during acute exercise.  
2. To investigate a wider number of miRNA using an array approach that may offer biomarker 
potential for skeletal muscle dysfunction in COPD. 
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1.1 Overview of Chronic Obstructive Pulmonary Disease  
 
COPD is a progressive lung disease caused primarily by cigarette smoking in the developed world and 
is one of the most prevalent lung diseases in the UK today.  Cases of COPD are increasing globally 
and one prediction is that by 2020 it will be the third leading cause of mortality and fifth leading 
cause of chronic disability worldwide (Lopez and Murray 1998).  
 
Clinical features of COPD 
Patients with COPD typically suffer from symptoms of breathlessness, a cough and limited capacity 
for exercise. Traditionally patients have been classified clinically according to the severity of their 
airways obstruction e.g. using the GOLD system (Rabe, Hurd et al. 2007) in which there are four 
stages. Patients are classified from stage I (least severe) to IV (the most severe) using the 
measurement of FEV1.  More recently, composite measures such as BODE score (BMI, airflow 
obstruction, dyspnoea and exercise capacity) (Celli, Cote et al. 2004) and ADO score (age, dyspnoea 
and obstruction) (Puhan, Garcia-Aymerich et al. 2009) have been used to assess disease severity. 
These measures additionally offer prognostic information. 
COPD is a heterogeneous disease with regards to clinical presentation, physiology, imaging, response 
to therapy, decline in lung function and survival (Han, Agusti et al. 2010). It is a disease in which only 
some patients develop significant secondary systemic complications.  All of these factors contribute 
towards the different patient phenotypes observed. COPD should be considered a complex 
syndrome with both pulmonary and extra-pulmonary manifestations (Han, Agusti et al. 2010).  
Secondary systemic complications and co-morbidities of COPD are increasingly recognised as 
important contributors towards morbidity and mortality of this patient group and an added burden 
to economic health. The secondary systemic complications include diseases which are at a higher 
incidence in COPD patients than expected such as cardiovascular disease, osteoporosis, diabetes and 
metabolic syndrome. This has led to the theory that COPD and these diseases share common 
aetiological mechanisms (Barnes 2010). Other secondary systemic complications include the loss of 
fat-free mass (FFM) or cachexia and skeletal muscle dysfunction.  
Weight loss is a common complaint of patients with chronic diseases such as COPD, heart failure and 
cancer. If this reduction in weight is a loss of FFM, it is termed cachexia. In COPD cachexia has been 
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defined by Schols et al (Schols, Broekhuizen et al. 2005) as a FFM <16kg/m2 in males and <15kg/m2  
in females.  Cachexia in GOLD II-IV patients is associated with substantially reduced median survival 
(Schols, Broekhuizen et al. 2005).   
 
A high proportion (estimated to be around 25%) of patients with COPD will develop cachexia (Schols, 
Broekhuizen et al. 2005) and an even higher proportion (45%) of COPD patients eligible for a 
pulmonary rehabilitation treatment programme have been found to be  underweight or have a low 
FFM (Schols, Soeters et al. 1993).  Furthermore, a loss of FFM will often co-exist with skeletal muscle 
dysfunction in patients with COPD.   
 
 
1.2 Skeletal muscle dysfunction in COPD 
1.2.1 Quadriceps skeletal muscle dysfunction 
 
The group of peripheral muscles principally studied and most affected in COPD patients are the 
quadriceps femoris muscles whose primary function is to assist locomotion. The group comprises 
four muscles: the vastus lateralis; vastus medialis; vastus intermedius; and rectus femoris.  The 
changes that affect these muscles, which are described below, have not been shown in other 
peripheral muscles to the same degree. For example, the strength of the diaphragm, adductor 
pollicis and abdominal muscles are relatively preserved in COPD patients (Polkey, Kyroussis et al. 
1996; Man, Soliman et al. 2003; Man, Hopkinson et al. 2005), as is that of the pectoralis major and 
latissimus dorsi  (Bernard, LeBlanc et al. 1998). The oxidative capacity of the deltoid has also been 
found to be preserved in COPD patients (Donker, Asgeirsdottir et al. 2005). 
 
Quadriceps dysfunction comprises both a loss of muscle mass and an alteration in muscle 
phenotype. Therefore it affects both the structure and function of the muscle.  Muscle dysfunction 
results, in those affected, first in a reduction in muscle endurance (Allaire, Maltais et al. 2004; Van't 
Hul, Harlaar et al. 2004), which is defined as the ability of a muscle to sustain a contraction over a 
period of time. Secondly, such patients experience premature muscle fatigue, defined as the 
reversible loss of muscle force due to work over time (Gosker and Schols 2008), and  thirdly, results 
in a reduction in muscle strength (Gosselink, Troosters et al. 1996).   
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Quadriceps dysfunction and exercise limitation 
 
Killian et al were the first group to demonstrate that cycling can provoke leg discomfort in COPD 
patients (Killian, Leblanc et al. 1992). It is now established that quadriceps dysfunction can 
contribute directly towards exercise limitation during both cycling and walking by affecting both 
muscle endurance and fatigue.  With regards to the effect on walking, experimentally, the six minute 
walk test is an easy to perform exercise test that reflects functional exercise capacity and the six 
minute walk distance correlates strongly with mortality (Pinto-Plata, Cote et al. 2004).  
When COPD patients are exercised under supervised conditions, in particular through cycling, it has 
been found that leg discomfort or fatigue is a frequent limiting symptom secondary to (or in some 
cases in addition to) that of breathlessness  (Man, Soliman et al. 2003).   
Another illustration of lower limb dysfunction contributing towards exercise limitation in COPD is the 
work of Williams et al (Williams, Patterson et al. 1992). These authors found that despite the 
ventilatory function in patients who had undergone a single or double lung transplant being 
restored, those patients still had reduced peak exercise workload when compared to predicted 
values 1-2 years after surgery.  The phenomenon that leg discomfort limits exercise has been 
confirmed by the observation that administration of a bronchodilator improved performance on a 
walking test but not a cycling task (Pepin, Saey et al. 2005).   
Importantly from a patient’s perspective, the fact that muscle dysfunction results in impairment of 
exercise ability has, in addition to limiting walking distance, direct implications for weight-bearing 
activities of daily living where these muscles are required, for example standing or rising from a chair 
(Polkey and Moxham 2011).   
 
Quadriceps dysfunction and reduction in strength 
 
Reduced quadriceps strength (measured either volitionally or non-volitionally) can be found 
throughout all stages of disease severity. It is now widely accepted that quadriceps dysfunction is 
independent of lung function.  A recent study found the prevalence of quadriceps weakness did not 
differ between the GOLD stages of disease (Seymour, Spruit et al. 2010).  Despite COPD patients at 
all GOLD stages potentially being affected, the loss of muscle strength in the more severe (GOLD II-
IV) COPD patients has been shown to be a better predictor of mortality than the degree of airways 
obstruction using FEV1  as % predicted (Swallow, Reyes et al. 2007). 
20 
 
Studies comparing strength in patients with COPD with healthy aged-matched controls have found 
that approximately 20-30% of COPD patients have reduced quadriceps strength (Gosselink, Troosters 
et al. 1996; Bernard, LeBlanc et al. 1998; Franssen, Broekhuizen et al. 2005). Reduction in strength 
also occurs in a non-cachetic state (Man, Soliman et al. 2003), demonstrating that muscle wasting 
happens independently of weight loss (Vermeeren, Creutzberg et al. 2006).  
 
The reduction in strength can largely be explained by the loss of muscle mass that occurs in COPD 
patients.  Some studies (Bernard, LeBlanc et al. 1998), have found that the reduction in strength is 
no longer present when strength measurement is corrected for the muscle cross-sectional area, 
suggesting that it is actually the reduction in the number of functional contractile units that leads to 
a reduction of strength in COPD patients. This hypothesis has been supported by in vitro 
assessments of vastus lateralis tetanic tension measurements in COPD patients compared to 
controls. When measurements for the two groups are normalised for bundle cross-sectional area, 
they were found to be similar (Debigare, Cote et al. 2003). As quadriceps weakness is more 
prevalent in COPD patients than loss of fat free mass or wasting (Hopkinson, Tennant et al. 2007), 
there are likely to be other contributory factors to quadriceps weakness.  
 
Quadriceps cross-sectional area can be measured in a non-invasive manner either by computerised 
tomography (CT), magnetic resonance imaging (MRI) or ultrasound, but the latter only measures the 
rectus femoris.  As muscle mass is a key determinant of quadriceps strength, it is perhaps 
unsurprising that mid-thigh cross sectional area measured by CT (Marquis, Debigare et al. 2002) has 
also been shown to be a good predictor of mortality, and that muscle mass is better at predicting 
mortality compared to using body weight alone or weight expressed as body mass index (BMI).  
Using the ultrasound technique, Seymour et al (Seymour, Ward et al. 2009) demonstrated that 
quadriceps rectus femoris cross-sectional area is reduced in COPD patients when compared to 
controls and in both these groups it related to strength.  
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1.2.2 Aetiology of quadriceps muscle dysfunction in COPD 
  
A number of potential mechanisms for skeletal muscle dysfunction in COPD have been proposed: 
reduced daily activity, systemic inflammation oxidative stress; hypoxia and hypercapnia; the use of 
corticosteroids; nutritional depletion; anabolic/catabolic hormone imbalance; genetic susceptibility 
and/or drugs.  It is not known how much each of these factors individually contributes towards the 
clinical syndrome; but consistent with the predilection of disease for quadriceps muscles, reduced 
daily activity is thought to play a major aetiological role alongside systemic inflammation. These 
possible aetiological factors are further discussed below.  
 
Physical Inactivity in COPD 
COPD patients often adopt sedentary lifestyles due to breathlessness and in some, this can precipitate 
a downward spiral of disease (Polkey and Moxham 2006).  Anaerobic quadriceps metabolism results 
in lactate and carbon dioxide production which stimulates ventilation and worsens breathlessness.  
Daily activity has been documented to be lower in COPD patients than in healthy controls and lower 
than recommended by international guidelines for physical health maintenance (Bossenbroek, de 
Greef et al. 2011). Recently, Watz et al (Watz, Waschki et al. 2009) demonstrated that physical activity 
and steps per day are reduced even in those with mild and previously undiagnosed disease (Van 
Remoortel, Hornikx et al. 2013).   
Large, prospective population based studies also support the relationships between physical inactivity 
and important clinical end-points in COPD. Physical activity is protective against hospital admissions 
(Garcia-Aymerich, Farrero et al. 2003) and all-cause and respiratory mortality in COPD (Garcia-
Aymerich, Lange et al. 2006). Physical activity can also modify the smoking-related decline in lung 
function therefore reducing the risk of COPD in those individuals (Garcia-Aymerich, Lange et al. 2007).  
 
Systemic inflammation and oxidative Stress 
Low grade systemic inflammation is thought to be reflected by higher circulating levels of pro-
inflammatory cytokines, such as tumour necrosis factor-alpha (TNFα), interleukin (IL) -6, -8,  -18  and 
acute phase proteins that have been found in COPD patients. They are postulated to originate either 
from the peripheral lung or from the respiratory muscles.  In a stable cohort of healthy aged controls 
quadriceps strength has been related to IL-6 and TNF-α levels (Yende, Waterer et al. 2006).  
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In vitro TNF-α can stimulate protein catabolic pathways and its activation has been shown in COPD 
patients with low body weight (Agusti, Morla et al. 2004).  TNF-α is also thought to affect cell 
apoptosis and/ or alter muscle contractility. However, quadriceps muscle biopsy findings in COPD 
patients have not consistently shown increased muscle levels of pro-inflammatory cytokines, 
including TNF-α, IL-6, Il-8, interferon gamma (IFNγ) and transforming growth factor beta (TGF-β), 
(Crul, Spruit et al. 2007; Petersen, Penkowa et al. 2007; Barreiro, Schols et al. 2008), and further work 
is required to determine the contribution of local inflammation towards muscle dysfunction. 
Hypoxaemia and inflammation are up-stream mediators of oxidative stress (Koechlin, Couillard et al. 
2004; Couillard and Prefaut 2005). An increase in reactive oxygen species (ROS) or reactive nitrogen 
species and/or a reduction in anti-oxidant capacity, leads to local oxidative stress damaging cellular 
components.  Oxidative stress can alter protein catabolism and anabolism, and induce cell death 
(Barreiro, de la Puente et al. 2005).  Perioxidation products from ROS-induced lipid membrane 
damage can be detected peripherally and have been shown to be elevated in COPD patients at rest 
and during an exacerbation (Supinski and Callahan 2007).   
Elevated anti-oxidant enzymes have been found in severe COPD patients with muscle wasting 
(Gosker, Bast et al. 2005; Barreiro, Rabinovich et al. 2009). However, this has not been replicated in 
similar studies, even when conducted in the same laboratory (Barreiro, Gea et al. 2003; Couillard, 
Maltais et al. 2003; Barreiro, de la Puente et al. 2005).  The former might suggest that anti-oxidant 
enzyme function may be inadequate in the muscles of COPD patients and therefore unable to 
respond to the increased oxidant stress after exercise (Couillard, Maltais et al. 2003). However given 
that exercise generally improves muscle function in COPD, the observation that whole body and 
localised limb exercise induces increased oxidative stress in COPD patients (Couillard, Koechlin et al. 
2002; Couillard, Maltais et al. 2003) questions whether oxidative stress is pathogenic or reflects the 
muscle repair cycle. 
 
Hypoxia and hypercapnia 
Limited studies (Gosker, Engelen et al. 2002; Jatta, Eliason et al. 2009) exist in COPD patients to show 
hypoxic patients have altered rates of myosin heavy chain protein synthesis.  However studies have 
failed to identify a consistent relationship between arterial hypoxia at rest and muscle dysfunction. 
Therefore, not all hypoxic patients develop muscle dysfunction, while severe muscle wasting may be 
observed in patients with satisfactory arterial oxygen tension (the ‘pink puffer’). 
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Hypercapnia may be acute, chronic or a combination of both and may contribute towards COPD 
quadriceps dysfunction by altering the intracellular acid-base balance.   In both experimental models 
and COPD patients, acute hypercapnia can cause intracellular acidosis, which reduces the amount of 
phosphocreatine and ATP, available for energy production (Gertz, Hedenstierna et al. 1977; Sahlin, 
Edstrom et al. 1983).  However as in the case of hypoxia, substantial muscle wasting may be observed 
in the absence of documented hypercapnia. 
 
Genetic susceptibility   
As more than 50% of very severe COPD patients have preserved quadriceps strength (Seymour, Spruit 
et al. 2010), studies have sought to demonstrate a genetic predisposition to a loss of muscle mass.  
The deletion (D) rather than the insertion (I) polymorphic variant of angiotensin-converting enzyme 
(ACE) gene is associated with preserved quadriceps strength in COPD (Hopkinson, Nickol et al. 2004). 
This variant is associated with higher tissue ACE and angiotensin II activity which may affect muscle 
growth, and reduced bradykinin levels.  
Bradykinin receptor polymorphisms were later studied (Hopkinson, Eleftheriou et al. 2006). The +9/+9 
(base pair repeat present) receptor polymorphism, which is associated with reduced gene 
transcription (Braun, Kammerer et al. 1996) and lower mRNA transcripts (Lung, Chan et al. 1997), was 
more prevalent in COPD patients with a low fat-free mass index.  However, this failed to explain the 
previously identified ACE gene findings as there was no interaction between the two genotypes on 
muscle strength (Hopkinson, Eleftheriou et al. 2006).  
Polymorphisms of the vitamin D receptor have also been studied in the COPD population. 
Polymorphisms of the receptor are associated with reduced (FokI polymorphism), or greater 
quadriceps muscle strength (BsmI polymorphism) in COPD patients (Hopkinson, Li et al. 2008). This 
association was not seen in healthy controls studied and so this suggests that muscle phenotype is 
more likely to result from a gene/ environment interaction.   
 
Nutritional depletion 
Nutritional supplementation alone does not appear to improve measurements of fat free mass, lung 
function or exercise capacity (Ferreira, Brooks et al. 2000) in COPD patients.  However, in combination 
with other anabolic stimuli, it can maintain or improve muscle mass, but with undetermined effects 
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on function (Op den Kamp, Langen et al. 2009). Future pulmonary rehabilitation programmes might 
incorporate individually tailored nutritional supplementation in selected patients to improve clinical 
outcome. Although, nutritional supplements have not yet proven to be beneficial in this context, the 
idea behind giving such supplementation is that at times of exercise, there is a greater metabolic 
demand.   
 
Anabolic/ Catabolic hormone imbalance 
Reduced circulating anabolic hormones testosterone and insulin-like growth factor-1 (IGF-1) have 
been reported in COPD patients (Debigare, Marquis et al. 2003).  Trials of testosterone have shown 
variable results; some trials have not shown a change in exercise capacity (Burdet, de Muralt et al. 
1997; Creutzberg, Wouters et al. 2003). Others however have reported that in male individuals in 
whom baseline levels are low, the combination of testosterone with resistance exercise training, can 
increase muscle mass and strength (Casaburi, Bhasin et al. 2004).   
Although the effect of long term, low-dose systemic corticosteroids on the proximal muscles is well 
described (Decramer, Lacquet et al. 1994), short term use of higher doses (prednisolone 30mg for 2 
weeks) did not cause significant skeletal muscle dysfunction or alter metabolic parameters during 
incremental cycle ergometry (Hopkinson, Man et al. 2004).  
 
Drugs 
Beta2 adrenergic receptor stimulation can affect skeletal muscle, and it has been claimed that some 
preparations (e.g. clenbuterol) can exert a positive effect on skeletal mass and decrease body fat 
(Emery, Rothwell et al. 1984; Lynch and Ryall 2008) (hence they may be considered “repartitioning 
agents”); properties which have been exploited by some athletes to enhance performance.   Animal 
studies have shown that  despite this, administration in mice can have an antagonistic effect on 
exercise performance (Ingalls, Barnes et al. 1996).  Many questions remain as to whether inhaled 
beta2 agonists, as used in COPD, contribute towards muscle dysfunction and to potential effects on, 
for example, fibre type composition (Lynch and Ryall 2008). 
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1.3 Acute exacerbations of COPD 
 
COPD patients deteriorate significantly during an acute exacerbation of COPD 
Patients with COPD can experience periods of significant deterioration in their condition which can 
be associated with a respiratory infection. These periods are described as acute exacerbations of 
COPD (AECOPD) and a useful working definition of such a period is “a sustained worsening of the 
patient's condition from the stable state and beyond normal day to day variation, that is acute in 
onset and necessitates change in regular medication in a patient with underlying COPD” (Rodriguez-
Roisin 2000). 
During an AECOPD, patients typically experience a deterioration in their lung function associated 
with worsening symptoms of breathlessness, cough and sputum production. Patients who suffer 
from more frequent exacerbations have been shown to suffer an increased rate of decline in lung 
function over time (Gorza, Sartore et al. 1986; Murphy, Adigun et al. 2012).  As well as being at 
higher risk of re-exacerbation, and re-hospitalisation, after an AECOPD (Garcia-Aymerich, Farrero et 
al. 2003; Donker, Mouillet et al. 2012), patients also suffer adversely in terms of quality of life during 
an exacerbation (Novakovic, Kassotakis et al. 1999) and afterwards.  
An AECOPD is associated with an increased mortality risk (Mouillet, Donker et al. 2013) both in the 
short term during hospital admission and in the longer term.  One large prospective study has shown 
that there is a high (45%) rate of all-cause mortality within 2 years of being admitted to hospital for 
an AECOPD (Piquet, Chavaillon et al. 2013), and patients who are most at risk of dying have a lower 
BMI, cardiac co-morbidities and have been previously hospitalised for COPD. FEV1 was found to be a 
poor predictor of survival.     
The loss of muscle strength during an AECOPD can be as high as 5% after 5 days of being admitted to 
hospital (Spruit, Gosselink et al. 2003). This is an important consequence of an AECOPD for an 
individual as quadriceps strength is a predictor of mortality and both quadriceps strength and 
physical activity have been demonstrated to predict healthcare use in COPD patients (Decramer, 
Gosselink et al. 1997; Garcia-Aymerich, Farrero et al. 2003).  
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Aetiology of worsening muscle dysfunction in AECOPD 
Physical inactivity is arguably the most important cause of muscle dysfunction during an AECOPD.  
Supportive evidence for this comes in part from immobility studies in man and the beneficial effects 
seen with pulmonary rehabilitation around the time of an AECOPD.  Pitta et al  (Pitta, Troosters et al. 
2006) observed that patients admitted to hospital with an AECOPD spend less than ten minutes 
walking per day, even if clinically improving and close to discharge. The rate at which elderly 
individuals lose muscle mass is greater than that in younger individuals over a given period of time 
(Kortebein, Ferrando et al. 2007), with no apparent sex differences (Kortebein, Ferrando et al. 2007).  
In contrast, exercise treatment as delivered in pulmonary rehabilitation (PR) around the time of 
disease exacerbation can not only deliver beneficial effects for the patient in terms of health related 
quality of life, but early PR post discharge can also increase exercise capacity (Man, Polkey et al. 
2004) and reduce re-exacerbation rates (Seymour, Moore et al. 2010).   
Raised circulating cytokine levels (including IL-8, which has been found to correlate with muscle 
force) (Spruit, Gosselink et al. 2003) suggest worsening systemic inflammation may also contribute 
towards the muscle dysfunction that occurs around the time of an AECOPD, although it is possible 
that circulating measures of inflammation are simply epiphenomena of exacerbation severity. Other 
proposed factors include increased oxidative stress, impaired energy balance, with an elevated 
resting metabolic rate on admission (Vermeeren, Schols et al. 1997), and malnutrition, due to loss of 
appetite as a result of worsening symptoms and an increase in circulating leptin, (Creutzberg, 
Wouters et al. 2000) an appetite-suppressant hormone and inflammatory cytokine.    
 
1.4 Pulmonary Rehabilitation as a form of exercise treatment for COPD 
patients 
 
Pulmonary rehabilitation is an evidence-based, multidisciplinary mode of treatment for chronic 
disease patients such as those with COPD. It comprises individually-tailored exercise training, as well 
as patient education and psychological and nutritional support (Nici, Raskin et al. 2009). It is now an 
integrated part of patient care for many COPD patients in the UK and its use is supported by both 
randomised controlled trials and meta-analyses (Lacasse, Goldstein et al. 2006).   
Exercise training can increase the exercise capacity of COPD patients by improving symptoms of 
skeletal muscle dysfunction in COPD (O'Donnell, McGuire et al. 1998; Mador, Kufel et al. 2001).  PR 
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improves patients’ healthcare status and symptoms of dyspnoea, but has no effect on lung function 
(Casaburi and ZuWallack 2009). The lack of improvement in lung function confirms that the 
beneficial effects of exercise are delivered elsewhere (i.e. improved peripheral or quadriceps skeletal 
muscle function or cognitive function).  
Despite the clear benefits of PR, this treatment is not available to all patients with COPD (often due 
to service provisions), some patients decline PR and there can be a high rate of drop-outs from PR 
programmes. Perhaps more importantly, not all patients demonstrate the same degree of clinical 
benefit: the effects can be variable between patients and are not necessarily sustained over a long 
period of time.  One study has shown that some patients return to baseline after 12 months 
(Resnick, Cohn et al. 2009). Furthermore, the quadriceps muscle changes appear not to be fully 
reversed after this exercise treatment (Bernard, Whittom et al. 1999). It is for this reason that some 
researchers are investigating augmenting PR, for example by using non-invasive ventilation and/ or 
oxygen during exercise to alleviate patients’ symptoms of breathlessness (Porszasz, Cao et al. 2013).   
 
1.5 Healthy adult skeletal muscle  
 
1.5.1 Adult skeletal muscle structure 
 
Skeletal muscle accounts for about 40% of body mass in man. Multinucleated myofibres are the 
basic cellular units of adult skeletal muscle. Each myofibre contains contractile proteins arranged in 
contractile units or sarcomeres.  These are arranged to form myofibrils along a longitudinal axis.  A 
basement membrane and sarcolemma surround each fibre and provide structural support. The 
(usually quiescent) satellite cells are located between these two layers and function to proliferate 
and provide myonuclei required during times of muscle injury or repair, and/ or muscle hypertrophy, 
and  to self-renew their population. 
 
The fibre proportions of an individual muscle are determined during development, but adult skeletal 
muscle is plastic and can adapt to different functional demands placed upon it by external stimuli.  
The contractile and metabolic properties of muscle affect skeletal muscle fibre type, and hence its 
structure and function.   
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1.5.2 Adult skeletal muscle fibre types 
 
Human skeletal muscle fibres are classified according to contractile characteristics, enzyme 
activities, morphological properties and metabolic properties (Zierath and Hawley 2004). The fibre 
types are summarised table 1.1 below. In mammals, there are three fast fibre populations called IIa, 
IIb (type IIb fibres are not present in human skeletal muscle) and IIx that are distinct from slow type I 
fibres (Van Laere, Nguyen et al. 2003). Healthy adult quadriceps muscle comprises approximately 
50% type I fibres and 50% type II fibres. It is of interest to note that the cytosolic free calcium 
concentration at rest is higher in slow, type I fibres compared to the fast twitch type II fibres which 
has implications for fibre type determination and maintenance (Van Laere, Nguyen et al. 2003). (This 
is further discussed in the control of muscle phenotype section below).  
 
 
Fibre type Contraction Morphological Metabolic profile 
Type I Slow, fatigue resistant, 
recruited at low 
stimulation frequencies 
High capillarity 
+mitochondrial 
density 
oxidative 
Type IIa Fast, fatigue sensitive, 
recruited at higher 
stimulation frequencies 
High capillarity 
+mitochondrial 
density 
oxidative 
Type IIx Fast, intermediate 
fatiguability 
Poor in 
mitochondria and 
capillary supply 
gylcolytic 
Table 1-1 A summary of the basic different properties of human skeletal muscle fibres types 
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1.5.3 Mechanisms involved in the control of muscle mass  
Muscle mass is determined by the balance between gain and loss of muscle mass. Skeletal muscle size 
can be increased by the addition of new myonuclei (satellite cell recruitment or hyperplasia) into 
growing and regenerating fibres, or by an increase in muscle protein synthesis (myofibre hypertrophy) 
(Otto and Patel 2010). Pathways involved in muscle atrophy include muscle protein breakdown, 
autophagy and myonuclear loss via apoptosis.    
 
Gain of muscle mass  
Muscle Protein synthesis: IGF-1 signalling   
The anabolic hormone and growth factor insulin-like growth factor (IGF) has a significant effect on the 
size of skeletal muscle. IGF-1 can increase satellite cell proliferation, myoblast differentiation and the 
formation of myotubes (Otto and Patel 2010). The importance of IGF-1 in the control of muscle mass 
has been observed in animal models: loss of IGF-1 leads to growth retardation and loss of muscle 
mass; by contrast over-expression of IGF-1 leads to muscle hypertrophy, increased muscle protein 
synthesis and myoblast proliferation.  
Stimulation of IGF-1 receptors can signal via several down-stream pathways to mediate effects on 
muscle. IGF-1 stimulates the phosphoinositide 3-kinase (PI3K)/ AKT pathway in skeletal muscle cells.  
Upon phosphorylation, AKT is able to activate mammalian target of rapamycin (mTOR), which in turn 
activates 70-kD ribosomal S6 protein kinase (p70S6k) (Rommel, Bodine et al. 2001) and inhibits 
eukaryotic translation initiation factor 4E binding protein-1 (4E-BP1) (Hara, Yonezawa et al. 1997), 
both of these actions stimulate muscle protein synthesis.   
Phosphorylation of AKT also inhibits glycogen synthase kinase-3β (GSK-3β) (Cross, Alessi et al. 1995) 
leading to the release of inhibition of eukaryotic initiation factor 2B (eIF2B), and an increase in muscle 
protein synthesis.  
 
Loss of muscle mass 
When the balance between muscle protein synthesis and muscle protein breakdown is disturbed in 
favour of the latter, muscle atrophy can occur. Autophagy and apoptosis are other methods by 
30 
 
which muscle mass can decrease. Myostatin has also been shown to be important in the control of 
muscle mass. 
 
 Muscle protein breakdown  
Two muscle-specific atrophy-induced ubiquitin ligase proteins assist with protein degradation via the 
ubiquitin-proteasome pathway (Bodine, Latres et al. 2001). The expression of these proteins, 
atrogin-1 (muscle atrophy F-box or MAFbx) and muscle-specific RING finger protein (MuRF)-1, is 
induced by forkhead box O (FoxO) and nuclear factor-κB (NFκB) transcription factors (Sandri, Sandri 
et al. 2004).  
These pathways can be inhibited by IGF-1 via the effects of phosphorylated AKT. Therefore, it seems 
in addition to the direct role IGF-1 plays in muscle protein synthesis, it can indirectly add to muscle 
bulk by limiting muscle atrophy pathways (Sandri, Sandri et al. 2004).  
 
The Autophagy- lysosome pathway and apoptosis 
Autophagy is an evolutionary conserved pathway or normal biological process of self-digestion that 
occurs in eukaryotic organisms (Hussain and Sandri 2013). Autophagic processes use lysosomes to 
degrade and recycle bulk cytoplasm, proteins and organelles. In skeletal muscle, autophagy removes 
protein aggregates and damaged mitochondria (Masiero, Agatea et al. 2009) to maintain muscle 
mass. Exercise, which can result in cellular damage, has been shown to activate autophagy in muscle 
(Grumati, Coletto et al. 2011).    
Apoptosis is a form of cell death that normally triggers the destruction of the entire cell. The process 
occurs in multinucleated skeletal muscle cells but is often limited, leading to reduced nuclear 
number rather than death of the entire cell. In the healthy state stimuli for skeletal muscle apoptosis 
have been shown to include immobilisation and acute exercise. At a cellular level, apoptosis can be 
activated by both internal (originating from the mitochondria) and external signals (ligand-mediated 
activation of plasma mediated death receptors). Both myonuclei within the muscle fibres and 
satellite cells can undergo apoptosis in both physiological and pathological states. The relative 
contribution of apoptosis in both of these cells types during muscle atrophy remains debated.   
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Myostatin  
Myostatin or growth differentiation factor-8, is a member of the transforming growth factor- β 
(TGFβ) super-family and is a potent negative regulator of muscle mass as demonstrated by naturally 
engineered or occurring mutations occurring in mice, cattle and humans (McPherron, Lawler et al. 
1997; McPherron and Lee 1997; Schuelke, Wagner et al. 2004).   
 
Myostatin can influence muscle wasting by affecting cell proliferation and differentiation as well as 
increasing protein breakdown.  Myostatin up-regulates p21 (a cyclin-dependent kinase inhibitor) 
which negatively affects activated satellite cell/ myoblast proliferation (Thomas, Langley et al. 2000). 
Myostatin can also down-regulate myogenic differentiation factors (MyoD, myf5 and myogenin) 
which function to inhibit myoblast differentiation (Langley, Thomas et al. 2002).  Myostatin has 
furthermore been shown to inhibit satellite cell activation and self-renewal (McFarlane, Hennebry et 
al. 2008). 
 
 
1.5.4 Mechanisms involved in the control of muscle phenotype  
 
Mechanisms leading to a shift in muscle fibre type or change in oxidative phenotype have mainly 
been studied in animal studies and in exercise in man. Fibre type switching in mice can be induced 
by changes in nerve activity arising from differing electrical stimulation (Schiaffino, Sandri et al. 
2007), and from drugs.  
In muscle, activation of the slow gene programme happens at the same time as a repression of the 
fast gene programme and vice versa.  The co-ordinated regulation of slow and fast gene 
programmes is thought to be mediated in part by transcription factors.  Transcription factors are 
proteins that bind to specific DNA sequences via a DNA binding domain to act as gene activators and 
repressors (Van Laere, Nguyen et al. 2003).   
 
The involvement of transcription factors in muscle adaptation is discussed below within the context 
of signalling pathways with particular reference to the nuclear factor of activated T-cells (NFAT) 
transcription factors, peroxisome proliferator-activated receptors (PPARs) and their transcriptional 
co-activator peroxisome proliferator activated receptor gamma co-activator alpha (PGC-1α) and 
myocyte enhancer factor-2 (MEF2). 
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Skeletal muscle phenotype is regulated by several independent signalling pathways.  
 
Exercise and training promote a muscle fibre shift towards a more oxidative type IIa phenotype from 
IIx, an increase in mitochondrial activity and content, and an increase in blood capillarity.  Muscle 
contractile activity or endurance exercise activates various protein phosphatases and kinases which 
in turn regulate transcriptional factors, to co-ordinate the genes involved in muscle fibre responses 
(Yan, Okutsu et al. 2011). These pathways are summarised in figure 1.1 and further explained in the 
text.  
 
 
 
Figure 1-1  A summary of pathways affecting skeletal muscle fibre type  
Exercise and training promote a muscle fibre shift towards more oxidative type IIa phenotype from IIx, an increase in 
mitochondrial activity and content and an increase in blood capillarity.  Muscle contractile activity or endurance exercise 
activates various protein phosphatases and kinases which in turn regulate the transcriptional factors PGC-1α, (PPAR γ) and 
MEF2 and NFAT to co-ordinate the genes involved in muscle fibre responses.  Modified and adapted from (Zierath and 
Hawley 2004)  
 
Calcium signalling and muscle fibre type 
Muscle contraction results in an increase in intracellular calcium; which signals via calcineurin (a 
calcium/calmodulin regulated protein phosphatase) and various kinases to ultimately activate 
myofibre gene expression.  
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Calcineurin (Cn) is thought to promote expression of slow fibre type by dephosphorylating and 
activating the NFAT transcription factors. The NFAT family of transcription factors act as ‘nerve 
activity sensors’ in skeletal muscle and act to control fibre type in an activity dependent manner 
(Levine, Bashir et al. 2013).  Upon activation, NFAT transcription factors translocate to the nucleus 
where they activate slow fibre specific promoters.  
Other factors have been more recently implicated in oxidative gene programme regulation. These 
include PGC-1α (a potent transcriptional co-activator) and MEF2 transcriptional factors. NFAT has 
been demonstrated to act synergistically with MEF2 and nuclear receptor PPAR γ. 
 
MEF2  
MEF2 transcription factors are major regulators of muscle differentiation. MEF2 has been 
demonstrated to be strongly activated by calcineurin (Ehrhardt, Brimah et al. 2007). In vivo evidence 
supports the role of MEF2 in regulation of the slow gene programme. AS MEF2c and d  knockout 
mice have been shown to have a decreased proportion of type I fibres in soleus and animals with 
over-expression MEF2c show increased proportion of type I fibres (Montarras, Morgan et al. 2005).  
 
PGC-1α and PPARS 
PGC-1α can interact with transcription factors and basal transcriptional machinery (Puigserver and 
Spiegelman 2003) to stimulate mitochondrial and oxidative enzymes (Schiaffino, Sandri et al. 2007).   
PGC-1α is regulated by calcium-dependent pathways (calcineurin and CamK) but at times of energy 
deprivation it is also regulated via AMP kinase (AMPK) and by p38 mitogen activated protein kinase 
(MAPK) (Van Laere, Nguyen et al. 2003).  
PGC-1α interacts with PPAR transcription factors. All three isoforms of PPARS (α β/δ and γ) are 
present in skeletal muscle, where PPAR-δ regulates the expression of genes associated with fatty 
acid utilisation and energy homeostasis (Luquet, Gaudel et al. 2005) and is present in higher levels in 
type I muscle fibres (Wang, Zhang et al. 2004). PPAR  signalling has been demonstrated to be 
induced by acute exercise in man (Mahoney, Parise et al. 2005) and have an affect oxidative 
signalling and to mediate a shift towards a slow fibre type phenotype (Luquet, Gaudel et al. 2005).   
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Other important transcription factors in the control of muscle mass and phenotype  
Transcription factor  Function and further details 
Myogenic regulatory factors (MRFs)  
myogenic differentiation 1 (MyoD) 
myogenic factor 5 (Myf5) 
myogenin  
MRF 4 
 
All able to induce myoblast traits in non-muscle cell lines (Weintraub, 
Davis et al. 1991). 
All key regulators in myogenic determination and terminal 
differentiation during embryogenesis. 
Act by binding to E-box regions in the promoter region of muscle 
specific genes (Ebert, Shelley et al. 2013). 
MyoD and myogenin may function to determine adult muscle fibre 
type. Mechanism not fully understood. 
 
Serum response factor (SRF)  
 
Binds to DNA regions termed CArG-boxes (Belaguli, Schildmeyer et al. 
1997). 
Muscle target genes includes actin and myosin I but not MHCIIa or 
MHCIIx.  
Can function to control muscle development and function. 
Nuclear transcription factor ƘB (NFκB)  
 
The NFκB family is made up of 5 family members RelA (p65), cRel, 
RelB, p50/p105 (NF-κB1), and p52/p100 (NF-κB2) that exist as either 
homodimers or heterodimers (Ghosh, May et al. 1998). 
In muscle, the most studied form is the p65/p50 heterodimer, which 
is thought to be important for muscle development. During muscle 
development in man, NFκB is thought to act as a mitogen during 
proliferation and a negative regulator of late stage muscle cell 
differentiation (Mourkioti and Rosenthal 2008). 
One well-studied mediator of NFκB expression is tumour-necrosis 
alpha (TNF-α). Experimental effects in muscle cell lines of TNF-α 
include: 
i) reducing myoD expression therefore affecting myogenic 
differentiation (Guttridge, Mayo et al. 2000) 
ii) Activate satellite cells in response to injury via p38 (Chen, 
Gerken et al. 2005), although with undetermined down-
stream targets  
iii) increase muscle proteolysis via ubiquitin conjugation to 
muscle proteins (Li, Lecker et al. 2003).   
Table 1-2 Summary of other important transcription factors in the control of muscle mass and phenotype 
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1.6 Muscle biopsy findings in COPD patients 
 
Quadriceps Muscle 
Studies examining muscle biopsies obtained from vastus lateralis of COPD patients have consistently 
shown a reduced proportion of type I fibres or a marked fibre-type shift towards a predominance of 
fast type II fibres (Jakobsson, Jorfeldt et al. 1990; Whittom, Jobin et al. 1998; Gosker, van Mameren 
et al. 2002).  These findings have been supported by analysing the proportion of quadriceps myosin 
heavy chain subtypes (Satta, Migliori et al. 1997; Maltais, Sullivan et al. 1999). 
The presence of hybrid fibres (i.e. those in which there appear to be characteristics of two fibre 
types) either I/IIa or IIa/ IIx is also described in muscle biopsies taken from COPD patients (Gosker, 
van Mameren et al. 2002). It is thought that the presence of intermediate fibres may represent 
those fibres that are changing from one fibre type to another over time. Moreover, type IIx fibres 
and those of hybrid type IIa/IIx atrophy at a higher rate than type I fibres (Gosker, Engelen et al. 
2002) thus, the reduction in single fibre cross-sectional area, in addition to the loss of number of 
functional units, appears to contribute towards loss of muscle mass in those with COPD skeletal 
muscle dysfunction.   
Fibre shift towards type II fibres, leads to a reduction in quadriceps muscle oxidative capacity or 
oxidative enzyme activity (which is in part explained by the reduced mitochondrial density 
associated with this shift (Gosker, van Mameren et al. 2002)) and capillary density (Jobin, Maltais et 
al. 1998). Enzyme changes associated with the shift also include a reduction in those associated with 
aerobic activity for example citrate synthase, 3-hydroxyacyl CoA dehydrogenase (Jakobsson, Jorfeldt 
et al. 1995; Maltais, Simard et al. 1996), adenosine-5′-triphosphate and creatine phosphate 
(Kutsuzawa, Shioya et al. 1995).   This creates a metabolic profile which produces a higher amount of 
lactate early on during exercise (from glycolysis) which, in turn, contributes directly towards exercise 
limitation (Maltais, Jobin et al. 1998).  
A systematic review and meta-analysis performed by Gosker et al (Gosker, Zeegers et al. 2007) has 
provided reference values for fibre type proportions for older, healthy adults and those with COPD 
GOLD III-IV based on myosin heavy chain analysis. On reviewing the data, they concluded that a type 
I fibre % of <27% and IIx > 29% was considered to be abnormally low and high respectively in 
quadriceps muscle. From the studies analysed, they also found that the % of type I fibres decreased 
with increasing disease severity as measured by FEV1 and a BMI, although there were limited data 
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for GOLD I-II patients.  Inverse associations between the proportion of type IIa fibres and markers of 
disease severity were also found, but this was not the case for % type IIx fibres. 
More recently, the work of Dr Natanek has added to this field (Natanek, Gosker et al. 2013).  In a 
large cohort of 114 COPD patients and 30 controls, analysis of vastus lateralis biopsies showed that 
24% of patients had normal histology despite having impaired lung function mainly in GOLD III stage 
of disease, 31% patients had evidence of fibre shift, 20% had isolated (mainly IIx/IIa) atrophy and yet 
only 25% had evidence of fibre shift and atrophy, therefore indicating that fibre shift and atrophy do 
not always co-exist. Reference ranges for fibre type proportions were also given by the authors and 
found to be similar to those in the previous meta-analysis. 
The table below summarises the consequences of quadriceps muscle dysfunction in COPD: 
Change Quadriceps muscle 
Clinical manifestations Reduced muscle endurance 
 Premature muscle fatigue 
 Reduction in muscle strength 
Structural changes Reduction in the proportion of type I oxidative fibres 
 Shift towards fast type II fibres 
 Hybrid fibres present (I/IIa or IIa/IIx) 
 Muscle fibre atrophy 
 IIx fibres and hybrid fibres atrophy at higher rate 
Functional changes Reduction in oxidative capacity/oxidative enzyme activity, increase in 
glycolytic enzymes 
 Reduction in aerobic enzyme activity 
 Reduction in capillary density 
Table 1-3 Summary of the clinical manifestations, structural changes and functional changes that occur in skeletal 
muscle dysfunction in COPD patients 
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Respiratory muscles 
In COPD, the respiratory muscles are affected differently from quadriceps peripheral muscles. The 
diaphragm is one of the most studied respiratory muscles in COPD.  Functionally, it is under a greater 
workload in patients with COPD compared to healthy individuals, due to hyperinflation and an 
increase in the work of breathing.  At a muscle fibre level, an estimated 40-60% of patients with 
severe emphysema have a reduction in cross-sectional area of all muscle fibres types (Levine, Kaiser 
et al. 1997) in the diaphragm and muscle changes have been noted to occur in early disease 
(Ottenheijm, Heunks et al. 2005).   
Despite the reduction in muscle fibre cross-sectional area, diaphragm strength has been found to be 
preserved in those with COPD when compared to controls and normalised for lung volume 
(Similowski, Yan et al. 1991). This is thought to be due to the fact that although the fibre type 
proportion shifts, in contrast to the quadriceps muscles, it does so towards a predominance of type I 
endurance fibres (increased by 20-50%) (Levine, Kaiser et al. 1997), thus adapting to the different 
functional demands. In line with this, the number of type IIx fibres is reduced when compared to 
healthy controls (Doucet, Debigare et al. 2004).   
The increase in type I fibres is associated with a corresponding increase in oxidative capacity and a 
reduction in glycolytic activity (Ottenheijm, Heunks et al. 2008). Similar fibre type changes have also 
been observed in the parasternal intercostal muscles of COPD patients (Levine, Nguyen et al. 2006).  
 
1.7 Molecular mechanisms underlying quadriceps dysfunction in COPD 
 
The cardinal molecular feature of quadriceps muscle dysfunction is muscle fibre shift. As previously 
explained, muscle fibre atrophy also occurs, and it is unclear whether these processes occur 
independently or are linked. There is evidence to suggest that there are several mechanisms 
responsible for the fibre changes that occur with quadriceps dysfunction and these are discussed in 
the following section. It is the understanding of these mechanisms that is important to identify any 
potential biomarker to be used in the context of skeletal muscle dysfunction in COPD. Proposed 
mechanisms for the loss of muscle mass that occurs in COPD are shown in figure 1.2 and the 
molecular similarities and/or differences to other chronic diseases will be briefly discussed in the 
section 1.7.1. 
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Figure 1-2 Molecular pathways implicated in the pathogenesis of skeletal muscle atrophy and dysfunction in COPD.  
(Donaldson, Maddocks et al. 2012) 
This figure summaries the proposed pathways involved in skeletal muscle atrophy in the quadriceps of COPD patients. In the skeletal 
muscle dysfunction associated with COPD there is thought to be an imbalance between muscle-protein synthesis pathways and those 
controlling muscle protein breakdown. ĺ denotes stimulation; ԉindicates inhibition. 
 
The role of myostatin has also been included in the figure. Myostatin is held in an inactive state by its pro-peptide, follistatin, and 
inhibitory binding proteins – growth and differentiation factor-associated serum protein-1 (GASP-1) and follistatin-like related gene, 
(FLRG) as shown. Upon activation, it binds to its transmembrane receptor activin receptor type IIB (ActRIIB), which then forms 
homodimers with activin receptor-like kinase 4 or 5 (Alk 4/5). The SMAD signalling pathway is then activated and translocation of this 
transcription factor complex to the nucleus occurs, where MyoD production and therefore myoblast proliferation and fusion are blocked. 
Myostatin is also proposed to increase proteosomal activity in a FoxO-dependent manner. Activation of MAP kinase is mediated via 
myostatin either via p38 or ERK1/2, which leads to the blocking of genes involved in myogenesis. 
 
Abbreviations: 4E-BP1, eukaryotic translation initiation factor 4E binding protein-1; Akt, protein kinase B; ERK, extracellular signal-
regulated kinase; eIF2B, eukaryotic initiation factor 2B; FoxO, forkhead box class O; GSK-3β, glycogen synthase kinase-3β; IGF-1, insulin-
like growth factor-1; IL-6, interleukin-6; MAP, mitogen-activated protein; mTOR, mammalian target of rapamycin; MuRF, muscle-specific 
RING finger protein; p70S6k, 70-kD ribosomal S6 protein kinase; PGC1α, peroxisome proliferator-activated receptor gamma co-activator 1-
alpha; PI3K, phosphoinositide 3-kinase; PPAR, peroxisome proliferator-activated receptor; SMAD, ; TNF-α, tumor necrosis factor-alpha; 
GASP-1, growth and differentiation factor-associated serum protein-1; IGF-R, insulin-like growth factor-1 receptor; Ca2
+
, calcium ion; 
NFκB, nuclear factor κB.   
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1.7.1 Maintenance of muscle Mass in COPD 
 
Balance between protein synthesis and protein degradation 
 
It is unclear as to whether a reduction in protein synthesis plays a more dominant role in muscle 
atrophy in immobilisation and age models than an increase in protein degradation. Certainly, during 
an AECOPD, which is a period of accelerated muscle loss in COPD patients, two studies suggest that 
both processes are important. 
Crul and colleagues (Crul, Spruit et al. 2007) studied 14 COPD patients admitted to hospital with an 
AECOPD. On day 4 of admission, quadriceps biopsies were taken and analysed for IGF-I, MyoD and 
myogenin protein levels and mRNA expression of IL-6, IL-8, TNF- α and IGF-I. Biopsy results taken 
from the AECOPD patients were compared to healthy controls (n=7) and clinically stable COPD 
patients (n=11).   
Firstly, these authors found that there was a reduction in IGF-1 mRNA expression in both the 
AECOPD patients and the stable COPD patients compared to the healthy controls. Secondly, they 
found that MyoD protein expression was lower in the hospitalised COPD patients (and not the stable 
patients) compared to the healthy controls. Together, these findings suggest a reduction in muscle 
protein synthesis in the AECOPD patients. Similar molecular changes with reference to MyoD and 
IGF-1 have previously been identified in animal models of disuse (Mozdziak, Greaser et al. 1999).  
The authors did not find any difference in markers of inflammation in the biopsy samples taken from 
those admitted to hospital (i.e. IL-6, IL-8, TNF- α mRNA expression) when compared to the other two 
groups.  
The second study (Crul, Testelmans et al. 2010) used a microarray approach to investigate gene 
expression in the quadriceps of patients admitted to hospital for AECOPD.  Biopsies were taken from 
15 COPD patients on day 4 of an admission to hospital for an AECOPD and results compared to 
findings from 9 stable COPD patients.  These authors found an increase in the expression of genes 
involved in protein catabolism (MuRF1 and atrogin), oxidative stress and apoptosis. The authors also 
found evidence for abnormal mitochondrial dysfunction in the quadriceps of COPD patients with an 
exacerbation of disease.    
An increase in muscle MuRF1 expression has further been demonstrated in a mouse model of 
AECOPD, and its expression dependent and mediated via NFκB (Langen, Haegens et al. 2012).  
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Two further studies have supported a role for ubiquitin-mediated protein degradation in skeletal 
muscle dysfunction in COPD patients during times of disease stability. Elevated levels of atrogin-1 
mRNA (Doucet, Russell et al. 2007; Plant, Brooks et al. 2010) and MuRF-1 mRNA (Doucet, Russell et 
al. 2007) have both been demonstrated in the quadriceps of COPD patients. With reference to the 
work of Doucet et al (Doucet, Russell et al. 2007), the MuRF and atrogin changes were noted to 
occur alongside elevated hypertrophy signalling, with an increase in AKT expression. An increase in 
the expression of 4E-BP1, P70S6K, and GSK-3β was also noted in those COPD patients with muscle 
atrophy when compared to patients with preserved muscle mass. This apparent paradox of an 
increase in hypertrophy signalling with the loss of muscle mass might suggest that COPD patients 
actually fail to activate muscle protein synthesis or have an inability to restore muscle mass a theory 
that would support the notion of synthetic or ‘anabolic resistance’ (Rennie 2009).  
 
However, as the increased activity of E3 ubiquitin ligases has not been demonstrated in all studies of 
stable COPD patients, the importance of these pathways during times of disease stability remains 
under question. For example, Natanek et al (Natanek, Riddoch-Contreras et al. 2013) analysed 
MuRF-1 and atrogin protein expression in biopsies taken from 32 stable COPD patients (16 with a 
low FFM and 16 with a normal FFM) and compared findings to 15 controls. Although atrogin levels 
were found to be significantly lower in COPD patients compared to the controls, median levels (25th, 
75th percentile) for COPD patients = 0.64(0.31,1.24) AU and for controls = 1.41(0.68,2.06)AU, p= 
0.03, they were not different between the low and normal FFM COPD patient groups and likewise, 
MuRF-1 protein expression was not found to differ between the groups studied.  
 
Whilst muscle protein degradation is suggested to be the dominant mechanism for muscle atrophy in 
rodents (Krawiec, Frost et al. 2005), humans studies using tracer methods to quantify protein 
synthesis suggest this is greatly suppressed in the immobilised post-absorptive state (de Boer, Selby et 
al. 2007), and that, in contrast to rodents, the contribution of protein degradation is minimal.  
Therefore, some authors question that the relative contribution of muscle protein breakdown in the 
process of disuse-induced muscle atrophy (Marimuthu, Murton et al. 2011).   
 
NFκB  
NFκB activation is becoming recognised as a contributor towards muscle atrophy in COPD suggesting 
an increased inflammatory state of muscle contributes towards skeletal muscle dysfunction in the 
disease.  
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In a study by Agusti et al  (Agusti, Morla et al. 2004) NFκB DNA binding activity was determined using 
an electromobility shift assay in quadriceps biopsies taken from 7 COPD patients with normal BMI and 
7 patients with a low BMI (<21kg/m2).  These authors demonstrated that there was a 30% increase in 
the level of DNA NFκB binding activity in the patients that had a low FFM.  
Fermoselle et al similarly found that in the quadriceps of muscle-wasted COPD patients (n=29) there 
was a significant increase in levels of p65 protein (one NFκB subunit) when compared to levels found 
healthy controls (n=10). Levels of p65 also showed a tendency to be increased in limb muscles of the 
non-wasted patients with a normal FFM index compared with control muscles (Fermoselle, 
Rabinovich et al. 2012).  
 
Myostatin 
Several lines of evidence support a role for myostatin in COPD quadriceps dysfunction.  Myostatin 
mRNA was significantly elevated in quadriceps biopsy material from COPD patients who had reduced 
quadriceps strength, when compared to control subjects (Plant, Brooks et al. 2010) and smokers have 
been found to have elevated myostatin mRNA (Petersen, Magkos et al. 2007).   Following an in-
patient resistance training programme, hospitalised COPD patients had reduced myostatin transcripts 
with trend towards an increase in MyoD and myogenin (Troosters, Probst et al. 2010).  After 
pulmonary rehabilitation, non-cachectic COPD patients demonstrated a reduction in myostatin 
protein with a reduction in MuRF-1 and atrogin-1 (Vogiatzis, Simoes et al. 2010), and a modest 
reduction in myostatin was found following PR with or without testosterone (Lewis, Fournier et al. 
2007).   Our group has also demonstrated a negative association between quadriceps muscle 
myostatin mRNA expression in COPD patients and quadriceps muscle strength in COPD patients (Man 
WDC 2010).   
 
MAPK 
Mitogen-activated protein kinases (MAPK) such as ERK 1/2 and p38 MAPK have been implicated as 
molecular mediators involved in the loss of muscle mass.  In the case of the former, in C2C12 cells 
exposed to TNF, ERK activation led to a greater expression of MAFbx/atrogin, suggesting that ERK 
could play a crucial role in the pathogenesis of muscle atrophy (Piehl-Aulin, Jones et al. 2009). p38 
MAPK has also been shown to mediate oxidative stress-induced MAFbx/atrogin gene expression and 
ubiquitin-conjugating activity in mouse skeletal muscle (Li, Chen et al. 2005). 
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Recent data from COPD patients demonstrated elevated ratios of phosphorylated to total levels of 
p38 MAPK and ERK 1/2 in the quadriceps muscle, compared to controls. These ratios were 
negatively associated with mid-thigh muscle cross-sectional area, supporting the hypothesis that the 
MAPKs may contribute to the development of skeletal muscle dysfunction in COPD (Lemire, 
Debigare et al. 2012). However this is not a consistent finding in the literature as these findings were 
not replicated in a much larger cohort of COPD patients (n=105) when compared to healthy controls 
(n=27) in which there was no difference in p38 MAPK signalling in the quadriceps (Riddoch-
Contreras, George et al. 2012). 
 
Mechanisms of muscle atrophy in other chronic diseases 
Cachexia in patients with chronic diseases other than COPD, such as chronic heart failure (CHF) or 
chronic renal failure (CRF), is also a strong independent risk factor for mortality (Debigare, Cote et al. 
2001) and the responsible molecular mechanisms remain under investigation. Figure 1.2 illustrates 
the potential molecular mechanisms which are thought to contribute towards muscle atrophy in 
COPD patients and how a disruption of either protein synthesis and/or degradation can result in loss 
of muscle mass. There are some similarities (and differences) in the molecular pathways thought to 
lead to muscle atrophy in other chronic diseases and using the examples of CHF and CRF this is 
expanded below.  
With reference to the balance of protein synthesis and protein degradation in heart failure patients 
and in particular to the anabolic IGF-1/AKT axis, one study has found that basal muscle expression of 
IGF-1, at both the mRNA and protein level, was significantly reduced (52%) in 47 non-cachectic CHF 
patients compared to 15 healthy subjects., but this reduction ccompanied a significant increase in 
IGF-1 receptor mRNA expression (Hambrecht, Schulze et al. 2002).  This change in IGF-1 is in contrast 
to the increase in IGF-1 mRNA recently found in the quadriceps of 31 COPD patients compared to 14 
healthy controls (Lewis, Riddoch-Contreras et al. 2012).  
The same group of authors have since undertaken a larger study of 60 non-cachectic CHF patients 
and 60 healthy controls and investigated catabolic pathways that are proposed to contribute 
towards skeletal muscle atrophy (Gielen, Sandri et al. 2012). They investigated, amongst other 
molecular targets of interest, MuRF-1 and atrogin mRNA and atrogin protein expression in 
quadriceps biopsies. The group found that expression of MuRF-1, but not atrogin, was significantly 
increased in those with CHF compared to the controls. They also replicated their IGF-1 findings from 
the previous study in this larger cohort of patients. The changes in ubiquitin ligase expression are 
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again at odds with at least one large study of COPD patients which showed no change in MuRF and a 
reduction in atrogin expression(Natanek, Riddoch-Contreras et al. 2013). However, similar to 
observations in COPD patients, these authors found a significantly greater amount of myostatin 
mRNA (54.3%) in the quadriceps of those with CHF compared to the healthy controls.  
In patients with CRF, disruption to the balance of protein synthesis and degradation has likewise 
been shown to be important in the development of muscle atrophy.  Although experiments have 
demonstrated a reduction in protein synthesis in CRF patients, it is more likely that an increase in 
protein degradation plays a greater role in the development of muscle atrophy.  
Reduced protein synthesis in muscle has firstly been demonstrated using measurements of labelled 
amino acid turnover in patients and experimental models. In one such study, where CRF patients 
(n=12) were compared to healthy controls (n=12), those with CRF were found to have a 27% lower 
rate of synthesis of mixed muscle proteins and a 37% lower rate of mitochondrial synthesis, but with 
similar rates of mitochondrial protein synthesis (Adey, Kumar et al. 2000). Other studies have 
analysed components of protein synthesis pathways and an example of one in which components of 
this pathway were found to be reduced is the work of Wang and colleagues. They studied a mouse 
model of CRF and found reduced levels of mTOR and p70S6K (Wang, Du et al. 2009). 
Bailey and colleagues (Bailey, Wang et al. 1996) investigated protein degradation pathways in the 
setting of CRF. They measured rates of protein degradation in incubated epitrochlearis muscles from 
CRF and sham rats and found that acidosis (secondary to the renal impairment) resulted in muscle 
atrophy, via activation of protein degradation, rather than suppression of protein synthesis. They 
also demonstrate that this protein degradation occurs via activation of the ATP–ubiquitin–
proteasome pathway, since there were significantly greater concentrations of ubiquitin and C3 
proteasome subunit protein in the muscle of the CRF rats compare to the controls.  
 
Other proposed important molecular mediators in CRF associated muscle atrophy include Caspase-3 
and myostatin, which (as shown in figure 1.2) interact with the ubiquitin-proteasome system (MuRF-
1 and atrogin) to degrade proteins (Wang and Mitch 2014).  
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Quadriceps Muscle fibre shift  
 
Muscle fibre shift can occur independently of muscle fibre atrophy in some COPD patients (Natanek, 
Gosker et al. 2013).  In COPD patients, the mechanisms responsible for muscle fibre shift are less 
extensively studied compared to those which affect muscle mass. Despite the limited studies, AMP 
kinase, PGC1α and PPARs are thought to play a role in this process.     
 
AMP, Calcineurin and muscle shift  
A recent study (Natanek, Gosker et al. 2013) supported the importance of AMPK in the development 
of fibre shift in those with COPD. Natanek et al studied 38 COPD patients, 13 of whom had fibre shift 
(i.e a low type I fibre proportion with an increase in the type IIa population without the type IIx fibre 
proportion exceeding the normal range), and compared the results to 23 healthy controls. They 
found that the median amount of protein expression was three-fold higher in the quadriceps of 
COPD patients who did not demonstrated fibre shift compared to those with fibre shift. Levels of 
phosphorylated-AMPK correlated with measures of quadriceps endurance.  This finding is presumed 
to result from an increase in oxidative and metabolic stress in the COPD patients.  
In the same study, calcineurin expression was also significantly increased in the quadriceps of COPD 
patients compared to controls and also increased in those with fibre shift compared to those 
without fibre shift.  Possible explanations proposed for these findings were either a resistance to 
calcineurin in those with COPD or increased levels may have a compensatory response (Natanek, 
Gosker et al. 2013).  
 
PGC1α and PPARs 
In one small study of 14 COPD patients and 9 control subjects,  PPAR-α and δ protein levels and PGC-
1α mRNA were significantly lower in the quadriceps of moderate/severe COPD patients compared to 
controls with a similar smoking history (Remels, Schrauwen et al. 2007). These authors found that in 
addition, PPAR-α mRNA expression was lower still in cachetic patients.   These findings might suggest 
that PPAR-γ or -α content and/ or function may be in some way involved in the change in both the 
oxidative gene programme and mitochondrial dysfunction that occur in the muscle of COPD patients 
(Remels, Gosker et al. 2008).  However, it is possible that the results of this study may simply reflect 
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the loss of type I fibres that occurs in COPD patients with disease progression.   This is because type I 
fibres have higher expression of PPARs, therefore the results may simply represent an association 
rather causation. However, against this explanation is the fact that similar muscle findings have been 
found in other disease models, such as cardiac failure (Garnier, Fortin et al. 2003) and diabetes 
mellitus (Roden 2005). 
 
MicroRNA have recently been implicated in the control and regulation of myogeneis and muscle 
phenotype. They will now be considered in detail with particular relevance to skeletal muscle and 
COPD and why they are being investigated as potential biomarkers of muscle dysfunction in this 
thesis.   
 
1.8 MicroRNA 
 
Mature microRNA (miRNA) are small (approximately 20-30 nucleotides long) non-coding RNA 
molecules.  Originally discovered in C. elegans nearly 20 years ago, they are known to target 
messenger RNA (mRNA) and function either to inhibit protein translation or to directly destabilise 
mRNA and enhance mRNA degradation (Guller and Russell 2010). They are highly conserved 
throughout evolution and play a significant role in fine tuning the tissue transcriptome.  Target 
prediction is difficult as individual miRNAs can target hundreds of mRNAs, and in turn, individual 
miRNAs can be regulated by a range of transcription factors some of which may be targets of the 
mRNAs that they control (Williams, Liu et al. 2009).   
 
1.8.1 Biogenesis of miRNAs 
 
Figure 1.3 is a schematic representation of how miRNA are formed in the nucleus and exported to 
the cytoplasm in a cell.  To summarise, miRNAs are transcribed in the nucleus as long primary 
transcripts (pri-miRNAs) (Bartel 2004) by the enzyme RNA polymerase II (Boyd 2008). This is the 
same enzyme that functions to transcribe protein coding genes. The pri-miRNA is then cleaved by a 
nuclear protein complex (called the ‘Microprocessor’) consisting of the ribonuclease (RNase) III 
endonuclease Drosha and DGCR8 along with other proteins, to produce a hairpin of approximately 
70 nucleotides, called the pre-miRNA.  
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The pre-miRNA is then transported to the cytoplasm by Exportin-5 in a Ran-GTP dependent manner 
(Ge and Chen 2011).  In the cytoplasm, processing by RNase Dicer results in the formation of the 
mature miRNA and a complementary strand from the stem loop.   The former becomes incorporated 
into RNA-induced silencing complex (RISC) where it interacts with the 3’UTR of mRNA at its seed 
sequence to exert its biological action (Bartel 2004; van Rooij and Olson 2007). Exact complementary 
binding to mRNA is not necessary for an effect on gene transcription (Lewis, Burge et al. 2005). 
 
 
Figure 1-3 Summary of miRNA biogenesis  
MicroRNA are formed in the nucleus and exported to the cytoplasm where mature miRNA function. They target mRNA where they either 
inhibit translation or degrade/destabilise the mRNA molecule. Adapted from (Alevizos and Illei 2010) 
 
Some miRNA transcripts encode for a single miRNA, but others are able to encode more than one 
miRNA or clusters of miRNAs (referred to as polycistronic transcripts). It is also known that up to one 
third of miRNA are encoded by introns of protein encoding genes and processed following mRNA 
splicing. Other miRNA genes can be found either next to known genes or in exons of untranslated 
genes (Boyd 2008).  
Of particular interest to this thesis and the proposed aims of the experiments, miRNA can be 
detected in the peripheral circulation and can be tissue-specific. These will now be considered 
further.  
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1.8.2 Circulating miRNA 
 
Origin of circulating miRNA 
 
MiRNAs have been detected in blood in a form that is resistant to endogenous RNAase activity 
(Mitchell, Parkin et al. 2008). Studies indicate that miRNA are released into the circulation and 
protected from degradation either by: i) being packaged into microvesicles (MV) or exosomes 
(Valadi, Ekstrom et al. 2007) or apoptotic bodies; or ii) through the formation of protein-miRNA 
complexes (Arroyo, Chevillet et al. 2011); or iii) through an association with high density lipoprotein 
(HDL) (Vickers, Palmisano et al. 2011).  
 
Microvesicles  
Early studies used cell culture experiments to illustrate that cell-derived exosomes or MVs contain 
miRNA in addition to mRNA (Valadi, Ekstrom et al. 2007). The work of Valadi et al (Valadi, Ekstrom et 
al. 2007) demonstrated that mast cell-derived exosomes can carry approximately 121 different 
miRNA.  
The miRNA detected in these peripheral MVs can both be specific to the cell of origin and organised 
in a selective pattern, which might suggest that there is some sort of organisation or 
compartmentalisation involved in the secretion of miRNA into the circulation.   
Pegatti et al (Pigati, Yaddanapudi et al. 2010) have described how 66% of miRNA released from 
breast cancer cell lines in exosomal vesicles were at quantities that reflected intracellular level, 13% 
of miRNA were released at lower levels (and therefore retained in the cell) and 21% of the miRNA 
seemed to be actively released and were at higher levels compared to their cell of origin.  These 
observations are in support of a theory that miRNA release can be selective and indicate that the 
extracellular and cellular miRNA profiles can differ. 
 
MiRNAs associated with protein complexes 
By analysing miRNA complexes in human serum and plasma, Arroyo and colleagues (Arroyo, 
Chevillet et al. 2011) have more recently demonstrated that vesicle-associated plasma miRNA only 
represent a small proportion of extracellular miRNA and that up to 90% of miRNAs in the circulation 
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are non-membrane bound. These non-membrane bound miRNA are associated with a protein 
complex, later identified to be Argonaute2 (Ago2), a key intracellular protein of miRNA-mediated 
RNA silencing.  A further study by Turchinovich et al (Turchinovich, Weiz et al. 2011) also found that 
most extracellular miRNA in plasma and cell culture are bound to Ago2. It is thought that the 
circulating miRNA associated with Ago proteins are non-specific remnants resulting from 
physiological activity of the cells and cell death and as a result, both Ago2 protein and miRNA remain 
stable for prolonged periods (Turchinovich, Samatov et al. 2013). 
Similar to that described for exosomes, it has been proposed that there may be a cell type-specific 
miRNA release mechanism. For example, Arroyo et al (Arroyo, Chevillet et al. 2011) found some 
miRNA were exclusively associated with vesicles (e.g. let-7a) whereas other miRNA (e.g. miR-122) 
were exclusively present in Ago2 complexes.  
 
MiRNAs associated with HDL  
Another method by which miRNA are carried in the circulation is within HDL particles, but HDL-
associated miRNA only constitute a small proportion of total circulating miRNA.  Vickers et al 
(Vickers, Palmisano et al. 2011) analysed miRNAs purified in HDL, low density lipoproteins and 
exosome pools from human plasma in healthy individuals and those with cardiac disease. They not 
only found that the HDL-miRNA profile was different from that in the exosomes-miRNA profile, but 
they also found that miRNA profiles were different in those with familial hypercholesterolaemia and 
in a mouse model of atherosclerosis, suggesting the HDL-miRNA profile can vary according to disease 
status. 
Despite these discoveries, it remains unclear how miRNA physically enter HDL particles in the 
circulation.  
  
Function of circulating miRNA 
It is unclear as to whether circulating miRNA have a biological function and if so whether miRNA can 
act in cell-to-cell communication, whether it be in a paracrine manner or if they can have an effect at 
a distant location after being secreted into the circulation and therefore act in more of an endocrine 
manner.  Evidence in the literature supports the former as a possible biological function mainly via 
exosome-mediated miRNA transfer, but for reasons expanded upon below, the latter seems unlikely.  
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Multiple cell culture models in the literature have shown cell-to- cell communication via extracellular 
miRNA contained in exosomes (Turchinovich, Samatov et al. 2013). One of the earlier studies 
supporting  the hypothesis that miRNA may have a paracrine role is the work of Collino et al (Collino, 
Deregibus et al. 2010). They demonstrated that MV derived from bone marrow can shuttle selected 
patterns of miRNA to epithelial cells. They also demonstrated that in vitro transfer and 
internalisation of miRNA in MVs can lead to down-regulation of targets in the recipient cells.  
Hergenreider et al (Hergenreider, Heydt et al. 2012) also demonstrated the transfer of miRNA via 
exosomes, in this case from human endothelial cells to smooth muscle cells. MiRNA within the MV 
derived from endothelial cells were able to modulate gene expression in co-cultured smooth muscle 
cells. These authors also found that MV containing miRNA were able to inhibit atherosclerotic lesion 
formation in the aorta of one mouse model of atherosclerosis.  
Fewer studies have investigated the role of HDL-associated miRNA in cell-to-cell communication and 
therefore their role is questionable, if any, in cellular communication. One study (Vickers, Palmisano 
et al. 2011) in the literature has shown that treatment of human hepatocytes with HDL particles 
taken from patients with hypercholesterolaemia can increase levels of miR-105 within the 
hepatocytes. This did not occur with HDL particles from healthy donors. There is no evidence to 
suggest that vesicle-free (i.e. Ago2-associated) miRNA can exert cell-cell communication effects in 
mammals. 
It is unlikely circulating miRNA function to affect cell behaviour in an endocrine manner. This is 
because the concentration of individual miRNAs in the circulation is very low and is lower than 
intracellular concentration, which reduces the likelihood of miRNA uptake from the circulation 
resulting in a high enough concentration to elicit a response in a cell (Williams, Ben-Dov et al. 2013).  
A further consideration as to whether these biological functions occur in vivo is that miRNA 
exchange has only been shown to occur in cultured cells and for several miRNA.  
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1.8.3 Muscle-specific miRNAs:  ‘MyomiRs’ 
 
Muscle expresses a number of muscle-restricted miRNAs which have been implicated in both 
myogenesis and the control of skeletal muscle phenotype.  
In skeletal muscle, the most widely studied miRNA include miR-1 and miR-206 which differ only by 4 
nucleotides, miR-133a, which is co-transcribed with miR-1, and miR-133b, which is co-transcribed 
with miR-206. In addition, two further miRNA, miR-208b and miR-499, have been shown to play a 
significant role in the establishment of a muscle phenotype. MiR-208b and miR-499 are specific to 
type I muscle fibres and are encoded by intronic regions in MHC genes, myh7 and myh7b 
respectively (van Rooij, Quiat et al. 2009). Mir-208 and miR-499 share sequence homology in seed 
sequences which suggests that they have overlapping targets (van Rooij, Liu et al. 2008).   
 
Muscle-specific miRNA and Myogenesis  
During skeletal muscle development myoblasts proliferate, exit from the cell cycle and differentiate 
into myotubes. As already discussed, this process is governed by several transcription factors. It is 
through their regulatory relationship with the transcription factors that microRNA have been 
implicated in myogenesis.   Key transcription factors in this process include the MRFs, myogenic 
Myf5, MyoD, myogenin and MRF4, in addition to MEF2 and SRF (Guller and Russell 2010). 
To further expand on the relevance of miRNA during myogenesis, (summarised in figure 1.4) miR-1 
expression is controlled by the myogenic transcription factors SRF, MyoD and MEF2. MiR-1 has been 
shown functionally by in vitro studies to repress histone deacetylase 4 (HDAC 4), which is a negative 
regulator of both cell differentiation and MEF2 (Chen, Mandel et al. 2006). A functional consequence 
of HADC4 repression by miR-1 is to increase follistatin production. Therefore, the net effect of an 
increase in miR-1 is to drive myoblast differentiation.  A further target of miR-1 includes IGF-1 (Elia, 
Contu et al. 2009) another important regulator of skeletal muscle growth. Similar to mir-1, miR-206 
has been shown to promote myotube formation in vitro (Williams, Liu et al. 2009) and has also been 
associated with regeneration after nerve injury (Williams, Valdez et al. 2009). 
In vitro work has demonstrated that miR-133 has a role opposite to miR-1 and works in an 
antagonistic manner.  MiR-133 functions to promote myoblast proliferation and this function is 
achieved by suppression of SRF (Chen, Mandel et al. 2006).  
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Mir-181 is a more ubiquitously expressed miRNA but has myogenic functions. Expression of miR-181 
significantly increases during myoblast differentiation and muscle regeneration (Ge and Chen 2011).  
One of target of miR-181 is  the homeobox protein Hox-A11, which has been reported to repress the 
transcription of MyoD (Yamamoto and Kuroiwa 2003). Therefore an increase in its expression will 
release inhibition of MyoD.  
 
Figure 1-4 Summary of skeletal muscle-specific miRNA involved in myocyte proliferation and differentiation  
During the development of skeletal muscle, myoblasts proliferate and differentiate into myotubes. This figure summarises how in skeletal 
muscle, muscle-specific miR-1, miR-133, miR-206 and miR-181 contribute towards this process via the interaction of transcription factors. 
ĺ denotes stimulation; ԉindicates inhibition. Adapted from (Guller and Russell 2010). 
 
 
Muscle-specific miRNA and muscle phenotype 
MiR-208b and miR-499 modulate the expression of slow MHC genes and therefore fibre type and 
performance, through regulation of transcriptional repressors, such as Sox6, Purβ , Sp3, HP-1β, 
which co-repress MEF2, and Thrap 1  (McCarthy, Esser et al. 2009; van Rooij, Quiat et al. 2009).   
Experiments in the double knock out (dKO) miR-208b; miR-499 -/- mouse have shown that the 
absence of both of these miRNA leads to reduced expression of slow MHC both at the protein and 
mRNA level in the soleus muscle, and an increase in the expression of fast myosins. Single KO mice 
did not demonstrate these abnormalities.  Furthermore, forced over-expression of miR-499 was able 
to reverse these fibre type changes in this mouse dKO model, to enhance the exercise performance 
of the animals studied and to reduce the levels of one translational repressor target (Sox6 mRNA).    
Experiments from single knock out mice demonstrated that the presence of miR-208b and miR-499 
can occur in the absence of each other, and therefore it is thought that the two encoding myosin 
genes are activated independently, leading to their corresponding myomiR expression. It therefore 
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appears these miRNAs may establish a feedback loop whereby their targets in muscle enhance their 
own and the host myosin expression, thus activating the slow gene programme and repressing the 
fast gene activation (van Rooij, Quiat et al. 2009).  
 
As microRNA are increasingly recognised as important mediators of cell growth and development, 
they can be tissue specific and they can be detected in the peripheral circulation, miRNAs are already 
under investigation as biomarkers of disease. 
 
1.8.4 Circulating miRNA as biomarkers of muscle diseases 
 
Circulating miRNA are already being studied as potential biomarkers of diseases in cancer, 
autoimmune diseases, osteoarthritis and multiple sclerosis amongst others (Alevizos and Illei 2010).  
Specifically with reference to muscle, miR-1, miR-133, miR-206, miR-208 and miR-499, have been 
investigated for their diagnostic and monitoring use in both cardiac conditions and neuromuscular 
conditions. These will be now be commented on in the below section and comparisons made with 
muscle expression of miRNA if appropriate.  
 
Circulating miRNA and cardiac pathology 
The main cardiac conditions in which circulating miRNA have been studied include ischaemic heart 
disease, heart failure, coronary artery disease and hypertension (van Empel, De Windt et al. 2012).  
Table 1.4 is adapted from Van Empel et al and highlights the circulating miRNA changes that have 
been noted from some studies in the literature, with special attention drawn towards the 
dysregulated levels of muscle-specific miRNA in these conditions.  
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Condition miRNA increased in plasma miRNA decreased in plasma 
Ischaemic heart disease miR-1 
miR-30c 
miR-133 
miR-145 
miR-208a 
miR-208b 
miR-499 
miR-663b 
miR-1291 
miR-126 
miR-197 
miR-223 
Heart Failure miR-29b 
miR-122 
miR-142-3p 
miR-423-5p 
miR-107 
miR-125b 
miR-126 
miR-139 
miR-142-5p 
miR-497 
Coronary artery disease miR-21 
miR-27b 
miR-130a 
miR-134 
miR-135a 
miR-198 
miR-210 
miR-370 
miR-17 
miR-92a 
miR-126 
miR-145 
miR-155 
miR-181a 
miR-221 
miR-222 
Hypertension hcmv-miR- 
-UL112 
Let-7e 
miR-296-5p 
Table 1-4 A summary of the dysregulated miRNA that have been found in the plasma of patients with different cardiac 
conditions.  
Muscle-specific miRNA are shown in red. Table adapted from (van Empel, De Windt et al. 2012).  
 
An acute myocardial infarction (AMI) results in cardiac myocyte death and a concomitant release of 
miRNA into the circulation. Several groups have sought to identify miRNA that may either aid an 
earlier diagnosis of AMI than currently available (by for example cardiac troponin), or serve as 
prognostic markers.  
It has been suggested that miR-208 might serve as a promising biomarker of acute cardiac muscle 
damage (Corsten, Dennert et al. 2010; D'Alessandra, Devanna et al. 2010)  This miRNA has been 
suggested as a potential marker of cardiac damage following an ischaemic event, since levels of miR-
208 not only increase rapidly and markedly (over 3000 fold) after the event, and plasma levels 
correlated with cardiac troponin levels. A large study of 444 patients performed by Fukushima et al 
(Fukushima, Nakanishi et al. 2011) found that levels of miR-208 were associated with mortality 
outcome at 6 months. However, this outcome was not present after adjusting for cardiac troponin 
levels.  
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Circulating levels of miR-499 have also been shown to be increased in patients after AMI. It has been 
suggested that blood levels of miR-499 might be able to discriminate those who have had an AMI 
from those who have not. One study has shown that levels of miR-499 on a ROC analysis, resulted in 
an area under the curve (AUC) of 0.92 (Cheng, Tan et al. 2010). Furthermore, although released 
slower into the circulation when compared to miR-1, miR-133 and miR-208 (levels shown to peak at 
24 hours in the study by (D'Alessandra, Devanna et al. 2010)), levels of miR-499 relate better to 
cardiac troponin levels in both humans and animal models of AMI (D'Alessandra, Devanna et al. 
2010).  As it can be seen in table 1.4, circulating levels of miR-1 and miR-133 have also been found to 
be elevated following AMI.  
Circulating levels of miR-1 have been observed to increase early on after an ischaemic event. One 
group found that levels of miR-1 were elevated at 6 hours in patients suffering from AMI and 
correlated with levels of troponin (Fichtlscherer, De Rosa et al. 2010). Whilst another group 
analysing the kinetics of miRNA release in cardiac patients with hypertrophic cardiomyopathy 
undergoing an operative procedure mimicking AMI (Liebetrau, Mollmann et al. 2013), demonstrated 
that elevated levels of miR-1 were significantly increased (>3-fold; p = 0.01) after 15 min, with a peak 
after 75 min (>60-fold; p < 0.001). This increase in miR-1 occurred alongside increasing levels of miR-
133 and miR-208 during the first 4 hours post procedure.  Although this means miR-1 has important 
qualities for a potential biomarker of cardiac damage, there remains a wide variation in the 
literature as to how sensitive and specific levels of miR-1 are with regards to diagnosing AMI; quoted 
AUCs for circulating miR-1 levels and a diagnosis of AMI range from 0.74 to 0.98 (van Empel, De 
Windt et al. 2012). 
The applications of miRNA to diagnose (or offer biomarker potential in) an ischaemic event are not 
yet established as there is already a highly sensitive indicator of cardiac injury, troponin, which is 
used in clinical practice and easy to quantify. There is also an overlap in miRNA levels between 
patients with unstable angina and AMI (Widera, Gupta et al. 2011).  
Currently, there remains insufficient data or evidence to support circulating levels of muscle-specific 
miRNA for prognostication in cardiac patients (Condorelli, Latronico et al. 2014). Although miR-208 
shows promise, no one miRNA has yet been shown to be associated with indices of left ventricular 
failure and remodelling or brain natriuretic peptide (Bauters, Kumarswamy et al. 2013), both 
important outcome measures.  It is worth noting that this final point highlights a discrepancy that 
can exist between, in this case, the amount or degree of cardiac muscle damage that has occurred 
and the measured levels of circulating muscle-specific miRNA.  
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Circulating miRNA and neuromuscular conditions  
Neuromuscular conditions are another group of muscle disorders in which circulating miRNA are 
being investigated for their use as biomarkers of disease. Conditions studied include the muscular 
dystrophies, congenital myopathies, inflammatory myopathies and motor neurone disease. 
Duchenne muscular dystrophy (DMD) is an inherited muscle disorder and one in which muscle 
miRNA have been shown to be dysregulated. The absence of the dystrophin protein in DMD leads to 
disruption of the link between the cytoskeleton and the extracellular matrix in the muscle fibres and 
results in muscle wasting, cycles of muscle fibre regeneration and degeneration, inflammation and 
gradual replacement of the muscles by connective and adipose tissue. Premature death is a 
consequence of progressive muscle weakness.  
 
Current biomarkers of disease include measures of creatine kinase (CK), which reflects the amount 
of muscle damage. The limitations of CK are that: measurements can be unreliable; serum CK levels 
correlated poorly with MRI muscle assessment; and levels can be influenced by the age of the child, 
by medication which does not affect muscle function, and are increased during times of physical 
activity (Cacchiarelli, Legnini et al. 2011).  
 
Levels of circulating miR-1, miR-133, and miR-206 have so far been studied in DMD patients and 
often referred to as ‘dystromirs’ in this context.   Despite reduced synthesis in dystrophic muscles, 
levels of miR-1 and  miR-133 have been found to be greatly elevated (one-hundred fold compared to 
healthy individuals) in the blood of DMD patients (Cacchiarelli, Legnini et al. 2011).  Levels of miR-
206 have also been found to be increased in the serum of DMD patients. Importantly for a clinical 
application, Cacchiarelli and colleagues have found that levels of these miRNA correlated with 
disease severity in the serum of both ambulatory patients and mouse models of the disease 
(Cacchiarelli, Legnini et al. 2011; Mizuno, Nakamura et al. 2011).  
A further two studies have supported the above findings. In the first study studying two animal 
models of DMD Mizuno et al (Mizuno, Nakamura et al. 2011) found elevated levels of miR-1, miR-
133a and miR-206 in serum of mdx mice and CXMDj dogs. These authors also noted that these levels 
were less affected by stress, when compared to the current biomarker CK.   
 
A more recent study involving a larger number of DMD patients (n=44) and Becker’s muscular 
dystrophy patients (n=5) by Zaharieva et al (Zaharieva, Calissano et al. 2013) compared levels of 
serum muscle-specific miRNA between those with muscle disease to 14 healthy controls. These 
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authors found that miR-1 (p = 0.005; 88.7-fold), miR-206 (p =0.0001; 2.35-fold), miR-133a (p = 0.008; 
10.17-fold) and miR-133b (p = 0.0008; 6.9-fold) were increased in the serum compared to healthy 
controls. This group also demonstrated that when the DMD patients were classified into those who 
were ambulant compare to those who were not, those in the former group had higher levels of 
circulating miRNA. In line with this, patients with scoliosis or undergoing treatment for scoliosis were 
found to have lower levels of miR-1, miR-133a and miR-133b. Of note, when the patients were 
grouped according to the presence or absence of cardiomyopathy, there was no difference in the 
levels of circulating miRNA (Zaharieva, Calissano et al. 2013). The study further showed that milder 
DMD patients had higher levels of circulating dystromirs compared to the more severe DMD 
patients, and so the measured miRNA levels were thought not to reflect muscle mass or bulk of the 
subjects studied.  
 
The last point to comment on from the above study is the association of the measured miRNA with 
age. It was found that levels of dystromirs were higher in the younger patients and lower in the older 
patients. Due to  change in levels with age, the authors have suggested that levels of miR-1, miR-
133a and miR-133b are more likely to function as biomarkers of disease or reflect the (reduced) 
residual muscle mass in the older group of patients.   
 
The relationship between serum and muscle muscle-specific miRNA is not always straightforward 
and has recently been explored by Roberts and colleagues in mdx mice (Roberts, Blomberg et al. 
2012). These authors analysed miRNA expression in different muscle groups in the mdx mouse 
(including the quadriceps, diaphragm and heart) alongside miRNA levels in the serum and discovered 
a complex relationship between the two measurements.  For each tissue analysed there was a set of 
miRNA found to be differentially expressed only in that tissue. Levels of miR-1, miR-133a, and miR-
206 were reduced in some muscles and modestly increased in other muscle samples analysed 
(Roberts, Blomberg et al. 2012).  
 
It has been suggested that the discrepancy between the miRNA expression profile of muscle and 
serum may indicate a specific biological response, such as specific miRNA export (Roberts, Blomberg 
et al. 2012), but the complexities of miRNA half-life, muscle pool size differential miRNA profiles in 
different skeletal muscles, relative muscle activity and non-skeletal muscle expressing some of the 
miRNAs means that passive release cannot be excluded. This discrepancy between blood and muscle 
levels for miR-1, was also noted in the study described above by (Zaharieva, Calissano et al. 2013), 
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where miR-1 levels were significantly increased in serum samples, but were reduced in skeletal 
muscle of DMD patients.  
 
 
Summary of circulating (muscle-specific) miRNA in other different muscle conditions 
 
Acute muscle inflammation 
Acute exercise can result in an acute inflammatory response in the muscle exercised. In healthy 
individuals, the response consists of disruption of the muscle architecture followed by infiltration of 
neutrophils and macrophages (Tidball 2005). Table 1.5 outlines the findings from studies 
investigating the response of circulating miRNA to acute exercise.  In order to compare changes that 
occur in the circulation to those that occur at the muscle level, studies analysing muscle responses to 
exercise have also been included in the table. These will be further discussed in the chapter 5.  
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Condition Model used Study miRNA  changes  
Acute Inflammation  
Blood miRNA changes 
 
 
 
Acute exercise in 
humans 
 
Uhlemann et al 2014 (Uhlemann, Mobius-Winkler et al. 2014) 
a) maximal symptom-limited exercise test b) bicycling for 4 h, 
c) running a marathon, and d) resistance exercise. Plasma 
samples analysed. 
 
a) Significant Increase in circulating miRNA-126 at maximum 
power, (2.1 fold), no change in miRNA-133. 
b) 4 hours of cycling increased plasma concentration of 
miRNA-126 (4.6 fold), no change in miR-133. 
c) Marathon running resulted in an increase of miRNA-126 
and miRNA-133. 
d) Eccentric resistance training led to an isolated increase of 
miRNA-133 level (2.1-fold) with unchanged miRNA-126. 
 
2. Nielsen et al 2014  (Nielsen, Akerstrom et al. 2014) 
  
13 young men, pre-training and after 60 minute cycle 
ergometer at 65% max exercise.  Bloods taken a) immediately 
after 1 hour exercise b) 1 hour after exercise and c) 3 hours 
after exercise. Levels compared to baseline values. Plasma 
samples.  
a) Immediately after exercise: miR-106a, miR-221, miR-30b, 
miR-151-5p, let-7i, miR-146a, miR-652, miR-151-3p all 
significantly decreased.  
b) 1 hour after exercise: miR-338-3p, miR- 330-3p, miR-223, 
miR-139-5p, miR-143 all significantly increased.  
c) 3 hours after exercise: miR-1 increased by 429%. miR-
133a, miR-133b increased by  252% and 454 %  (p=0.001) . 
 
 
4.  Aoi  et al  2013 (Aoi, Ichikawa et al. 2013) 
11 young men. Cycled 70% VO2 max for 60 mins. Serum 
samples taken.  
When compared with baseline, levels of miR-486 were 
significantly reduced after acute exercise (100 ± 43% to 56 ± 
41%, P = 0.013). 
 No change in miR-1, miR-133 or miR-206. 
3. Baggish et al 2011 (Baggish, Hale et al. 2011) 
Young, male student athletes (n=10) undertook acute 
exhaustive cardiopulmonary exercise testing. Bloods taken 
prior to exercise, immediately after and 1 hour after resting.    
Immediately after exercise: Circulating plasma levels of miR-
146a (3.00 ± 0.71 fold change, mean ± SEM), miR-222 (2.46 ± 
0.41 fold change), miR-21 (1.89 ± 0.28 fold change), and 
miR-221 (3.58 ± 0.89-fold change) increased. Levels then 
significantly decreased 1 hour after rest. 
No change in levels of miR-20a, miR-328, miR-210 and miR-
133a.  
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Acute Inflammation  
Muscle miRNA changes 
 
 
 
Acute exercise in 
humans 
 
1. Drummond et al 2008 (Drummond, McCarthy et al. 2008) 
Older (n=6) and younger men (n=6) studied. Quadriceps 
biopsies taken before exercise, 3 and 6 hours after leg 
extension exercise.  
Higher baseline Pri-miR expression in older men compared 
to younger men.  
miR-1 expression significantly reduced (50%)  in younger 
men at 3 hours.  No other changes in mature miRNA 
expression.  
2. Nielsen et al 2010 (Nielsen, Scheele et al. 2010) 
Quadriceps biopsies from young men (n=10), 60 minutes of 
acute endurance exercise (cycle ergometry at 65% VO2 max).  
Biopsies taken before, immediately after and 240 mins after 
exercise 
 
Expression of miR-1, miR-133 significantly increased 
immediately after acute exercise.  
3.  Davidsen et al 2011 (Davidsen, Gallagher et al. 2011) 
56 young men studied. Divided into ‘low-responders’ and 
‘high-responders’ with regards to muscle mass gain after 
resistance training. Quadriceps biopsies taken from 8 high 
responders and 9 low responders before (top and bottom 
20%) and 48 hour after exercise miRNA response to training 
studied.  
After training: miR-378, miR-29a, miR-26a down-regulated in 
‘low-responders’ by 0.4, 0.6 and 0.4 relative change 
compared to baseline, miR-451 up-regulated in ‘low-
responders’, relative change 4 fold compared to baseline. 
Proposed by authors to be compensatory response to 
training as no such response observed before training.  
 
4. Russell et al 2013 (Russell, Lamon et al. 2013) 
Young adult (n=9), moderate intensity endurance cycling. 
Quadriceps biopsies taken at rest and 3 hours after exercise. 
3 hrs following an acute exercise bout, Drosha, Dicer and 
exportin-5, miR-1, -133a, -133-b and miR-181a all increased 
by 60%, 35%, 40% and 35% respectively.  
Expression of miR-9, -23a, -23b and -31 was decreased by 
50%, 24%, 27% and 28% respectively 
 
Table 1-5 Changes in plasma and muscle miRNA levels with acute inflammation
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Chronic muscle inflammation 
There is a relative paucity of data on different circulating miRNA profiles in chronic inflammatory 
muscle diseases. One recent study has analysed muscle miRNA profiles in different inflammatory 
myopathies, but as yet levels of these miRNA have not been examined in the circulation of such 
patients. The results from the study of muscle miRNA are summarised in table 1.6 below. As it can 
be seen from the table, the dysregulated miRNA include those which are muscle-specific, but as 
previously commented on in the case of DMD, this does not necessarily mean that similar miRNA 
changes would be observed in the blood if such a study was to be conducted.  
Condition Model used Study miRNA  changes  
Chronic 
Inflammation 
Muscle  and 
muscle cell line 
miRNA changes 
Inflammatory 
myopathies  
1. Georgantas et al 2014 
(Georgantas, Streicher et al. 
2014)  
Muscle biopsies (quadriceps or 
biceps) analysed from 29 patients 
with inflammatory myopathies: 
dermatomyositis (DM), 
polymyositis (PM) and Inclusion 
body myositis (IBM) and 
compared to samples from 16 
healthy controls.  
In vitro cell line experiments 
carried out for mechanistic 
purposes.  
Significant reduction in miR-1, 
miR-133a/b, miR-378 in all muscle 
samples from patients compared 
to controls. miR-206 reduced in 
DM patients.  
Mir-155, significantly increased in 
all myositis samples, miR-146, 
miR-221 increased in IBM and PM 
samples.  
Elevated pro-inflammatory 
cytokines observed in all types of 
myopathies in biopsy material.  
 
TNF α inversely correlated with 
reduced miR-1, miR-133 and miR-
206 miRNA expression in the 
inflammatory myopathy subtypes.  
 
TNFα inhibited the expression of 
miR-1, miR-133 and miR-206 and 
suppressed the differentiation of 
C2C12 myoblasts to 
myocytes/myotubes in an NFκB  
dependent manner. This block in 
differentiation by TNF α was 
relieved by overexpression of miR-
1, miR-206, or miR-133a/b. 
Table 1-6 Muscle and muscle cell line miRNA changes in chronic inflammatory conditions 
 
Myasthenia gravis (MG) is a chronic, T-cell mediated, autoimmune disorder and one in which 
patients present with symptoms of fatigable weakness of their skeletal muscles. The primary 
pathology in the majority of cases is the presence of auto-antibodies which target nicotine 
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acetylcholine receptors and reduce neuromuscular transmission. Blood from patients with MG 
shows active inflammation, and although antibody titre aids diagnosis, it has little predictive value 
with regards to the degree of muscle weakness or response to therapy.  
Using an array approach, followed by testing miRNA in a validation cohort, Punga et al (Punga, Le 
Panse et al. 2014)  found that miR-150, miR-21 and miR-27 were increased significantly in those with 
MG compared to healthy controls. Despite miR-150 being increased 2.5 fold in the initial analysis of 
4 MG patients compared to 4 healthy controls, where levels were found to be responsive to 
thymectomy, the AUC was moderate at 0.84 for diagnosis of MG. Furthermore, in the validation set 
where there were 16 MG patients compared to 16 healthy controls, levels did not correlate well with 
clinical status of the patient, i.e. whether patient had previously had removal of their thymus or not.  
 
Muscle regeneration and degeneration 
As previously discussed, there is evidence to suggest that muscle degenerative pathways are 
activated in chronic diseases such as COPD (which this thesis will focus on), as well as chronic heart 
failure, diabetes, and chronic renal failure (CRF) patients. At the muscle level, there are some 
molecular changes that occur that have been shown to be common amongst these diseases and are 
thought to be related to the pathogenesis of disease or to suggest that muscle degenerative 
pathways are activated (as already discussed in section 1.71). However, as it will now be briefly 
explained, circulating miRNA profiles of muscle degenerative diseases have so far not been shown to 
be consistent, albeit studies looking into this are still in their infancy.  
With reference to the study of changes in muscle expression or circulating levels of skeletal muscle-
specific miRNA in diabetes, one study has found that muscle-specific miRNA are significantly reduced 
in the muscle of patients with type 2 diabetes. This group of authors found that when comparing 
patients with type 2 diabetes to those patients with either impaired glucose tolerance or patients 
with normal glucose tolerance, expression of miR-133a was reduced five times in vastus lateralis 
skeletal muscle samples (Gallagher, Scheele et al. 2010). Expression of miR-133a was also associated 
with fasting glucose levels, where higher levels of fasting glucose were associated with lower miR-
133a expression. Muscle expression of miR-206 was also reduced in type 2 diabetic patients when 
compared to the controls in the same study (Gallagher, Scheele et al. 2010). However, as it can be 
seen in table 1.7 below these miRNA have not been documented to be different in the circulation of 
type 2 diabetic patients. Therefore they are unlikely to represent suitable biomarkers of skeletal 
muscle atrophy/dysregulation in this clinical circumstance in the future.  
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The first systematic analysis  performed by Zampetaki et al (Zampetaki, Kiechl et al. 2010) of 
circulating miRNA in plasma of diabetes patients showed decreased levels of 10 miRNAs in those 
individuals (table 1.7) including miR-15a, miR-20b, miR-21, miR-24, miR-126, miR-191, miR-197, miR-
223, miR-320 and miR-486  and an increase in miR-28-3p . Of the miRNAs studied, miR-486 was the 
only muscle-specific miRNA that was found to have decreased in the plasma of those individuals 
with type 2 diabetes. 
 
Condition miRNA increased in plasma miRNA decreased in plasma 
Diabetes miR-9 
miR-28-3p 
miR-29a 
miR-30d 
miR-34a 
miR-124a 
miR-146a 
miR-375 
miR-503 
miR-15a 
miR-20b 
miR-21 
miR-24 
miR-126 
miR-191 
miR-197 
miR-223 
miR-320 
miR-486 
 
Table 1-7 A summary of the dysregulated miRNA that have been found in the plasma of patients with diabetes mellitus  
Table adapted from (van Empel, De Windt et al. 2012). miRNA changes taken from (Zampetaki, Kiechl et al. 2010), (Kong, Zhu et al. 2011), 
(Nielsen, Wang et al. 2012). Muscle-specific miRNA are shown in red. 
 
So far there are only a few studies in the literature which have analysed circulating miRNA levels in 
CRF patients. Because miRNA are cleared via the renal tract, studies are complicated by the fact it 
has been shown that there is a strong correlation between levels of detectable miRNA and 
glomerular filtration rate (Neal, Michael et al. 2011). Thus, when studying more severe CRF patients 
on haemodialysis (who are the group presumed to have greater levels of muscle degeneration 
compared to the milder CRF patients), detectable levels of miRNA will be lower in the circulation. It 
is for this reason that miRNA have been studied in urine samples of CRF patients. There is no data in 
the literature that explores muscle-specific miRNA in CRF patients. 
 
Muscle remodelling – Cardiac hypertrophy as an example 
Cardiac hypertrophy is deﬁned as an increase in heart size without changes in myocyte number. 
Hypertrophic cardiac growth can occur either in response to pathological or physiological 
haemodynamic overload. In the latter case, the structure and function of the heart muscle is 
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preserved. In the former, remodelling associated with hypertrophy involves interstitial fibrosis and 
has been shown to be associated with miRNA dysregulation.  
In vivo studies in the literature have investigated muscle miRNA changes associated with cardiac 
hypertrophy mainly in mouse models of the disease. Relatively little is known about changes in levels 
of circulating miRNA in patients with cardiac hypertrophy. The blood miRNA changes that have been 
investigated in two recent studies associated with cardiac hypertrophy are summarised in table 1.8.  
Blood miRNA dysregulated in cardiac hypertrophy Details of study 
(Roncarati, Viviani Anselmi et al. 2014) 
 
miR-27a, -199a-5p, -26a, -145, -133a, -143, -199a-3p,  
-126-3p, -29a, -155, -30a, and -21 
miR-199a-5p, -27a, and -29a 
Hypertrophic cardiomyopathy patients= 41, compared to 
controls n=41. miRs quantified by qPCR. ECHO and cardiac 
MRI performed.  
All significantly increased in plasma of patients with 
hypertrophic cardiomyopathy. 
Levels of these miRs correlated with degree of 
hypertrophy and miR-29a levels correlated with degree of 
fibrosis. 
(Wen, Song et al. 2014) 
 
 
miR-133a 
64 patients with end-stage renal failure (ESRF) undergoing 
haemodialysis (HD) compared to 18 healthy controls. 
ECHO performed and blood miR-133 levels quantified 
using qPCR.  
MiR-133a levels significantly lower in those with ESRF and 
left ventricular hypertrophy (LVH), compared to those 
without LVH and controls. Levels of miR-133 did not 
change with HD. 
Plasma levels of miR-133 negatively correlated with ECHO 
measures of LVH.  
Table 1-8 Blood miRNA changes associated with cardiac hypertrophy 
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1.9 What is already known about muscle-specific miRNA in COPD? 
  
Previous work in our group has analysed quadriceps expression of muscle-specific miRNA in a large 
cohort of well-characterised COPD patients and compared the findings to those of aged-matched 
healthy controls. Dr Lewis et al  (Lewis, Riddoch-Contreras et al. 2012) found that there was a 
significant 2.5 fold reduction in miR-1 in the quadriceps of COPD patients compared to controls. In 
keeping with the proposed biological functions discussed in section 1.8.3 of miR-1 and miR-499, 
quadriceps miR-1 expression was associated with a low-fat free mass and miR-499 expression 
associated with the number of type 1 fibres in the biopsy material. Further findings of this work 
included the observation that an important up-stream regulator of miR-1 (SRF) was lower in patients 
compared to the controls and one target of miR-1 (HDAC4) was also increased. Together the results 
of this work suggest that the SRF-miR-1 axis may be an important contributor towards the muscle 
phenotype in COPD patients. 
 
1.10 Summary  
The studies in this thesis will follow on from the previous work performed in our group on the 
analysis of quadriceps muscle miRNA in COPD patients. As well as investigating muscle-specific 
miRNA for their biomarker potential, it is hoped that the studies performed may add to our 
understanding of the mechanisms contributing to skeletal muscle dysfunction in COPD.  
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 2 .  Methods 
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2.1 Physiological Methods 
 
2.1.1 Patient recruitment and outline of studies  
 
Chapter 3:   Circulating microRNA levels in COPD patients compared to controls 
The cohort of patients and controls were recruited by a previous researcher in the group, Dr. A. 
Natanek, who also performed the physiology testing and obtained the biological specimens. Results 
from this cohort have been already been published (Natanek, Gosker et al. 2013). I analysed the 
plasma samples from 103 COPD patients in the cohort and 25 control subjects in this thesis and 
interpreted the results.    
Ethical approval for the study was obtained from the Royal Brompton and Harefield NHS Trust and 
Ealing and West London Mental Health Trust Research Ethics Committees (06/Q0404/35 and 
06/Q0410/54). Written informed consent was obtained from all study participants.  
Patients with COPD according to the Global Initiative in Obstructive Lung Disease guidelines 2004 
(Rabe, Hurd et al. 2007) (36 female and  67 male) were enrolled from clinics at the Royal Brompton 
Hospital  (GOLD I or II n= 34, III = 38, IV= 31) . Healthy age and gender matched controls were 
recruited by advertisement. Exclusion criteria included a diagnosis of heart, renal or liver failure, 
systemic inflammatory, metabolic or neuromuscular disorders, patients on warfarin or a 
moderate/severe exacerbation of COPD (i.e. requiring intervention) within the preceding 4 weeks.  
 
Chapter 4: Circulating microRNA levels in COPD patients admitted to hospital with an acute 
exacerbation of COPD compared to stable COPD patients 
I tested the plasma samples in this study that had been obtained from a collaborating group 
(Professor M. Steiner, Leicester) within the umbrella of the COPD MAP consortium. Their patients 
were admitted to hospital for an acute exacerbation of COPD; the plasma tested in this study came 
from those participating in a hospital trial at the time of recruitment entitled ‘Can REhabilitation 
delivered immediately on hospitalisation for an Acute exacerbation of Chronic respiratory disease 
improve long term Health outcomes? (The REACH trial)’. Ethics approval number 09/H0403/76. 
The COPD patients admitted to hospital for an acute exacerbation were recruited (n=60), tested and 
blood sampling performed by the investigators within 24 hours of admission. There were two 
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hospitals involved in patient recruitment, Glenfield and Kettering Hospitals. Plasma from stable 
COPD patients (n=24) was also obtained from the collaborating group for comparison purposes.  
All patient recruitment, physiological measurements and blood sampling were performed by 
investigators in the collaborating group.    
Plasma samples were collected in lithium heparin tubes and therefore the method for measuring 
circulating microRNA needed to be adapted from that used in the other studies in the thesis. I 
worked with Dr Amy Lewis to optimise the method which is discussed in more detail in the relevant 
Chapter. I analysed the samples and interpreted the results.  
 
Chapter 5: The effects of acute exercise on circulating microRNA  
Patients in this study were part of a larger, European, multi-centre study entitled ‘Non-interventional 
cross-over study to reduce items of the draft PROactive tools as a measure of physical activity in daily 
life in patients with COPD’. All subjects gave written informed consent and the protocol was 
approved by the National Research Ethics Service Committee in London, Bloomsbury ethics number 
11/ LO/0711. Inclusion and exclusion criteria are detailed in the chapter.  
COPD patients were recruited from the Royal Brompton and Harefield NHS Foundation Trust 
hospital and healthy controls from a database held at the hospital. 20 COPD patients and 11 healthy 
controls had muscle biopsies.  
COPD patients were recruited by myself and other researchers working on the study (Ms R. Tanner, 
Ms C. Davey, Dr Y. Raste), I recruited the healthy controls. All subjects underwent clinical 
examination and history to check eligibility for study; I and other researchers performed this.  
Methods used in this study are detailed below.  Physiological measurements of patients and controls 
(to include baseline anthropometric measurements, quadriceps strength measurements, 
measurements of body composition, 6 minute walk distance, activity monitor measurements) were 
performed by all researchers working on the study, including myself.  I supervised all the 
cardiopulmonary exercise tests for COPD patients and healthy controls, and performed the 
quadriceps muscle biopsies and blood sampling, with assistance from Ms R. Tanner and Ms C. Davey 
(an assistant is required to perform muscle biopsy safely and efficiently). I analysed all the 
physiological and biological data obtained from this study.  
68 
 
Chapter 6:  Circulating microRNA levels in COPD patients with low fat-free mass index  
The study was designed to investigate other circulating microRNA of interest in a specific selected 
smaller cohort of patients.   The selection of patients allowed different analyses to be performed.  24 
plasma samples were analysed, 8 from COPD patients with retained or normal fat-free mass 
(NFFMI), 8 COPD patients with a low fat free mass (LFFMI) and 8 from healthy controls with 
preserved fat free mass. All subjects were male and samples originated from the same cohort used 
in Chapter 3 (where physiology data and biological specimens were obtained by Dr Natanek). The 
validation study analysed stored plasma samples taken from 21 COPD patients with LFFMI, 17 COPD 
patients with NFFMI and 12 healthy aged –matched controls also from the Natanek cohort. 
I tested all of the plasma samples and interpreted the results.  
 
2.1.2 Clinical examination, anthropometric measurements and laboratory blood tests 
 
The physiological methods described below are specifically those used in Chapter 5 where I tested 
the patients and controls and obtained biological specimens.  
 
2.1.3 Body composition 
 
Assessment of fat free mass and body composition was performed by electrical bioimpedence. 
(Bodystat 1500; Bodystat, Isle of Man, UK). A disease-specific equation was applied in patients with 
COPD (Steiner, Barton et al. 2002).  Fat free mass index (FFMI) was calculated as fat free mass (FFM) 
in kg/height in m2.  
 
2.1.4 Volitional assessment of muscle strength: quadriceps maximum voluntary 
contraction (QMVC) 
 
Assessment of quadriceps strength was performed using the method described by Edwards et al 
(Edwards, Young et al. 1977). Subjects were seated in a specially designed couch with their knee 
flexed at 90° angle over the end of the couch.  Maximum quadriceps isometric strength was 
measured via an inextensible ankle strap positioned just proximal to the malleolus and connected to 
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the strain gauge.  Output from the strain gauge was recorded using LabChat7 software (AD 
instruments).  The equipment was calibrated using a suspended weight prior to subject testing by 
either myself or the researcher conducting the test.  
Using their dominant leg, subjects were asked to extend their knee maximally against the strap with 
visual feedback and verbal encouragement until no further increase in QMVC occurred.   They were 
asked to perform 5 repeated sustained maximal isometric contractions of between 5 and 10 seconds 
duration, with a gap of 30-60 seconds between each for recovery.  Verbal encouragement was given 
in a standardised manner throughout and quality of manoeuvres was visualised and assessed at the 
time of testing.  The highest QMVC in kg sustained over a 1 second period was taken for the result.  
 
2.1.5 Measurements of daily activity 
 
All subjects wore the two physical activity monitors, the Actigraph GT3X and DynaPort MoveMonitor 
(McRoberts) for 7 days duration to assess measurements of daily activity,  
We used 2 activity monitors since the choice of activity monitor was under investigation as part of 
the PROactive study.  Subjects were instructed to wear the monitors from first thing in the morning 
and then take to them off before going to bed.  All subjects wore both monitors together and 
therefore data from each monitor were analysed for the same days. Data were included if the 
subject wore the device for >10 hours per day and six full days worth of data were used for each 
subject. 
 
Actigraph activity monitor (GT3X plus) 
Monitors were programmed according to manufacturer’s instructions, with a sample rate at 30Hz 
and biometric information input into the device prior to wearing.  
The device was worn by the subject on a belt located on the right side of their waist at the front to 
monitor step count over a period of 7 days. This monitor is a triaxial accelerometer measuring 
movement in the vertical, horizontal and perpendicular axis.  
 For the purposes of this study, average step count for each subject per day, was calculated by 
exporting the data using ActiLife 5.7 Data analysis software (ActiGraph) in 60 second EPOCs.  
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DynaPort  MoveMonitor  (McRoberts) 
This was worn by the subject on a belt located in the middle of their lower back, again after 
programming according to manufacturer’s guidelines and using individual anthropometric details. 
Automated analysis of data recorded by the triaxial accelerometer was performed by McRoberts 
after the device data were collected.  I then calculated the average time the subject spent walking, 
standing and in activity for each day in minutes.   
Physical activity data from the patients in chapter 5 of this thesis formed part of the background 
patient characteristics.  Analysis of physical activity data in this thesis included data obtained from 
both monitors, i.e. step count, and time spent walking, standing and in activity for all subjects.  
These parameters were chosen for the purpose of the study, as they are comparable to those used 
in other published studies of COPD patients and represent measures applicable to daily life.   
 
2.1.6 Pulmonary function tests 
 
Spirometry was assessed in the morning according to ERS-ATS guidelines post bronchodilators.  
Static lung volumes were assessed using a body-box (whole body plethysmography) and single 
breath transfer factor for carbon dioxide measured. Healthy volunteers had hand-held spirometric 
measurements only which I performed. 
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2.1.7 Assessment of breathlessness  
 
Subjects scored their level of breathlessness using Modified MRC (mMRC) Dyspnoea score. 
Grade          Description of Breathlessness 
0 I only get breathless with strenuous exercise. 
1 I get short of breath when hurrying on level ground or walking up a slight hill. 
2 
On level ground, I walk slower than people of the same age because of breathlessness, or have to stop 
for breath when walking at my own pace. 
3 I stop for breath after walking about 100 yards or after a few minutes on level ground. 
4 I am too breathless to leave the house or I am breathless when dressing. 
 
2.1.8 Exercise testing 
 
Six minute walk test 
Each subject performed a six minute walk test (6MW) according to the ATS guidelines (American 
Thoracic Society, 2002) in a standardised manner with standard encouragement on a 30-metre level 
course.   The Borg CR10 scale, a category scale with ratio properties from 0-10, (Borg 1982) was used 
to record level of breathlessness and leg fatigue at the start and end of the test.  In addition heart 
rate, blood pressure and oxygen saturation were recorded.  The distance achieved over six minutes 
was recorded and if a patient stopped, the need for stopping and the reason for doing so was also 
noted.  
 
Cycle Ergometry 
 An incremental exercise test was conducted to reach and assess the peak exercise tolerance of the 
subjects.  Subjects were exercised on a magnetically braked cycle ergometer breathing through a 
mouthpiece with a nose clip attached. Metabolic data were measured using an Oxycon device, 
Jaeger Systems, Germany, on a breath by breath basis. Data recorded during exercise were averaged 
for 8 breaths (i.e. breath 1-8, 2-9, 3-10 etc). The system was calibrated for volume and gas analysis 
prior to each test and adjustments made for humidity and room temperature. Healthy controls were 
exercised for 10 minutes on a weekly basis.  
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The incremental cycle protocol started with 2 minutes of baseline resting measurements, followed 
by 2 minutes of unloaded cycling.  Workload was increased at a rate of 10 Watts per minute for 
COPD patients and 20 Watts per minute for the healthy controls. Unloaded cycling oxygen uptake 
(VO2), peak work rate, peak VO2 and peak carbon dioxide output (VCO2), peak heart rate, peak 
ventilation (VE) were measured.  Peak values were those obtained in the last 30 seconds of the 
incremental test.  Oxygen saturations and ECG monitoring were performed for the duration of the 
test, blood pressure was measure before and immediately after the test. All subjects also had 
capillary blood gas tensions measured before and immediately after exercise and Borg’s scale of 
breathlessness and Borg’s rating of perceived exertion were recorded before and throughout the 
test every 2 minutes.  
During the test, verbal encouragement was given so that the subject reached their maximum 
performance.  Subjects were asked to maintain a cadence of 60-70 revolutions per minute. A digital 
cadence meter was visible throughout the test. The test was stopped by patient’s symptoms (for 
example leg discomfort or breathlessness) or by me (the investigator) if there was any concern. The 
reason for cessation of exercise was recorded.  
 
2.1.9 Quadriceps muscle biopsy using microbiopsy technique 
 
Percutaneous core needle biopsies of the vastus lateralis were performed aseptically under local 
anaesthesia using a microbiopsy technique (Hayot, Michaud et al. 2005) using the BARD® 
MAGNUM® Biopsy system.  This is a spring-loaded, re-useable tissue biopsy device which is used in 
conjunction with disposable MAGNUM® Biopsy needles.   
In chapter 5, muscle sampling was performed in the right leg after contraindications were excluded 
and consent obtained.  All subjects had fasted overnight. The subject was positioned on the couch 
with their head at 45° and both legs flat.  Muscle bulk was palpated to identify optimum sampling 
site of vastus lateralis.   
Firstly the area was cleaned and a sterile field created.  5-10mls 2% lignocaine were infiltrated into 
the area.  A small, 1cm, stab incision was made in the skin with a scalpel, in a vertical direction 
perpendicular to the line of vastus muscle.  The biopsy needle was loaded into the handheld device 
and then advanced through the incision under sufficient pressure as to feel the fascia outside the 
muscle at the tip of the needle, again in a downward direction.  The instrument was set to a depth of 
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15mm and up to five core biopsies were obtained, depending on amount of tissue obtained and 
patient tolerance.  
Muscle biopsies were performed before and one hour after incremental exercise testing in the same 
leg but through different incisions, approximately 3-5 cm apart to avoid any influence on the studied 
molecular pathways. There has been previous evidence to suggest that although muscle signalling is 
not elicited when repeated muscle biopsies are taken through a single skin incision, IL-6 mRNA and 
STAT3 phosphorylation increase in injured muscle (Guerra, Gomez-Cabrera et al. 2011).  
After biopsies were taken, the skin was closed with steri-strips and pressure bandaging was applied. 
The subject was then observed for a short while to check for immediate complications.  
Muscle samples obtained were divided.  One piece was placed on top of OCT on a cork disc. This was 
then placed in cooled isopentane until the OCT changed colour from clear to white (indicating it was 
frozen) and then put into a cryovial before freezing in liquid nitrogen.  The remainder of the muscle 
was frozen directly in liquid nitrogen in cryovials and then later transferred to -80°C for storage until 
analysis.  
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2.2 Molecular Methods   
 
2.2.1 Plasma microRNA quantification 
 
Pre-analytical considerations for plasma analysis 
Very few studies have looked at analytical variables when measuring circulating miRNA levels.  Due 
to the relatively recent discovery of miRNA and the analysis of circulating levels, the influence of 
certain factors remain undetermined; for example which type of blood sample to use and the 
collection method, stability over time, time of taking sample and the effect of eating or fasting (Kroh, 
Parkin et al. 2010).   
 
Choice of blood sample for microRNA analysis 
MiRNA can be isolated and measured from serum, plasma, whole blood or white blood cells. Plasma 
is the cell-free supernatant after blood has been collected in the presence of an anticoagulant and 
serum is the supernatant that has been collected in the absence of an anticoagulant and when blood 
has been allowed to clot. Levels of miRNA between serum and plasma have been shown to correlate 
by some (Mitchell, Parkin et al. 2008), but not by all (Heegaard, Schetter et al. 2012). Likewise, 
miRNA levels have been found by some to be higher in plasma when compared to serum, but the 
opposite has been reported (Wang, Yuan et al. 2012).  All samples analysed in this thesis are plasma. 
 
Plasma Sample collection 
For chapters 3, 5 and 6 blood samples obtained from those participating were collected in EDTA 
(anticoagulant) storage tubes. Blood collected by the collaborators for chapter 4 was in lithium 
heparin tubes.  
For EDTA collected blood, the blood was centrifuged immediately for 10 mins at 4° C at 2000g 
(Eppendorf centrifuge 5804 R, Epppendorf USA) and the supernatant then pipetted into eppendorf 
tubes, avoiding the buffy coat interface. The supernatant was centrifuged again at the same settings 
and the plasma supernatant removed and transferred to a cryovial for storage. Samples were stored 
at -80°C (ThermoFisher Revco Elite ULT1386-5-W, Thermoelectron, UK) prior to analysis.  
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Storage of sample prior to testing 
All plasma samples tested had been stored at -80°C prior to use.  None of the samples had been 
previously de-frosted, to eliminate any effect of freeze thawing on sample analysis.  Although some 
studies have shown that freeze thaw cycles have a minimal effect on miRNA analysis (Mitchell, 
Parkin et al. 2008) and therefore results are not affected by this process.  
 
RNA extraction and purification 
The method followed was adapted from Kroch et al (Kroh, Parkin et al.) and all samples were 
defrosted on ice to room temperature. 
4ml of Qiazol Lysis reagent solution (Qiagen) was added to 400µl of thawed plasma sample, vortexed 
and left to stand for 5 minutes.  A stock of synthetic C. elegans miRNA, (concentration 5 fmol/µL) 
was prepared to use as a spiked-in exogenous control; sequence of Cel-miR-39, 5’-
UCACCGGGUGUAAAUCAGCUUG-3’; (Invitrogen).   5µl of this was added to the denatured plasma 
sample and vortexed.  
800 µl of molecular grade chloroform were added to the sample, vortexed for 30 seconds and 
centrifuged for 25 minutes at 4000rpm at 4°C.  The aqueous phase for each sample was then 
transferred to a new collecting tube and RNA was isolated using the miRNeasy Mini RNA isolation kit 
according to the manufacturer’s protocol (Qiagen, Inc).   3 mls of ethanol was then added to the 
sample and mixed by pipetting, 700 µL of this was then pipetted onto an RNeasy® Mini column in a 2 
ml collection tube. The column was centrifuged at >8000g for 15 s at room temperature and the 
flow- through discarded. This step was repeated until the entire sample had passed through the 
column. 700 µL of Buffer RWT (supplied with kit) was put on to the column and centrifuged for 15s 
at 8,000g, the flow through again discarded.  500 µL of Buffer RPE was then added to the column 
and centrifuged at 8,000g for 15s and flow through discarded. This step was further repeated but 
the samples were centrifuged for 2 minutes. The RNeasy® Mini column was transferred to a new 
tube and centrifuged at full speed in a benchtop microcentrifuge for 1 minute.  Finally, the RNeasy® 
Mini column was transferred to a collection tube and RNA samples were eluted from the columns in 
50µl RNAse free water and stored at -80°C.   
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2.2.2 SYBR® Green Dye-Based Gene Expression Detection 
 
SYBR is a fluorescent double stranded DNA binding dye which increases in amount during cycles of 
denaturation and polymerisation where primers anneal and PCR product was generated.  
Fluorescence is used to detect the threshold cycle (Ct) during qPCR reaction when the level of 
fluorescence gives signal over the background and is in the linear portion of the amplified curve. The 
fluorescence detected correlates with the amount of DNA present in the sample.   
 
MicroRNA cDNA synthesis/ Reverse Transcription 
For microRNA cDNA synthesis and poly (A) tailing from RNA, an NCode™ VILO™ miRNA cDNA 
Synthesis kit was used according to the manufacturer’s guidelines.  11µl of RNA was pipetted into 
one well on a 96 well plate, in which the cDNA was later stored.  RNA was heated to 65°C for 5 
minutes, and then placed on ice for 2 minutes.  cDNA master mix was prepared  (each reaction 
contained  4µl of 5X reaction, 2µl of 10X SuperScript enzyme mix and 3µl of DPEC water).  9µl of this 
master mix was then added to the heated RNA.  The reaction was then incubated at 37°C for one 
hour and terminated by heating to 95°C for 5 minutes. 80µl of sterile water was then added to give a 
total RT product volume of 100µl of cDNA.  cDNA was stored at -20°C.   
 
Polymerase chain Reaction (PCR)  
50µl PCR reactions were performed to optimise annealing temperatures and validate custom made 
miRNA primers prior to quantitative PCR.  Each reaction contained 25µl Express Sybr® Green 
JumpStart™ Taq Ready Mix (Sigma) detection reagent, 1µl of 10µM universal qPCR Primer, 20µl 
sterile water, 1µl 10µM miRNA forward primer and 3µl cDNA. 
The PCR amplification programme used  95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds, 
60°C for 1 minute, 72°C for 1 minute, the reaction was terminated at 72°C for 10 minutes.  Different 
annealing temperatures were tested.  
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Forward miRNA gene primer sequences used (Invitrogen):  
miRNA- specific forward primer Primer sequence 5’ to 3’  
C. elegans- miR 39 TCA CCG GGT GTA AAT CAG CTT G 
miR-1 CCG GTG GAA TGT AAA GAA GTA TGT  AT 
miR-499 GGC TTA AGA CTTGCA GTG ATG TTT 
miR- 133 UUU GGU CCC CUU CAA CCA GCU G 
miR- 206 UGG AAU GUA AGG AAG UGU GUG G 
miR-181 ATT CAA CGC TGT CGG TGA GT 
miR-16 TAG CAG CAC GTA AAT ATT GGC G 
miR-122 TGG AGT GTG ACA ATG GTG TTT 
 
PCR products were separated by electrophoresis through a 2% agarose gel and visualised with 
ethidium bromide to confirm the size of the product. A negative control was tested for each 
reaction.  
 
Quantitative real-time PCR (qPCR) 
For the first study in chapter 3, Express Sybr® GreenER™ miRNA qRT-PCR kit was used according to 
the manufacturer’s guidelines (Invitrogen).  Each reaction contained 10 µl Express Sybr® GreenER™ 
qPCR SuperMix with Premixed ROX, 0.4µl forward miR primer 10µM, 0.4µl universal reverse qPCR 
primer 10µM, 6.2µl sterile water and 3µl cDNA.   
The qPCR reactions were run on the 7500 Fast Real-Time PCR System (Applied Biosystems, UK.) with 
the following cycle program: 50 °C for 2 minutes, 95 °C for 10 minutes, then 40-50 cycles of 95 °C for 
15 seconds, 60°C for 60 seconds. A dissociation curve/ melt curve stage was run with the first 
reaction.  Each sample was tested in duplicate on 96 well plates sealed with ABI MicroAmpTM optimal 
adhesive film, an equal number of controls subjects were on each plate to avoid the introduction of 
any plate bias, alongside a negative control (water).  
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Express Sybr® GreenER™ miRNA qRT-PCR kit was discontinued by the manufacturer and therefore 
the reagents in this thesis were changed to Quanifast SYBR Green (Qiagen) for chapter 4 and 5.   
Each reaction consisted of 10 µl Quanifast SYBR Green (Qiagen), 0.4µl forward miR primer at 10µM, 
0.4µl universal reverse qPCR primer at 10µM, 6.2µl sterile water and 3µl cDNA. The qPCR reactions 
were run on the 7500 Fast Real-Time PCR System (Applied Biosystems, UK.) with the following cycle 
program:  95 °C for 5 minutes, 2-step cycling: denaturation 95°C for 10s and  combined annealing/ 
extension  at 60 °C for 30 s for 40 cycles.  
 
Dilution series and generation of standard curves for plasma miRNA 
PCR products were successively diluted to generate a dilution series per miR tested.  qPCR reactions 
(as above) were performed on these dilutions to generate standard curves.  8 dilutions were 
generated to give Ct values to cover the range of the tested samples.  Standard curves for the miRs 
tested were used to align the results across plates if needed.  
 
Relative quantification of plasma miRNA 
Samples were tested in duplicate and analysis of data was performed using the comparative cycle 
threshold (Ct) method and normalised using the delta delta Ct method (∆∆ Ct)(Livak and Schmittgen 
2001).  A threshold was set during the exponential phase of amplification, and baseline/ background 
signal subtracted which was standardised across the plate(s).  Ct values for the genes of interest 
were then obtained therefore during the exponential phase of amplification.  Average Ct values per 
sample were normalised to an exogenous spiked in control, C. elegans 39.   
 
Adjusting results to standard curve plate 
Plates used in these experiments can only accommodate 96 samples. Therefore if multiple plates 
were tested due to large sample sizes, plate alignment was performed using the following method.  
A standard curve was generated from dilution series for each miR tested.  By running the same 
dilution series as the external standard curve on each plate per miR tested. The standard curve on 
the testing plate and external standard curve were compared, and degree of agreement determined 
using the linear equation y= mx+c.  Due to the large sample sizes in some of the studies, plate 
alignment was performed when multiple plates were run per gene. 
79 
 
For each miR tested, the Ct values from testing the same sample twice were averaged per subject. If 
replicates were poor, samples were excluded from the results.   Average Ct results for replicates (per 
subject tested) on each plate, were then aligned as above. The aligned value was then normalised 
using the corresponding C. elegans 39 result per sample tested.     
 
2.2.3 TaqMan ® probe based qPCR analysis  
 
Chapter 6 in this thesis used Taqman® based analysis.  RNA extraction of the samples was as 
described above.  
This method relies upon the presence of a specifically designed fluorogenic probe which is specific to 
a target gene to detect the target as it accumulates during PCR.   Primer binding and extension of 
DNA strand leads to cleavage of the dye from the probe and measurable fluorescence.  
 
SYBR- based RT leads to the addition of a poly-A tail which enables cDNA synthesis of all miRNAs 
within a single RT reaction. In order to be able to test for multiple miRs in array cards, megaplex RT 
primers were used which are commercially available for Taqman® assays. 
 
RT of Plasma RNA samples using Megaplex TM RT primers 
RNA isolated from plasma was reverse transcribed to cDNA using MultiScribe™ Reverse 
Transcriptase with Megaplex™ RT Primers (human pools A and B, Version 3.0, Applied Biosystems) 
according to the manufacturer’s instructions.   Primer human pools A and B Megaplex™ RT Primers 
are highly multiplexed RT primers designed to convert up to 377 miRNA each and 3 endogenous 
small RNA (to serve as controls) to cDNA prior to real-time analysis, and are required to run the 
TaqMan® Array MicroRNA Card.  
Each RT reaction consisted of 3µl RNA and 4.5µl reaction mix. The reaction mix per sample consisted 
of 0.8 µl Megaplex™ RT Primers (10x), 0.2µl dNTPs (100 mM), 1.5µl MultiScribe™ Reverse 
Transcriptase (50 U/μL), 0.8µl 10✕ RT Buffer, 0.9 µl MgCl2 (25 mM), 0.1µl RNase Inhibitor (20 U/μL),  
and 0.2µl  Nuclease-free water.  The RNA and reaction mix were first incubated on ice for 5 minutes 
and then cDNA was synthesised by 40 cycles of 16°C for 2 min, 42°C for one minute, 50°C for 1 
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second.  Heat deactivation at 85°C for 5 minutes terminated the reaction. cDNA was stored at -80°C 
until used.  
 
Pre-amplification of Megaplex™ RT products  
Pre-amplification of Megaplex™ RT products was performed using Megaplex™ PreAmp Primers 
(Applied Biosystems) to enhance assay sensitivity of detection. 2.5 μl of RT product was added to 
22.5 μl of Pre-amp reaction mix.  Per reaction this consisted of 12.5 μl TaqMan® PreAmp Master Mix 
(2x), 2.5 μl Megaplex™ PreAmp Primers (10x) and 7.5 μl Nuclease-free water. The RNA and reaction 
mix was incubated on ice for 5 minutes and then amplification was achieved by the following 
thermal cycling parameters: Hold at 95 °C for 10 minutes, hold at 55°C for 2 minutes, hold at 72°C for 
2 minutes, followed by 12 cycles of 95 °C for 15 sec and 60 °C for 4 min.  The reaction was 
terminated by heating to 99.9 °C for 10 min and pre-amplified cDNA diluted by addition of 75μl of 
0.1× TE buffer pH 8.0 (Qiagen) and stored at -80°C. 
 
TaqMan® Array MicroRNA Cards Real- Time PCR Reactions 
The DNA polymerase from the TaqMan® Universal PCR Master Mix amplifies the preamplified target 
cDNA using sequence specific primers and probe on the TaqMan® MicroRNA Array.  The presence of 
the target is detected in real time through cleavage of the TaqMan probe by the polymerase 5’ – 3- 
exonuclease activity. 
The amplified cDNAs were quantified using Human TaqMan® Array MicroRNA Cards (Cards A and B, 
V.3.0 Applied Biosystems). Each card reaction mix contained 450 µl of TaqMan® Universal PCR 
Master Mix, No AmpErase® UNG, 2x, 9 µl of diluted PreAmplified product and 441 µl  Nuclease-free 
water.  The mixture was inverted 6 times and centrifuged briefly then 100 µl of the PCR Master Mix 
was dispensed into each port of the array card. The cards were then centrifuged and sealed 
according to manufacturer’s instructions prior to loading on an ABI 7900HT thermocycler. The 
7900HT System combined with an automation accessory meant a maximum of 24 TaqMan® arrays 
were loaded onto the automation accessory at a time.  Array cards were run under the 384 well 
TaqMan® Low Density Array default thermal-cycling conditions defined by SDS 2.4 software.  
For analysis, all cards were calibrated to a single control sample with one detection threshold set 
across all samples and assays using RQ manager software. Ct values were then exported and using 
the ΔΔ Ct method, results were normalized to the geometric mean of U6 and RNU48 for each 
sample.  Data were standardised by log transformation. 
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Quantification of single microRNAs using TaqMan® probes 
For the quantification of individual microRNAs, custom designed primers and probes were 
purchased for each test gene from Applied Biosystems. Amplification was carried out on cDNA 
preamplified as described above which was diluted further by 1 in 5 with water prior to qPCR.  
Experiments were run according to the manufacturer’s instructions.  Per reaction Master mix 
consisted of 5 μl of TaqMan Universal Master Mix II with UNG, 2.5 μl of sterile water, 0.5 μl of 
custom designed x20 primer, and 2 μl of Pre-amp cDNA. Each reaction was performed in duplicate 
and the average Ct value normalised to the corresponding geometric mean of U6 and RNU48 using 
the ΔΔ Ct method. 
 
2.2.4 Plasma IGF-2 ELISA 
IGF-2 (Human Insulin-like Growth Factor-II) protein was quantified in plasma samples taken from a 
larger number of COPD patients (n= 36) and controls (n= 11) in chapter 6, to include those 
individuals included in the screen study. Samples were tested using an ELISA kit from Mediagnost kit 
and run according to the Manufacturer’s instructions.  
 
2.2.5 Quadriceps muscle analysis  
 
RNA extraction from biopsies 
The Precelleys® lysing kit was used to homogenise muscle samples prior to RNA extraction.   Samples 
obtained from each individual were weighed prior to homogenisation to check RNA extraction 
efficiency, weights varied between 0.02g – 0.06g.  Using the Soft tissue homogenising kit, CK14 from 
the manufacture, the samples were transferred using pre-cooled instrument into 2ml standard tube 
containing 1.4mm ceramic (zirconium oxide) beads and 500μl of TRIzol Reagant (Life Techonolgies, 
Invitrogen).  
Samples were then transferred on ice and loaded into the holders of a Precelleys® 24 technology (8-
figure multi-directional motion) centrifuge.  The 2 ml tubes were locked in place and the programme 
set according to manufacturer’s guidelines: 2 cycles consisting of 5500 x rpm for 10 seconds and 5 
second pause, with 2 minutes between each cycle.   
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The supernatant containing the TRizol and the homogenised muscle was then transferred into a new 
collecting eppendorf tube and further vortexed. 100μl of cholorform was then added and again 
vortexed well.  After being left at room temperature for 2 minutes at room temperature, the 
samples in their containing eppendorf were centrifuged for 15 minutes at 4 °C at 10, 000 rpm in a 
benchtop centrifuge.  
A clear separation of phases was seen and the aqueous upper phase was transferred into a new 
microcentrifuge tube, without disturbing the protein interface.  To precipitate the RNA, 250μl of 
cooled isopropyl was added. The sample was centrifuged again at 4°C for 10 minutes at 10,000rpm. 
Following this, a pellet was visible at the bottom of the tube.  The supernatant was removed without 
disturbing the pellet and washed twice with 500μl 75% ethanol. The pellet was suspended in 30μl of 
RNAase free water and stored at -80°C until used.  
Extracted RNA quantification and quality was determined using a Nandrop Spectrophotometer 
(Nanodrop ND1000, Wilmington, USA) and purity assessed by reviewing the 260:280 absorbance 
ratio. A ratio of 2 is taken to represent pure RNA with no contamination.  
 
Muscle mRNA quantification 
 
Reverse Transcription for mRNA analysis  
This was performed using Omniscript RT kit (Qiagen). Total RNA was diluted to a concentration of 
150ng in 11 µl of water. This was then heated to 65°c for 5 minutes. The heated RNA was then 
placed on ice for 2 minutes after which 9µl of reaction mix was added. The reaction mix contained 
2µl of x10 buffer, 2µl of dNTPs at 5mM, 0.5µl random hexamer primers, 0.5µl RNAse inhibitor, 1µl 
(0.1M) DTT, 1µl Omniscript reverse transcriptase (Qiagen) and 2µl of sterile water. The reaction 
mixture was incubated for 2 hours at 42°C, and then diluted into 200µl volume (x10) with water and 
stored at -20°C until used.  
 
SYBR®  qPCR analysis for mRNA 
Primer pairs used in each qPCR reaction are in the table below. As with microRNA analysis, each pair 
was validated prior to use by visualising and checking size of the amplification product and running a 
melt curve during qPCR reaction.  
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Each sample was tested in duplicate in 96 well plates sealed with ABI MicroAmp TM optimal adhesive 
film.  3µl of cDNA was added to 10 µl Quanifast SYBR Green (Qiagen), 2µl of the forward and reverse 
primer mix (2pmol/µl), and 5µl sterile water to give a reaction volume of 20µl. 
The qPCR reactions were run on the 7500 Fast Real-Time PCR System (Applied Biosystems, UK.)  with 
the following cycle program:  95°C for 5 minutes, 2-step cycling: denaturation 95°C for 10 s and  
combined annealing/ extension  at 60 °C for 30 s for 40 cycles. Analysis of data was again performed 
using the comparative cycle threshold method and normalised using the delta delta Ct method (∆∆ 
Ct)(Livak and Schmittgen 2001) using RPLPO.  
 
Muscle microRNA quantification  
 
SYBR ®qPCR analysis  
MicroRNA cDNA synthesis/ reverse transcription was performed (as above) using an RNA 
concentration of 150ng in 11 µl of water in all reactions.  cDNA was stored at -20°C for  subsequent 
experiments. For microRNA quantification the SYBR based-qPCR analysis method was followed, 
small 5S ribosomal RNA was used as the normalising gene. This has been used in previous work 
analysing microRNA expression in tissues, including that from our group (Lewis, Riddoch-Contreras 
et al. 2012). 
 
Primer sequences used in muscle biopsy analysis: 
Gene Forward primer sequence Reverse primer sequence 
 
RPLPO 5’ CTACAACCCTGAAGTGCTTGATATC 3’ 5’ GCAGACAGACACTGGCAACAT 3’ 
5S RNA 5’ATCTCGGAAGCTAAGCA 3’ 5’ GGTCTCCCATCCAAGTACT 
MHC I 5’CCCTGGAGACTTTGTCTCATTAGG 3’ 5’ AGCTGATGAC CAACTTGCGC 3’ 
 
MHC IIa 5’TCACTTATGACTT TTGTGTGAACCT 3’ 5’CAATCTACCTAA  ATTCCGCAAGC-3’ 
 
MHC IIx 5’ TGACCTGGGAC TCAGCAATG 3’ 5’ GGAGGAACAAT CCAACGTCAA 3’ 
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3 .  Increased skeletal muscle-specific microRNA in the blood of COPD 
patients  
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3.1 Introduction 
 
Published data suggest that there is considerable heterogeneity in quadriceps muscle fibre size and 
fibre type proportion in patients with COPD (Natanek, Gosker et al. 2013).  Therefore, any potential 
therapeutic agents employed to increase muscle mass or reverse muscle fibre shift (either used on a 
stand-alone basis or to augment the effects of pulmonary rehabilitation) would need to function 
notwithstanding this heterogeneity. Specifically, not all patients would necessarily need drugs to 
target both of these aspects of skeletal muscle dysfunction.  
A further consideration is that drugs might be developed either to improve muscle mass or to 
reverse fibre shift alone. Assuming that such drugs were to become available, it would be necessary 
to investigate potential biomarkers of skeletal muscle composition to ensure that COPD patients 
received appropriate treatment.   
The control of muscle mass and phenotype is complex, involving numerous transcription factors as 
well as the factors that they regulate and that control them.  Previous studies have found that 
activity of the serum response factor pathway is suppressed in the quadriceps of COPD patients 
(Lewis, Riddoch-Contreras et al. 2012) and amongst the targets of this pathway are several muscle-
specific microRNA.   
In relation to muscle, much attention has focussed on the muscle-specific miRNA, miR-1, miR-499, 
miR-206 and miR-133a (known as MyomiRs) and miR-181. Quadriceps expression of miR-1 was 
suppressed 2.5 times in patients with COPD when compared to healthy controls and expression of 
both miR-1 and miR-499 were positively associated with muscle mass in those patients (Lewis, 
Riddoch-Contreras et al. 2012).  
Circulating levels of muscle-specific miRNA in the literature have to date principally been 
investigated for their biomarker potential in the context of cardiac ischemia and primary muscle 
disorders. As discussed in more detail in the introduction chapter, in patients with cardiac ischaemia, 
levels of miR-1, miR-133 and miR-499 have been found to be increased in the circulation after the 
initial ischemic event and return to baseline 5 days after treatment (D'Alessandra, Devanna et al. 
2010). In patients with progressive muscle wasting disorders, such as Duchenne muscular dystrophy 
(DMD), significantly higher levels of circulating miR-1, miR-133 and miR-206 have also been found 
and the respective levels have been shown to correlate with clinical severity (Cacchiarelli, Legnini et 
al. 2011). Although cardiac ischaemia and DMD are different pathologies, in both conditions the 
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higher levels of circulating muscle-specific miRNA were found to be as a result of muscle damage 
and increased muscle turnover respectively. The data from these studies would suggest that if 
skeletal muscle fibre composition or mass is significantly affected by a different process or 
pathology, such as that which occurs in the muscle dysfunction associated with COPD, then this too 
would be detectable in the circulation by measuring miRNA levels (subject to the levels being 
sufficient so as to be detectable).  
For these reasons, I designed this study to investigate the biomarker potential of muscle-specific 
miRNA in the circulation of COPD patients.  The first aim of the study was to investigate whether it 
was possible to measure muscle-specific miRNA in the plasma of COPD patients. The second aim was 
to investigate whether levels of miRNA would be different in the plasma of the COPD patients as a 
result of quadriceps muscle dysfunction when compared to a group of healthy controls. Assuming 
that there were differences in the levels of miRNAs between COPD patients and healthy controls, it 
was anticipated that this would enable potential biomarkers of skeletal muscle dysfunction in COPD 
to be identified.  It was further hoped that the results from this study would add to the 
understanding of mechanisms leading to skeletal muscle dysfunction and fibre type abnormalities in 
COPD.  
 
3.1.2 Hypotheses 
 
The hypotheses of the study are: 
1. Levels of muscle-specific miRNA will be elevated in the plasma of the COPD patients when 
compared to those of aged-matched healthy controls. 
This hypothesis was tested by quantifying muscle-specific miRNA in plasma samples taken from 
COPD patients and comparing them to those measured in aged-matched healthy controls.  Plasma 
levels of miRNA were quantified using RT-qPCR.  
2.  Levels of muscle-specific miRNA will relate to quadriceps biopsy findings (which would include 
fibre type cross-sectional area and fibre type proportions). 
The quantified miRNA levels were compared to quadriceps biopsy findings from the same patients 
(data collected by Dr Natanek). Correlations were made between plasma miRNA levels and muscle 
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data and it was investigated as to whether miRNA level(s) could predict muscle fibre phenotype in 
COPD patients. This was undertaken by performing a receiver operator curve analysis.  
 
3.2 Methods 
3.2.1 Patient recruitment 
 
Patients were included as outlined in the methods chapter. In summary, patients with COPD 
according to the Global Initiative in Obstructive Lung Disease guidelines 2004 (36 female and 67 
male) were enrolled from clinics at the Royal Brompton Hospital (GOLD I or II n= 34, III = 38, IV= 31) 
and 25 healthy control patients were recruited for comparison purposes. The plasma samples 
analysed in this study were from a large cohort of patients that were recruited, physiologically 
tested and from which biological specimens were taken by Dr. A. Natanek. Dr. Natanek analysed the 
quadriceps biopsies for muscle fibre type and composition (reported in (Natanek, Gosker et al. 
2013)); the results of which are included in the analysis of this study. I analysed the plasma sample 
and interpreted the results.  
 
3.2.2 Molecular methods 
 
Details on plasma sample collection, RNA extraction, miRNA quantification can be found in the 
methods chapter.  
To summarise, plasma samples were defrosted and then the RNA extracted and purified. This was 
achieved using a commercially available kit which uses a column-based extraction method. Once the 
RNA was extracted from the plasma, reverse transcription was performed on the RNA to generate 
miRNA cDNA. The cDNA was then used in quantitative PCR experiments to quantify the muscle-
specific miRNA of interest (miR-1, miR-133, miR-206, miR-181, miR-499).  
Analysis of qPCR data was performed using the delta delta Ct method and normalised to a spiked in 
exogenous control.  
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The relative quantity of miRNA was then log-transformed for analysis. This was done to stabilise the 
variance in the dataset (as variance increases with Ct value) and to give equal weighting to samples 
with low levels.  
 
3.2.3 Statistical analysis 
 
This is the first study in the literature to measure circulating miRNA in COPD patients. Therefore, as 
there were no previous results available, it was not possible a priori to perform a power calculation 
to determine the minimal sample size required to detect either a significant difference in the levels 
of circulating muscle-specific miRNA from controls or the association of the miRNAs with muscle 
parameters. All available samples from the cohort were tested. This study should therefore be 
considered a pilot study.  
Data is this chapter was analysed and figures constructed using Prism 5 (GraphPad Software inc., San 
Diego, CA, USA) or Aabel (Gigawiz). 
Differences in miRNA levels between patients and controls were calculated by Student’s or un-
paired t-test for normally distributed data and by Mann-Whitney U test for data that did not fit a 
normal distribution.  These results were not corrected for multiple comparisons.  
Correlation analyses between miRNA levels and physiological data or quadriceps data were 
performed assuming linearity using Pearson correlation coefficient. To interpret the correlation data 
I have taken p<0.05 as an indicator of association to allow investigation of the likely relationships 
within the data. There was no correction made for multiple comparisons. 
Comparison of single variables across the GOLD stages was performed by one-way analysis of 
variance (ANOVA) and the analysis was corrected for multiple testing using a Bonferroni-Dunn 
Correction. 
To explore whether plasma muscle specific miRNA levels were able to predict type I quadriceps shift, 
a ROC analysis was performed and area under the curve (AUC) values calculated.  
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The results from this chapter have been previously published in Donaldson, A. Natanek, S. A. Lewis, 
A. Man, W. D. Hopkinson, N. S. Polkey, M. I. and Kemp, P. R. 2013, Increased skeletal muscle-specific 
microRNA in the blood of patients with COPD, Thorax (Donaldson, Natanek et al. 2013).  
 
3.3 Results 
 
3.3.1 Patient physiological data and quadriceps phenotype 
 
The physiological characteristics of the subjects are summarised in table 3.1. This data has been 
previously published by Natanek et al (Natanek, Gosker et al. 2013). Consistent with a diagnosis of 
COPD, the patients had impaired lung function marked by a reduction in FEV1 as % predicted, 
reduced gas transfer and reduced arterial blood oxygen tensions on air.  There was no difference in 
age, body mass index or arterial blood carbon dioxide tensions between the COPD patients and the 
controls. Mean fat-free mass index (FFMI) was not significantly different between the COPD patients 
and the controls, although trends toward lower values were noted for the COPD group.   
The COPD patients had a significantly reduced quadriceps force compared to controls, judged by 
maximal voluntary contraction force.  Exercise capacity, measured by a six-minute walk distance, 
was significantly reduced in the COPD patients. 
Quadriceps muscle fibre size and proportion data have been previously reported by Natanek et al 
(Natanek, Gosker et al. 2013). In that report, and of relevance to the current data, it was found that 
the COPD patients were noted to have a markedly reduced size of type IIx fibres (p= <0.0001), with 
numerically more type II fibres and a significant reduction in type I fibres.  For the present study, it 
was found that there was a reduction in MHC I mRNA (MYH7B) but an increase in MHC IIa (MYH2) 
and MHC IIx (MYH1) mRNA in the COPD patients when compared to the control subjects (table 3.1).   
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Condition Control COPD 
significance of 
difference, p value 
number 25 103  
M (f) 14 (11) 67 (36)  
Age 67 (8) 67 (8) 0.76 (T) 
Height (cm) 168 (8.9) 168  (8.6) 0.89 (T) 
Weight (Kg)* 69.1 (83.5, 62.0) 68.8 (80.6, 59.5) 0.34 (MW) 
BMI (kg/m
2
)* 24.8 (27.1, 24.0) 24.1 (27.0, 21.4) 0.13 (MW) 
FFMI (kg/m
2
)* 16.4 (19.8, 15.2) 15.7 (17.2, 14.5) 0.06 (MW) 
Smoking Pack year* 0 (9, 0) 45 (61, 34) < 0.001 (MW) 
Current smokers n=16 n=0  
FEV1 (% pred)* 110 (114, 101) 42 (57, 27) < 0.001 (MW) 
RV/TLC (%) 37(4.8) 57 (9.2) < 0.001 (T) 
TLCO (% pred) 91 (14.2) 43 (17.6) < 0.001 (T) 
PaCO2 (kPa) 5.28 (0.4) 5.14 (0.6) 0.34 (T) 
PaO2 (kPa) 11.0 (1.2) 9.31 (1.3) < 0.001 (T) 
6MWD (m) 614 (83) 394 (120) < 0.001 (T) 
SGRQ* 2 (8, 0) 54 (64, 43) < 0.001 (MW) 
Best MVC (kg) 35.8 (10.2) 29.5 (10.2) 0.01 (T) 
Best TwQ (kg)* 8.6 (11.4, 7.0) 7.6 (9.2, 6) 0.08 (MW) 
MVC/wt (kg/kg)* 0.49 (0.38, 0.57) 0.41 (0.37, 0.51) 0.01 (MW) 
MHCI mRNA (AU)* 32 (48, 20) 7.3 (14.5, 4.6) < 0.001 (MW) 
MHCIIa mRNA (AU)* 1.6 (2.3, 0.9) 2.5 (3.8, 1.5) 0.05 (MW) 
MHCIIx mRNA (AU)* 5.2 (8.1, 4.2) 11.4 (19.3,8.0) < 0.001 (MW) 
 
Table 3-1 Physiological characteristics and muscle mRNA results of the COPD patients and controls  
Values are mean ± SD for normally distributed data or median (75th, 25th percentile) for non-normally distributed data  in either COPD or 
healthy group (indicated by  * ).  p values were calculated by un-paired t test (normally distributed data, T), or the Mann–Whitney test 
(non-normally distributed data, MW) and are shown in bold when p<0.05. MHC mRNA was quantified determined by qPCR and normalised 
to the expression of RPLPO in the same sample.  See abbreviation list at start of thesis for abbreviations. Physiological data and sample 
collection by Dr. Natanek.  
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Further analysis of the characteristics found that when the COPD patients were divided into GOLD 
stages of disease severity the FFMI of the GOLD III and IV patients was lower than that of the GOLD 
stage II patients (p= 0.0011 and p= 0.0002 respectively). There was also a positive association 
between the FFMI of the COPD patients and lung function as measured by FEV1 % predicted (r= 0.42, 
p=<0.01).   
There were no significant differences in strength between the COPD patients when classified 
according to disease severity.  
There was however a significant difference in exercise ability as measured by a six-minute walk 
distance within the COPD patient group. The six-minute walk distance was significantly lower in the 
GOLD IV patients compared to the GOLD II patients, p=0.023, and when compared to the GOLD stage 
III patients, p=<0.0001.  
 
3.3.2 MiRNA levels in the plasma of the COPD patients compared to the control subjects 
 
Circulating levels of miR-1, miR-499, miR-206 and miR-133 were significantly increased in the plasma 
of patients with COPD compared to the levels in control subjects (table 3.2 and figure 3.1). MiR- 1 
and miR-499 showed the most significant increase in levels between the COPD patients and the 
control: miR-1 levels were 2.5 times higher in the COPD patients compared to the controls on 
analysis of non-logged data; and miR-499 was increased 1.5 fold.  There was no increase in levels of 
miR-181 (p=0.052).   
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 Subject group 
miR tested 
COPD  Control  COPD  Control  COPD  Control  COPD Control COPD  Control COPD  Control  COPD Control 
miR-1 miR-1 miR-499 miR-499 miR-133 miR-133  mir-206 mir-206 miR-181  miR-181 miR-16 miR-16  miR-122  miR-122 
25% Percentile  1.28 0.84 3.67 2.79 2.301 1.99 2.24 1.86 3.35 2.66 3.86 3.81 3.25 3.15 
Median  1.64 1.36 4.02 3.70 2.55 2.27 2.47 2.11 3.53 3.41 4.10 4.04 3.41 3.37 
75% Percentile  1.89 1.61 4.31 3.92 2.71 2.43 2.77 2.31 3.74 3.70 4.32 4.23 3.76 3.59 
Mean  1.61 1.27 4.04 3.60 2.57 2.31 2.55 2.20 3.52 3.25 4.01 3.96 3.5 3.38 
Std. Deviation  0.46 0.47 0.59 0.80 0.48 0.58 0.46 0.55 0.34 0.52 0.35 0.35 0.43 0.32 
Std. Error  0.05 0.10 0.06 0.17 0.05 0.12 0.05 0.11 0.03 0.11 0.04 0.08 0.05 0.07 
Passed 
normality test 
(alpha=0.05)?  
Yes  Yes  No  Yes  No  No  No  No  No  No  Yes  Yes  No  Yes  
 
 
Table 3-2 Summary of plasma miR levels in the COPD patients and the controls 
The numerical results for the experiments are summarised in the above table. This table shows the results for each miR analysed (i.e. miR-1, miR-499, miR-133, miR-206, miR-181 and for the non-muscle specific miR-
16 and miR-122) in the plasma samples for both the COPD patients and the control group.  The results are expressed as log normalised values for each miRNA and the median, 25th and 75th percentile, mean, 
standard deviation and standard error are given for each miRNA tested. As per the methods miRNA results were normalised to spiked in exogenous control C . elegans values. Each group result was tested for 
normality using the D’Agostino & Pearson omnibus normality test.  
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Figure 3-1 Muscle derived miRNAs were elevated in the plasma of patients with stable COPD 
The data are presented as log normalised levels with the notched boxes showing median and inter-quartile range (IQR), error bars at 10th 
and 90th percentile, outliers are also shown.  COPD GOLD stage I and II patients are represented by red filled circles, GOLD stage III patients 
are represented by green filled circles and IV patients are represented by grey filled circles. Controls are shown as blue filled circles. 
Statistical significance was calculated by un-paired t-test for miR-1 and Mann-Whitney as the non-parametric alternative for the other 
miRs, p values are shown. Numerical result values for each group are shown in table 3.2.    
 
 
There was no difference between COPD patients and controls in plasma levels of miR-16 and miR-
122, which was to be expected since both had been included as non-muscle specific miRNA controls 
(figure 3.2). MiR-16 has been used in other studies as a control miRNA (Kroh, Parkin et al. 2010) and 
miR-122 is a liver-specific miRNA that was chosen in this study to be used as a second non-muscle 
specific miRNA to serve as a control. There were also no differences in the spiked in exogenous 
control C. elegans 39 raw cycle threshold values in the COPD patients compared to the controls (p= 
0.308). Mean average (± SD) Ct value for the patients was 18.9 ± 2.1 and for the controls it was 19.4 
± 2.3.    
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Figure 3-2 Plasma levels of non muscle-specific miRNAs were not different between the COPD patients and the controls 
The data are presented as log normalised levels with the notched boxes showing median and IQR, error bars at 10th and 90th percentile, 
outliers are also shown.  COPD GOLD stage I and II patients are represented by red filled circles, GOLD stage III patients are represented by 
green filled circles and IV patients are represented by grey filled circles. Controls are shown as blue filled circles. Statistical significance was 
calculated by un-paired t-test for miR- 16 and Mann-Whitney as the non-parametric alternative for miR-122. Numerical result values for 
each group are shown in table 3.2.    
 
 
3.3.3 Plasma levels of muscle-specific miRNA and lung function  
 
Plasma levels of miR-1 did not associate with FEV1 as % predicted in the COPD patients (figure 3.3 a). 
Levels of miR-499, miR-206 and miR-133 were found to have a modest positive correlation with FEV1 
as % predicted within the COPD patients (miR-499 r=0.26, p=0.007, miR-206 r=0.26, p=0.008, miR-
133 r=0.24, p=0.018 figure 3.3.b, c and d). Similar to miR-1, levels of miR-181 and miR-122 did not 
correlate with FEV1 % predicted in the COPD patients.  
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Figure 3-3 Association of plasma miRNAs with lung function as measured by FEV1 % predicted 
In the figures COPD GOLD stage I and II patients are represented by red filled circles, GOLD stage III patients are represented by green 
filled circles and IV patients are represented by grey filled circles. Controls are shown as blue filled circles. 
(a) miR-1 levels did not associate with FEV1 % predicted in the COPD patients.  Levels of miR-499 (b) and miR-206 (c) were found to be 
highest in those with early stage COPD, i.e. GOLD stage I and II patients. If the controls were excluded from the analysis (not shown in the 
figure), just within the COPD patients, levels of miR-499 and miR-206 were found to have a modest positive correlation with FEV1 as % 
predicted (miR-499 r=0.26, p=0.007, miR-206 r=0.26, p=0.008). Levels of miR-133 were also found to correlated in the COPD patients only 
with FEV1 as % predicted (not shown in figure) r= 0.24, p=0.018. Levels of miR- 181, did not correlate with FEV1 as % predicted in the COPD 
patients (e). There was no association with the control miRNA, miR-122 (f) and lung function when measured as FEV1 % predicted.   
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When those miRNA levels that were found to be higher in COPD patients, as compared to the 
controls, were further analysed (according to GOLD stage of disease severity), plasma levels of miR-
499, miR-206 and miR-133 showed a distinct and similar pattern in which (although plasma levels 
were generally higher in the COPD patients compared to the controls), miR levels within the COPD 
patients were highest in the COPD patients with the most preserved lung function (figure 3.4 a and 
b).    
ANOVA analysis for miRNA levels between the groups according to the GOLD stages of COPD and the 
controls is shown in figure 3.4. Using an adjusted α=0.005 to account for multiple testing, it can be 
seen that miR-1 levels were higher in the GOLD stage III patients compared to the controls 
(p=0.0006) and higher in the GOLD stage IV patients compared to the controls, (p=0.0049). Plasma 
levels of miR-499 and -206, were higher in the GOLD stage II COPD patients compared to the 
controls (p=0.002 and p=0.0009 respectively). There were no differences across the groups in levels 
of the two control miRs, miR-16 and miR-122, and levels of miR-181 (figure 3.4b).  
 
 
Figure 3-4 a  Association of plasma miR-1, miR-499, miR-133 and miR-206 levels with GOLD stage of disease 
Figure 3.4 shows notched box and whisker plots depicting log normalised plasma miR levels in the COPD patients classified according to 
GOLD stage and compared to controls. Distribution of the data points is shown as are the confidence intervals 10th and 90th percentile and 
the outliers. Significant differences were determined by ANOVA using Bonferroni's Multiple Comparison Test. C= control, GI to GIV are 
GOLD stages I to IV. (** p<0.005 vs control, ANOVA adjusted α=0.005). COPD GOLD stage I and II patients are represented by red filled 
circles, GOLD stage III patients are represented by green filled circles and IV patients are represented by grey filled circles. Controls are 
shown as blue filled circles. Plasma levels of miR-1 were significantly elevated in the GOLD stage III and IV patients when compared to 
controls. Levels of both miR-499 and miR-206 were significantly elevated in the GOLD stage II patients when compared to controls, but not 
in the other GOLD stages of COPD patients.   
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Figure 3.4 b Association of plasma miR-16, miR-122 and miR-181 levels with GOLD stage of disease 
Figure 3.4 shows notched box and whisker plots depicting log normalised plasma miR levels in the COPD patients classified according to 
GOLD stage and compared to controls. Distribution of the data points is shown as are the confidence intervals 10th and 90th percentile and 
the outliers. Significant differences were determined by ANOVA using Bonferroni's Multiple Comparison Test. C= control, GI to GIV are 
GOLD stages I to IV. (** p<0.005 vs control, ANOVA adjusted α=0.005). COPD GOLD stage I and II patients are represented by red filled 
circles, GOLD stage III patients are represented by green filled circles and IV patients are represented by grey filled circles. Controls are 
shown as blue filled circles.   
 
3.3.4 Plasma levels of muscle-specific miRNA and muscle strength and mass  
 
Plasma levels of miR-1, fat-free mass and type I fibre cross-sectional area 
Within the COPD patient group there was a moderate correlation between FFMI and FEV1 (r=0.42, 
p<0.001, figure 3.5a) and a less statistically significant correlation between FEV1 and quadriceps 
strength as % predicted (r=0.21, p=0.037).  Plasma miRNA levels were therefore compared with FFMI 
and strength measured by quadriceps maximum voluntary contraction.   
Plasma miR-1 levels were found to negatively correlate with FFMI when the COPD patients were 
analysed either with or without the controls (r= -0.21, p= 0.036 and r= -0.2, p= 0.03 respectively, 
figure 3.5). This correlation was however not robust enough to distinguish those COPD patients with 
a normal FFMI from those with a low FFMI (figure. 3.6).  To determine whether smoking had an 
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effect on this correlation, analysis of the data including just the ex-smoking COPD patients (therefore 
excluding current smokers) found that the FFMI of the COPD patients was more strongly associated 
with plasma miR-1 levels (r=−0.30, p=0.005) when compared to association in the entire COPD 
patient cohort. Plasma miR-1 levels did not associate with quadriceps strength.  
 a.       b. 
 
Figure 3-5 Relationships between FFMI and FEV1 % predicted and miR-1 and FFMI in the COPD patients 
Figure a. shows the relationship between FFMI in kg/m2 and lung function expressed as FEV1 % predicted in the COPD patients. The COPD 
GOLD stage I and II patients are represented by red filled circles, GOLD stage III patients are represented by green filled circles and IV 
patients are represented by grey filled circles. It can be seen that there is a moderate correlation between the two physiological 
parameters measured in the COPD patients. b. Plasma miR-1 levels were found to negatively correlate with FFMI, when COPD patients 
were analysed either with or without the controls. The figure shows the relationship within the COPD patients only.  
 
 
Figure 3-6 Plasma miR-1 levels in the control subjects compared to the COPD patients classified according to their FFMI 
COPD patients were divided into those with normal fat free mass and reduced fat free mass index.  A cut off of 15kg/m2 in females and 
16kg/m2 in males was used to separate the patients into those with normal and low fat free mass index. MiR-1 levels are shown for these 
groups and control subjects using diamond mean comparison plots. ANOVA testing between the groups showed p= 0.005 and significant 
differences between low FFMI compared to controls (p= 0.001) and normal FFMI compared to controls (p= 0.014), but not between 
normal compared to low FFMI patients (p= 0.251).  Therefore from the results of the study it was not possible to distinguish between 
those COPD patients with a normal FFMI from those with a low FFMI.  
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Plasma levels of miR-1 also correlated with quadriceps type I fibre cross-sectional area in the COPD 
patients (r=−0.27, p=0.027). This is shown in figure 3.7.  
 
 
Figure 3-7 Plasma miR-1 levels negatively correlated with type I fibre CSA in the COPD patients 
This figure shows the relationship between cross-sectional area of quadriceps type I fibres (data obtained and previously published by Dr 
Natanek (Natanek, Gosker et al. 2013)) and the plasma levels of miR-1 in the COPD patients.  A negative relationship can be seen where 
r=−0.27 and p=0.027. As per the other figures, the COPD GOLD stage I and II patients are represented by red filled circles, GOLD stage III 
patients are represented by green filled circles and IV patients are represented by grey filled circles. 
 
Plasma levels of miR-133, miR-499 and miR-206 with quadriceps strength  
There were weak correlations between the plasma levels of miR-133, miR-499 and miR-206 with 
quadriceps strength measured as MVC corrected for weight in the COPD patients tested (r=0.23 and 
p=0.022, r0.20 and p=0.036 r =0.21p=0.034 respectively).  These associations are shown in figure 
3.8.  
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Figure 3-8 Relationships between plasma miR-133, miR-499 and miR-206 levels and QMVC corrected for weight in the 
COPD patients 
The relationship between plasma levels of miR-133, miR-499 and miR-206 are shown with quadriceps strength as measured by QMVC 
corrected for weight.  A weak positive relationship can be seen for all where (r=0.23 and p=0.022, r=0.20 and p=0.036 r =0.21 and p=0.034 
respectively).   The COPD GOLD stage I and II patients are represented by red filled circles, GOLD stage III patients are represented by 
green filled circles and IV patients are represented by grey filled circles 
 
Together, these data suggest that there is only a limited association between plasma miRNA levels 
and quadriceps muscle mass. 
There was no association of miR-499, miR-206 or miR-133 plasma levels with fat-free mass or any 
quadriceps fibre type CSA.  
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3.3.5 Plasma levels of skeletal muscle specific miRNA and muscle fibre shift 
 
Mir-499 and quadriceps type I fibre shift 
MiR-499 is co-expressed with MHC type 1 mRNA (van Rooij, Quiat et al. 2009), therefore I 
investigated the relationship between plasma miR-499 levels and type one fibres.  
A determination of fibre type proportion and fibre size in the quadriceps muscle samples from the 
COPD patients and the controls included in the plasma analysis had previously been performed by 
Dr. Natanek.  The COPD patient muscle samples were defined as exhibiting type I fibre shift if the 
proportion of type one fibres (T1%) in the biopsy was below the 2.5th percentile for the control group 
(less than 31% type I fibres) (Natanek, Gosker et al. 2013).  
None of the miRNA measured were associated with TI% in the entire COPD patient group.  However, 
restricting the analysis to those COPD patients with GOLD stage III and IV disease showed a weak 
association between plasma miR-499 levels and TI% (r=0.26, p=0.033, figure 3.9a).  Relationships 
examined between the plasma levels of the other miRs and TI% in GOLD III and IV patients were not 
significant, (for miR-1 r=0.2 and p=0.088, for miR-181 r=0.21 and p=0.102, for miR-133 r= 0.23 and 
p=0.064 and for miR-206 r= 0.2, p=0.086). 
When the levels of plasma miR-499 were analysed in the entire COPD patient group, the levels were 
found to be significantly lower in those COPD patients whose quadriceps had evidence of 
pathological type I fibre shift compared to those without (figure 3.9 b).  
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Figure 3-9 Association of plasma miR-499 and fibre proportion in patients with GOLD III and IV COPD 
a. Comparison of fibre proportion and plasma miR-499 levels in patients with GOLD III and IV COPD showed a weak association of plasma 
miR-499 with the percentage of type I fibres in quadriceps biopsies (r=0.26, p=0.03). GOLD stage III patients are represented by green filled 
circles and IV patients are represented by grey filled circles 
b. Comparison of plasma miR-499 in all of the COPD patients with fibre-shift (defined as a T1% below the 2.5th percentile for the control 
cohort) with those without fibre shift had higher plasma miR-499. Median (25th, 75th percentile) log AU = 4.113 (3.781, 4.412) and 3.898 
(3.594, 4.126) respectively, p=0.026. Error bars for median group values and IQR and shown.  
 
Furthermore, in the COPD patients the plasma levels of miR-499 were found to be positively 
associated with the six-minute walk distance (r=0.22, p=0.028; figure 3.10).  
 
 
Figure 3-10 Association between plasma miR-499 levels and six-minute walk distance in the COPD patients 
Comparison of 6 minute walk distance with plasma miR-499 showed a weak association in the entire patient cohort (r=0.22, p=0.028). The 
COPD GOLD stage I and II patients are represented by red filled circles, GOLD stage III patients are represented by green filled circles and 
IV patients are represented by grey filled circles.  
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3.3.6 Plasma skeletal muscle-specific miRNA levels and prediction of quadriceps type I 
fibre shift 
 
To determine whether plasma levels of skeletal muscle-specific miRNAs could be useful in identifying 
changes in muscle fibre-type and therefore be useful in predicting type I fibre shift, a Receiver 
Operating Characteristic (ROC) curve analysis was carried out to discriminate the GOLD stage III and 
IV COPD patients according to the presence of type I fibre shift.  
The ROC curve analysis was first carried out using levels of miRNA alone, then using only the 
physiological data of the patients (TLCO% and 6MW% predicted), and finally using a combination of 
these factors by multiplication. This was done to determine which, if any, would be superior 
predictors of quadriceps type I fibres shift. All values were multiplied by -1 to classify the COPD 
patients according to the presence of type I fibre-shift. The results of this analysis are shown in table 
3.3 and figure 3.11.   
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TLCO% 6MWD%pred miR-1 miR-499 miR-133 miR-206 miR-181 AUC 
+       0.79 
 +      0.78 
  +     0.63 
   +    0.71 
    +   0.69 
     +  
+ 
0.66 
0.61 
+ +      0.83 
+  +     0.84 
+   +    0.83 
+  + +    0.86 
+ + + +    0.87 
+ + + +  + + 0.89 
Table 3-3 ROC analysis multiplied by −1, predicting presence of type I fibre shift 
Components included in each ROC analysis are indicated by +. 6MWD, 6 min walk distance % predicted; TLCO, transfer factor of the lung 
for carbon monoxide. AUC= area under the curve 
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The ROC curve analysis showed that the physiological parameters were better predictors of type I 
fibre-shift than the levels of plasma miRNA when used alone (figure 3.11 a,b, e-h).  However, if the 
physiological measures and miRNA levels were combined for the COPD patients, it was found that 
this improved the prediction of type I fibre shift to give a ROC area under the curve (AUC) of 0.89 
(figure. 3.11 c).  Indeed this combined score was significantly different in patients with type I fibre 
shift, compared to those without (figure 3.11 d).    
Similar to the combined score, there were statistically significant differences found between 6 
minute walk distance as % predicted between those with and without presence of type I fibre shift, 
(p=<0.0001) and TLCO % predicted in those with and without type I fibre shift (p=<0.0001) in the 
group of GOLD III and IV patients. Both of these physiological parameters are clinically useful as 
markers of exercise capacity (6MWD) and disease severity (TLCO % predicted) in COPD patients and 
as one might expect, mean values were higher for both in those without evidence of quadriceps 
fibre shift.  Mean (SD) values for 6MWD % predicted for those with and without type I fibre shift = 
61.85 (21.67) and 84.24 (17.11) respectively and for TLCO % predicted for those with fibre shift= 
30.82 (11.86) and without fibre shift = 45.23 (15.36).  
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Figure 3-11 ROC analyses of physiological parameters alone or in combination with plasma miRNA levels to discriminate 
patients according to presence of type I fibre-shift in GOLD III and GOLD IV COPD patients 
GOLD III and IV patients were defined as having quadriceps type I fibre-shift or not as described in the main text.  ROC analysis was then 
performed using; TLCO expressed as % predicted (a),  6 minute walk distance expressed as % predicted (b), Combination score generated, 
combining TLCO % predicted, 6MWD % predicted, plasma miR-1 level, plasma miR-499 level, plasma miR-181 level and plasma miR-206 
level (c).  Areas under the curves a (AUC) are shown in each graph.  (d) Comparison of the combined score in patients with or without 
fibre-shift.  GOLD III and IV patients with fibre-shift have a significantly different score (p<0.001) from patients of the same disease severity 
without fibre-shift. 
ROC analysis is also shown for presence of type I fibre shift using plasma levels of; miR-1 (e), miR-206 (f), miR-181 (g), miR- 499 (h).  Areas 
under the curves are shown for each miR.   
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If the ROC curve analysis was expanded to include the remainder of the COPD patients (i.e. those 
with GOLD stage I and II who did not show any association with T1% and plasma miR-499 levels), this 
reduced the value of both the physiological and the miRNA values as predictors of fibre shift (e.g. 
TLCO% AUC = 0.70 and combined score AUC=0.79).   
 
3.3.7 Plasma levels of miR-499 and markers of inflammation 
 
The measured miRNA levels were examined with the nuclear levels of the transcription factor NFκB 
in the muscle, specifically the nuclear NFκB p50 and NFκB p60 subunits in the COPD patients, to 
investigate any associations.  These measurements were carried out by Dr. Natanek using a 
transcription factor ELISA.  
Dr. Natanek found that there was no difference in the NFκB p65 and p50 binding DNA in the muscle 
of the COPD patients compared with that of the controls (p=0.134 and p=0.968, respectively). Her 
results also showed that there was no relationship of these factors with muscle mass, fibre type or 
function in the COPD patients or the controls.  
However, if the analysis of NFκB in the COPD subjects is interpreted in light of the plasma miRNA 
findings, then there was a correlation with levels of miR-499 (r=0.23, p=0.021). Further restricting 
the COPD patients to those with GOLD stage I and II only strengthened the association of NFκB p50 
with miR-499 (r=0.58, p<0.001), figure 3.12 a. When only the GOLD III and IV patients were analysed 
there was no association between miR-499 levels and expression of nuclear NFκB p50 in the muscle 
(r=0.142, p=0.255), figure 3.12 b.   
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Figure 3-12 Levels of plasma miR-499, mir-206 and miR-133 correlated with the amount of nuclear NFκB in the 
quadriceps of GOLD I and II COPD patients 
In patients with GOLD I and II COPD there was a direct association between NFκB p50 (r=0.58, p<0.001) and miR-499 (a) that was not 
present when analysing patients with GOLD III and IV COPD (r=0.142, p=0.25 (b). In patients with GOLD I and II COPD NFκB p50 was also 
correlated with miR-206, r=0.4 p=0.016 (c) and miR-133, r=0.47, p=0.006 (d). The COPD GOLD stage I and II patients are represented by 
red filled circles, GOLD stage III patients are represented by green filled circles and IV patients are represented by grey filled circles.  
 
 
While plasma levels of miR-1 did not correlate with NF-κB p50 in either the COPD patients or the 
controls, levels of miR-133 (r=0.47, p=0.006) and miR-206 (r=0.4, p=0.016) were found to be 
associated with NFκB p50 in the GOLD stage I and II COPD patients. This is shown in figure 3.12 c and 
d. 
There were no associations found between plasma miRNA levels and NFκB p65 expression.  
a b 
c d 
Log normalised miR-499 (AU) 
Log normalised miR-499 (AU) 
Log normalised miR-206 (AU) Log normalised miR-133 (AU) 
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Plasma miRNA levels were also compared with circulating levels of tumour necrosis factor α (TNF-α), 
interleukin 2 (IL-2) and interleukin 5 (IL-5). (Analysis that had also been carried out by Dr Natanek 
using plasma Luminex assays).  
In the COPD patients, plasma levels of miR-206, miR-133 and miR-499, but not miR-1, were 
associated with the plasma levels of the cytokines (figure 3.13, table 3.4). Specifically in the COPD 
patients with GOLD stage III and IV disease,  the strongest associations between the circulating 
cytokines and circulating miRNA levels were found for miR-206 and the weakest associations were 
found for miR-499 (figure 3.13 and table 3.4).  
 
 
Figure 3-13 Association of plasma IL-2 with miR-206 and miR-499 
a. miR-206 was not associated with plasma IL-2 in GOLD I/ II patients but b. was positively associated with plasma IL-2 in GOLD III/IV 
(,r=0.39, p<0.001). miR-499 was not associated with IL-2 in patients with GOLDI/II (c) or in patients with GOLD III/IV COPD (d). IL-2 was 
measured using a Luminex assay for plasma cytokines.  The COPD GOLD stage I and II patients are represented by red filled circles, GOLD 
stage III patients are represented by green filled circles and IV patients are represented by grey filled circles. 
  
a b 
d c 
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 miR-499 miR-133 miR-206 
Patient 
group cytokine r p r p r p 
GOLD I/II IL-2 0.33 0.056 0.35 0.049 0.32 0.07 
IL-5 0.22 0.202 0.23 0.201 0.42 0.016 
TNF-α 0.25 0.162 0.28 0.118 0.36 0.038 
GOLD 
III/IV 
IL-2 0.15 0.223 0.37 0.002 0.39 <0.001 
IL-5 0.238 0.052 0.39 <0.001 0.38 <0.001 
TNF-α 0.27 0.023 0.25 0.042 0.36 0.038 
ALL IL-2 0.33 <0.001 0.34 <0.001 0.36 <0.001 
IL-5 0.31 0.002 0.32 <0.001 0.34 <0.001 
TNF-α 0.22 0.026 0.22 0.025 0.27 0.007 
 
Table 3-4 Pearson correlation coefficient for the association between plasma miRNA levels and levels of circulating 
cytokines  
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3.4 Discussion 
This study has shown that it is possible to measure skeletal muscle-specific circulating miRNA in 
COPD patients. This is the first report in the literature in which such miRNA in the plasma of COPD 
patients have been measured and those results have been compared to the results from healthy 
controls.   
The main finding of this study is that in stable COPD patients plasma levels of muscle-specific miRNA, 
namely miR-1, miR-499, miR-133 and miR-206 (but not of two control miRNAs, miR-16 and miR-122), 
were increased when compared to healthy aged-matched controls.  These data might suggest that 
the muscle wasting and/or increased muscle turnover which is associated with COPD occurs even in 
stable conditions.  Furthermore, the results from this study show that different miRNAs have distinct 
plasma profiles dependent on the disease severity and on the proportion of oxidative fibres that 
remain in the quadriceps.   
The measured levels of the skeletal muscle-specific miRNA alone show only a weak discrimination of 
those patients with type I fibre-shift as compared to those without. The addition of miRNA levels to 
TLCO% predicted and 6MWD% improves the ability to determine the presence of type I fibre shift in 
GOLD stage III and IV COPD patients (but not the GOLD stage I and II patients).   
Finally, the results of this study show that in mild/moderate disease (GOLD stage I and II) the plasma 
levels of miR-499 are associated with nuclear NF-κB p50 but not NF-κB p65, whereas in the more 
severe patients (GOLD stage III and IV) the plasma levels of miR-206 and miR-133 are associated with 
inflammatory cytokines. From this one could hypothesise that in early-stage COPD muscle wasting is 
driven primarily by inactivity (implied by the correlation found between miR-499 and NFκB p50), but 
that in the later stages of disease muscle wasting is more strongly associated with higher levels of 
systemic inflammation (implied by the relationship of miRNA with circulating cytokine levels). This is 
explained further below.  
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3.4.1 Significance of findings 
Since it was found that it was possible to measure levels of plasma miRNA, I was able to pursue the 
second aim of this study which was to identify biomarkers of skeletal muscle dysfunction and fibre 
abnormalities in COPD. These results and the origin of the measured miRNA will be considered with 
reference to the above aims in the following sections.  
 
Plasma skeletal muscle-specific miRNA and skeletal muscle dysfunction in COPD  
Increased levels of circulating muscle-specific miRNA have been shown to be associated with muscle 
wasting in both in animals and in man.  For example, in patients with Duchenne muscular dystrophy 
(DMD) and in the mouse mode of the disease, mdx mice, serum levels of miR-1, miR-133 and miR-
206 have been found to significantly elevated (Cacchiarelli, Legnini et al. 2011; Mizuno, Nakamura et 
al. 2011).  The fold increases have been found to be 88.7 fold, 10 and 2.35 fold respectively in serum 
of DMD patient when compared to healthy controls in a recent study (Zaharieva, Calissano et al. 
2013). The results of these studies would suggest that the increases in circulating miRNA observed in 
this study may be derived from atrophying muscle or muscle with an elevated turnover.   
Although circulating muscle-specific miRNA also originate from cardiac muscle the reasons why it is 
proposed that the elevated miRNA in this study originated from the peripheral (quadriceps) muscles 
is commented on in section 3.4.2. Similar to the studies of DMD patients, the greatest fold increase 
in miRNA levels in this study was miR-1 (2.5 fold). 
The pattern of loss of muscle mass that occurs in COPD patients could either be: continual loss at a 
low rate; occur just at times of exacerbation with variable recovery during disease stability; or a 
combination of the two. As the COPD patients in this study were clinically stable and exacerbation-
free for 4 weeks, the results might suggest that the elevated miRNA levels represent muscle loss in 
the absence of a current or recent exacerbation.   
However, when considering the source of miRNAs it is important to note that there is unlikely to be 
a straightforward relationship between the amount of miRNA in the circulation and the amount of 
muscle mass that is measured at that time. This is for two reasons. Firstly, as discussed in the 
introduction chapter, studies have found that there can be a dissociation of findings between 
circulating and local (muscle) miRNA expression and secondly, the half-life of circulating miRNAs 
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have not been determined and are likely to be complex and dependent on the proportion of each 
miRNA associated with Ago 2, HDL or in exosomes.   
 
Plasma levels of miRNA and muscle strength 
If the COPD patients were grouped into those who had evidence of quadriceps weakness (n= 50) and 
those with preserved muscle strength (n=53), where quadriceps weakness was defined as a QMVC in 
kilograms less than 120% of the patient’s body mass index (Swallow, Reyes et al. 2007), there was no 
difference in any muscle-specific miRNA levels between these two groups. This is possibly explained 
by the findings of Natanek et al (Natanek, Gosker et al. 2013) where physiological measurements of 
quadriceps strength and endurance were not reliable markers of an abnormal muscle phenotype in a 
cohort of 114 COPD patients.  In that cohort of patients, there was no significant difference in these 
physiological measures between patients with normal muscle architecture, fibre shift, fibre atrophy 
or both fibre shift and fibre atrophy. Therefore, those individuals who were clinically ‘weak’ in this 
study could have normal muscle histology and as a result, might not be expected to have altered 
circulating levels of muscle-specific miRNA.  
 
Plasma levels of miR-499, miR-133 and miR-206 and disease severity 
Although plasma levels of miR-499, miR-133 and miR-206 were found to be elevated in the COPD 
patients compared to the controls, within the COPD patient group the highest plasma levels were 
associated with better lung function.   
This apparent paradox may be the result of the wasting process and the change in muscle fibre-type 
that occurs as the disease progresses over time.  The more severe COPD patients have less muscle 
mass or reserve from which miRNA originate when compared to the milder COPD patients. It could 
be that the result of this reduced muscle bulk (the presumed source of the miRNA measured in this 
study) is a corresponding reduction in circulating levels of certain muscle-specific miRNA.  
Specifically in relation to miR-499, as COPD progresses patients at a more advance stage of the 
disease have a greater loss of type I muscle fibres. This is particularly relevant to miR-499 as it is part 
of the MHC I/ MyH7B gene and therefore is only expressed in type I fibres.  Consequently, if there is 
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a reduction in the number of quadriceps type I fibres there may be a corresponding reduction in 
circulating miR-499 as the total pool of miR-499 reduces.  
In relation to miR-206 and miR-133, although these are not known to be fibre-specific it is possible 
that the patterns of expression of these miRNAs differ in type I and II muscle fibres. It is unknown 
whether they do in fact differ (and this has not been studied) but any difference could explain the 
results in this study and specifically the relationship between levels of miR-133 and miR-206 and 
disease severity.   
 
Plasma levels of miR-499 and markers of inflammation as measured by NF-kB expression 
The results of this study show that in COPD patients with GOLD stage I and II disease, plasma miR-
499 levels directly correlated with quadriceps nuclear expression of the transcription factor NF-κB 
p50 but did not correlate with NF-kB p65.  From the observed relationship between plasma miR-499 
levels and nuclear NF-kB p50 expression it could be hypothesised that NF-κB p50 activation 
promotes either the loss of type I fibres or the export of miR-499 from type I fibres.   
There is evidence to suggest that miRNA can be actively and selectively exported, depending upon 
the cell line (Collino, Deregibus et al. 2010). Therefore, it is plausible that NF-κB p50 could drive the 
export of miR-499 from type I muscle fibres.  
An accepted function of miR-499 in muscle is the maintenance of the slow MHC gene programme 
(i.e. maintaining the type I slow-oxidative phenotype). As such, the directed secretion of miR-499 
might be part of the process required for fibre type switching (loss of type 1 fibres) in COPD patients 
in response to inactivity.  This process of miR-499 secretion might be most active when type I fibres 
are relatively preserved in number, i.e. in the earlier stages of the disease.  
As miR-499 levels correlated with only NF-κB p50 expression it could be that the observed increase 
in plasma miR-499 levels is associated with the non-canonical NF-κB pathway that utilises NF-kB p50 
and Bcl-3 (rather than the classical pathway which utilises the NF-κB p65 subunit with which miR-499 
levels were not associated).  
The proposal that type I fibre loss or miR-499 levels are associated with the non-canonical NF-κB p50 
pathway takes into consideration the  findings of Hunter et al  (Hunter and Kandarian 2004). These 
authors found that in a mouse model of unloading-induced atrophy (a model similar to that found in 
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man with inactivity or COPD), complexes comprising p50 and Bcl3 subunits translocate to the 
nucleus to regulate target gene transcription (Hunter and Kandarian 2004).  
However a note of caution should be applied to this interpretation of the data and the suggestions 
made above. That is because this study is cross-sectional and the association found between miR-
499 levels and NF-κB p50 expression in the GOLD stage I and II COPD patients does not necessarily 
mean that these factors are causally related and this study was not designed to investigate 
mechanisms of muscle wasting. 
 
Plasma levels of miR-133 and miR-206 and markers of inflammation as measured by circulating 
cytokines 
The results of this study showed that plasma levels of miR-133 and miR-206 were associated with 
levels of circulating cytokines IL-2, IL-5 and TNF-α. In contrast to the results found for miR-499 which 
related to early-stage COPD patients, these associations for miR-133 and miR-206 were strongest in 
the more severe COPD patients, i.e. the GOLD III and IV COPD patients.  
This observation might suggest that in the more severe COPD patients the higher levels of miR-133 
and miR-206 are in some way related to greater levels of systemic inflammation. It is possible that 
inflammation may be driving the muscle wasting that occurs in this group of patients and the 
resultant higher circulating miRNA levels.  An alternative explanation could be that the plasma 
cytokines and the plasma miRNA are related in a manner which is independent of NF-κB as there 
was no association between plasma miRNA levels and NF-κB p65.  Therefore it could be speculated 
that the predominant contributor to muscle wasting is likely to change with disease severity.  It may 
be that the associations with inflammation are only present in these patients because the 
contribution of inactivity towards the disease process has lessened or no longer important. But, as 
explained for the observation between miR-499 levels and NF-κB p50 expression, this remains 
speculative. 
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Plasma skeletal muscle-specific miRNA levels as biomarkers of skeletal muscle fibre type 
abnormalities in COPD 
Assessment of muscle fibre composition and change is only achievable using muscle biopsy analysis. 
Muscle biopsies are invasive, not tolerated by all, and cannot be performed under certain 
circumstances (for example in those on long-term anticoagulation). Because of these potential 
difficulties in taking biopsies, it was an aim of this study to investigate whether levels of skeletal 
muscle-specific miRNA could represent a less invasive way to study muscle fibre abnormalities in 
COPD patients.  
The data in this study found that the levels of circulating miRNA and physiological measurements 
(whether taken independently) are not able to replace a muscle biopsy and determine the presence 
of type I fibre shift in COPD patients.  
However, when these measures were combined in the more severe COPD patients, it was possible 
to improve the discrimination of patients according to the presence of quadriceps type I fibre shift. 
This was most likely due to the greater changes in the quadriceps that would have occurred in those 
patients with severe lung impairment.  
If the miRNA profiles of the subjects were to be expanded to include other miRNA that were not 
tested in this study, it might be possible to improve predictive power further in this group of 
patients. Possible miRNA candidates are considered in the final study of this thesis. Any potential 
biomarker would then need to be validated in a larger separate cohort of patients for further 
assessment.  
 
3.4.2 Limitations of the study 
Origin of circulating skeletal muscle-specific miRNA  
The miRNA tested in this study are known to be highly enriched in muscle. However, cardiac muscle 
is also a potential source of the circulating miRNA measured in this study, except for miR-206. MiR-
206 is exclusively expressed in skeletal muscle and has not been found to be detectable in the heart 
(Fichtlscherer, Zeiher et al. 2011).  The patterns of plasma levels of miR-499 and miR-133 were found 
to be similar to that of miR-206, therefore they are likely to be derived from skeletal muscle.  
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The nature of this study is such that is it not possible to determine which skeletal muscle(s) 
preferentially contributed towards the measure miRNA levels. However, the quadriceps is known to 
be the predominant muscle affected in COPD patients, albeit they only contributes approximately 
13% towards total muscle mass. It is unlikely that the diaphragm contributed toward the increase in 
the miRNA levels in the COPD patients. If this was the case then it would have been predicted that 
there would be an increase in miR-499 levels with increasing GOLD stage of disease (whereas it was 
found to decrease in GOLD stage III and IV patients). This is because with advancing COPD there is a 
shift in diaphragm muscle fibre type in the opposite direction to that which occurs in the quadriceps 
(i.e. towards at TI predominance). This relationship was not found.  
It is for these reasons, that the measured miRNA in this study are thought to primarily originate from 
the quadriceps muscles in the COPD patients. 
 
Design of the study 
This study measured circulating miRNA levels in a cohort of COPD patients and healthy controls at 
one time point only. Cross-sectional studies are limited in their ability to suggest mechanisms of 
pathology. Therefore the results in this study can only lead to speculation as to what (if any) the role 
of circulating miRNA is in COPD and mechanisms of disease.  
The next two studies in this thesis extend the work undertaken in this current study. This study 
examined levels of miRNA at a time of disease stability. A biomarker of any disease needs to be able 
to detect clinical change that occurs and therefore the assessment of circulating miRNA in COPD 
patients during an exacerbation was investigated.   
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4 . The Effects of an acute exacerbation of COPD on circulating 
microRNA levels 
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4.1 Introduction  
 
Knowledge regarding circulating miRNA remains in its infancy and only a small number of studies 
have investigated circulating miRNA levels in patients hospitalised for an acute exacerbation of any 
disease.  The majority of these studies have focused on cardiac events, e.g. cardiac ischemia,  
(Kuwabara, Ono et al. 2011), heart failure (Tijsen, Creemers et al. 2010) and acute pulmonary 
embolism (Xiao, Jing et al. 2011).  Studies in cancer patients have evaluated the role of miRNA in 
monitoring progression of disease, rather than those admitted to hospital; in any event cancers tend 
not to be subject to acute exacerbation.  
The first study in this thesis demonstrated that stable COPD patients have increased circulating 
muscle-specific miRNA compared to healthy controls.  In order to evaluate circulating miRNA as 
potential biomarkers of quadriceps skeletal muscle phenotype, I considered it worthwhile to 
investigate their relationship further.  Thus, this second study considers the relationship during an 
acute exacerbation of COPD (AECOPD), which is recognised to be a time of accelerated muscle loss, 
in which immobility and inflammation are both documented.  In the first study circulating miRNA 
levels were associated with specific patient clinical parameters in stable COPD patients. This second 
study will also investigate these relationships during an exacerbation.   
Existing literature, from both studies of animals and humans of immobility or disuse, such as bed-
rest or limb suspension, can add to the understanding of potential contributory mechanisms 
towards the loss of muscle bulk and function during an AECOPD.  The few studies specifically 
evaluating the role of muscle-specific miRNA in these circumstances possibly support miRNAs as 
molecular mediators in this context. Of these, the following are of particular interest.  
Bed rest in healthy male adults has been shown to reduce skeletal muscle metabolic capacity and 
muscle miR-1 and miR-133 content (Ringholm, Bienso et al. 2011).  For example, Ringholm et al 
found that alongside loss of muscle mass, there was a 9% reduction in miR-1 expression and 8% 
reduction in miR-133 expression in vastus lateralis biopsies after seven days of bed rest.  
In rats, one group of authors have demonstrated that after a entrapment of a sciatic nerve using a 
silastic tube,  miR-1 expression was reduced by 50% in the affected soleus muscle at three and six 
months after the injury (Rau, Jeng et al. 2010). These authors also found that when the sciatic nerves 
of the rats were then decompressed at 6 months after the initial entrapment, expression of miR-1 
did not change, but remained significantly decreased when compared to the sham operated rats.  
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However, an AECOPD is more complex than immobility alone: the observed muscle changes may 
also be triggered by increased systemic inflammation (Spruit, Gosselink et al. 2003), although it is 
well established that there is increased physical inactivity around the time of exacerbation (Pitta, 
Troosters et al. 2006).     
Based on the studies outlined above, the hypothesis of this study is that expression of muscle-
specific miR-1 may be reduced in muscle during an AECOPD and this will be reflected in the 
increased plasma levels in those admitted to hospital with an AECOPD compared to stable COPD 
patients.  
 
4.1.1 Hypothesis 
 
The hypothesis of this study is that circulating muscle-specific miRNA levels will be increased in 
COPD patients admitted to hospital with an AECOPD compared to stable COPD patients. 
This hypothesis was tested by analysing miRNA levels in plasma samples taken from COPD patients 
admitted to hospital with an AECOPD. Samples were taken within 24 hours of hospital admission. 
The results were then compared to those obtained from analysing miRNA in plasma samples taken 
from stable COPD patients.  
 
4.2 Methods 
 
4.2.1 Patient recruitment 
 
COPD patients admitted to hospital with an AECOPD (n=60) and stable COPD patients (n=24) were 
recruited and tested by our collaborating hospital (samples donated by Dr Mick Steiner and Dr Neil 
Greening).  All subjects gave written informed consent and the protocol was approved by the 
National Research Ethics Service Committee by Nottingham Research Ethics committee.  Ethics 
approval number 09/H0403/76.  
All plasma samples in this study were collected in lithium heparin tubes within 24 hours of 
admission, by our collaborators and transferred (frozen) to Imperial College. The samples in the 
other studies in this thesis consisted of plasma that had been collected in EDTA tubes.  As the 
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presence of heparin can significantly interfere with miRNA detection, method adjustment and 
optimisation was necessary.  I worked with Dr Amy Lewis on method optimisation to include 
treatment of RNA with heparinase prior to reverse transcription (RT) and pre-amplification of RT 
products to increase miRNA detection.  
 
4.2.2 Molecular method optimisation 
 
Heparinase treatment for samples collected in lithium heparin  
Heparin co-purifies with RNA and is known to inhibit reverse transcriptase and polymerases, both of 
which are required for cDNA synthesis.  Therefore RNA samples extracted from blood initially taken 
in lithium heparin collection tubes, were treated with heparinase using a method adapted from 
Heegaard et al (Heegaard, Schetter et al. 2012) before reverse transcription was performed.   
Briefly, 10 µl of RNA was incubated for one hour with 0.25 µl Ribolock RNAase inhibitor (Ribolock 
Thermo Scientific),  1µl of 10 X heparinase buffer (Biolabs)  and 1µl Heparinase  I (Bacterial 
Heparinase Enzymes from Flavobacterium heparinum , HE P-ENZ I Iduron, UK), diluted 1:50 in 0.2 % 
BSA.    Reverse transcription was then performed as in the methods chapter, with an adjusted  8µl of  
cDNA master mix (containing  4µl of 5X reaction, 2µl of 10X SuperScript enzyme mix and 2µl of DPEC 
water) and products diluted to total volume of 200 µl with sterile water.  
 
Pre-amplification of Reverse transcription products prior to plasma miR quantification 
Samples treated with heparinase were found to amplify less when compared to the method used in 
the first study.  It was therefore decided that the cDNA for each sample should be pre-amplified 
prior to the qPCR reaction. This was so that the miRNA levels could be detected more easily by 
enhancing sensitivity.  This method is commercially available for Taqman® based qPCR reactions 
(and described in chapter 5), but at the time of these experiments, was not available for Sybr-based 
qPCR, therefore method optimisation was required. This was achieved in two steps: 
(i) The first step was to determine whether pre-amplification would alter PCR dynamics and 
therefore the detection of the miRNA of interest.   
(ii) In the second step, experiments were performed to determine how much pre-amplification was 
required to increase the level at which the miRNA was detectable. 
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The method is summarised in the flow diagram below and further explained in the following text.  
 
  
Step one:  
For pre-amplification, it was necessary to design a ‘primer mix’ that contained the forward miRNA 
primers for the miRNA of interest. The primer mix was used to amplify all of the corresponding 
miRNA cDNA in one reaction before individual miRNA qPCR reactions were carried out.   
Different primer sets were designed to determine whether the kinetics of the final qPCR reaction 
were affected in the presence of an excess of competitive inhibitors, i.e. the other miRNA primers. 
The primer sets were tested to assess whether there was a limit to how many forward primers could 
be used in combination and if any particular combination affected PCR kinetics more than another. 
The following primer mix sets were designed: 
Set 1:  Contained forward primers for miR-1, C.elegans-39, miR-499 and universal reverse primer 
Set 2: Contained forward primers for miR-1, C.elegans-39, miR-499, miR-16 and universal reverse 
primer 
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Set 3: Contained forward primers for miR-1, C.elegans-39, miR-499, miR-122 and universal reverse 
primer 
Set 4: Contained forward primers for miR-1, C.elegans-39, miR-499, miR-122, miR-16, miR-133 and 
miR-206 and universal reverse primer 
The primers in each set were made up to a concentration of 10µM, and to a total working volume of 
100µl with sterile water.  
Pre-amplification of cDNA templates was performed using each of these primer sets to generate a 
pre-amplification product.  Each pre-amplification reaction contained 10µl of Quanifast SYBR Green 
(Qiagen), 0.4 µl of primer mix 6.6µl of sterile water and 3µl of a chosen cDNA template.  
Pre-amplification was initially performed with 12 cycles of PCR followed by a 1 in 4 dilution of the 
product.  This pre-amplified product made was then used to generate standard curves for each 
miRNA in the primer set. The method for the generation of the standard curves is the same as that 
which was used in chapter 3 and outlined in the methods chapter section 2.2.2: Dilution series and 
generation of standard curves for plasma miRNA. 
The standard curves generated for the pre-amplified product were then compared to those 
generated using non pre-amplified product from the previous experiments in chapter 3. Comparison 
of these curves meant that it was possible to investigate whether the addition of excess primers (at 
the pre-amplification stage) interfered with the ultimate qPCR amplification of a single product and 
therefore to ensure no competitive inhibition in the reactions was occurring.  
The standard curves generated remained linear using the pre-amplified products.  The results for 
primer set 4 (where the maximum combination of primers was used) are shown in figure 4.1.  It can 
be seen that the standard curves do not shown any competitive inhibition of qPCR product in the 
presence of other primers and thus it was concluded that there was no effect on qPCR dynamics.   
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Figure 4-1 Comparison of standard curves between non-amplified cDNA and amplified cDNA 
Standard curves were run using non-amplified and pre-amplified cDNA from the plasma samples. Pre-amplification enabled all miRNA to 
be detected and did not alter PCR dynamics- i.e. no competitive inhibition as shown in a. For miR-1 and b. for miR-16, a chosen control 
miR.  
 
Initially plasma miR-181 levels were not analysed in this study as levels were not found to be 
different between patients and controls in the first study. However, in light of the results obtained in 
the exercise intervention chapter in this thesis, the levels of miR-181 were then tested using the 
samples from this study. This primer mix contained only miR-181 and C. elegans, again at the same 
concentration and final working volume.  
 
Step two:  
Experiments were then performed to determine by how much each sample should be pre-amplified 
to increase detectability of the miRNA of interest to levels similar to those found in the first study in 
chapter 3. In order to investigate this, different pre-amplification cycle numbers and dilutions were 
tested. 
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Pre-amplification was first performed using 12 cycles of PCR, followed by either 1:4, 1:8 or 1:16 
dilution. From the results of these experiments, it was calculated and then experimentally confirmed 
that 18 cycles of pre-amplification followed by a 1:3 dilution shifted the Ct value leftwards or 
downwards by 12 cycles/ sample to give resultant Cts in similar range to those in study 3.  This 
amplified cDNA product was stored and used in subsequent experiments to quantify the relevant 
miR level. 
After the pre-amplification stage, the experiments were continued as per the methods section in this 
thesis using the Sybr Green qPCR based detection method.  
 
4.2.3 Statistical analysis 
 
Power calculation and sample size 
There are no previous data in the literature describing changes in levels of circulating muscle-specific 
miRNA with immobility in man or during a hospital admission. Therefore, power calculations were 
based on the results of the first chapter in this thesis and on the limited studies (commented on in 
the introduction to this chapter) in which muscle expression of miR-1 significantly changed with bed 
rest and peripheral nerve entrapment. It was therefore hypothesised that miR-1 levels were the 
most likely to change within the context of an AECOPD and likely to increase in the circulation. A 
power calculations based on miR-1 was therefore carried out. 
Sample size calculations indicated that a minimum of 23 patients were required in each group to 
detect a 2.5 fold change in levels of miR-1 between patients admitted to hospital with an AECOPD 
and stable COPD patients, with 80% power at the 5 % significance level. This was calculated using 
unlogged miR-1 levels from the first study in this thesis, with mean (SD) COPD plasma miR-1 level= 
7.8256E-07 AU (1.3956E-06).   
In total, samples from 60 patients who were admitted to the hospital with an AECOPD were 
analysed and compared with the results from 25 stable COPD patients. This sample size would have 
enabled a 1.5 fold change in miR-1 levels to be detected.   
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Data analysis 
The results from the experiments performed in this chapter were analysed and figures constructed 
using GraphPad Prism Version 5.0 (GraphPad Software, San Diego, California, USA). To detect 
significant differences in characteristic between the groups, either an un-paired T test or Mann-
Whitney test was used. To detect significant differences in miRNA levels between the groups, an un-
paired T test or Mann-Whitney test was again used. Significant differences were taken if a p value 
was <0.05. 
Correlations were made between miRNA levels and measures of quadriceps strength using Pearson’s 
correlation. No corrections were made for multiple testing and a p value of <0.05 was taken to 
indicate a statistically significant correlation.  
 
4.3 Results 
 
4.3.1 Patient characteristics and physiology 
 
The characteristics of the two groups of COPD patients in this study are shown in table 4.1.  The 
patients in the AECOPD group were: more subjectively breathless (as indicated by a significantly 
higher MRC score); had impaired lung function with a significantly lower FEV1% predicted; and had 
significantly lower oxygen saturation at rest with a significantly higher resting heart rate. The 
patients admitted to hospital also had loss of muscle function as assessed by quadriceps strength, 
where the AECOPD patients had a significantly lower QMVC when corrected for weight or BMI. 
These findings are consistent with what is known about patients who are admitted to hospital with 
an exacerbation of COPD. 
  
127 
 
Characteristic AECOPD patients  Stable COPD  
significance of difference, p 
value  
Number  60  24   
Male (female)  27 (33)  14 (10)   
Age (years)  69 (77, 62)  67 (76, 58)  0.29 (MW)  
Height (m)  1.7 (0.1)  1.6 (0.1)  0.15 (T)  
weight (kg)  69.2 (18.5)  70.1 (19.1)  0.83 (T)  
BMI (kg/m2)  25.4 (6.0)  26.7 (5.2)  0.37 (T)  
Pack year smoking  45 (22)  48 (28)  0.68 (T)  
current smokers (ex)  14 (45)  6 (17)    
MRC grade  3.9 (0.7)  3.5 (0.6)  0.010 (T)  
FEV1 (% pred)  43(17)  56 (19)  0.006 (T)  
SpO2 (%)  93 (3)  94 (2)  0.030 (T)  
Resting HR (bpm)  90 (12)  82 (15)  0.023 (T)  
Best QMVC (kg)  11.4 (18.4, 8.0)  30.1 (43.0,22.3)  P<0.0001 (MW)  
QMVC/wt (kg/kg)  0.16 (0.26, 0.12)  0.4 (0.64,0.31)  P<0.0001 (MW)  
QMVC/BMI (kg/kg/m2) 0.45 (0.74,0.30) 1.09 (1.65, 0.82) P<0.0001 (MW) 
Weak (non-weak) (<120%BMI)  55 (2)  12 (12)   
Previous LVRS (n)  3  1   
SGRQ total  70.7 (17.4)  no data   
 
Table 4-1 Characteristics of the COPD patients included in this study 
Table of baseline characteristics in the two groups of COPD patients tested; stable COPD patients and those admitted to hospital with an 
AECOPD. Values shown are with mean (SD) or median (75th, 25th percentile). Differences in group means are calculated either using un-
paired t test (T) or Mann-Whitney test (MW) for non-parametric data.  Significance of difference is shown by p value. Those in bold are 
significantly different. This data was collected by the collaborating group (Dr Mick Steiner and Dr Neil Greening).   
128 
 
4.3.2 Plasma microRNA results showed no difference between the groups tested 
 
There were no significant differences found in the plasma levels of muscle-specific miRNA between 
the AECOPD patients compared to the stable COPD patients. The results are shown in table 4.2 and 
figures 4.2 and 4.3. 
 
miRNA log AU  AECOPD patients  Stable COPD  significance of difference, p value  
miR-1  1.1 (1.8, 0.7)  1.2 (1.8, 0.8)  0.50 (MW)  
mirR-499  0.4 (0.5)  0.3 (0.5)  0.39 (T)  
miR-133  1.8 (2.2, 1.3)  1.6 (2.1, 0.9)  0.29 (MW)  
miR-206  3.2 (2.7, 3.7)  3.0 (3.6, 2.3)  0.25 (MW)  
miR-181  1.6 (0.8)  1.7 (0.8)  0.64 (T)  
miR-16  2.6 (0.5)  2.7 (0.6)  0.83 (T)  
miR-122  0.1 (0.4)  0.2 (0.5)  0.91 (T)  
 
Table 4-2 Summary of plasma miR results for the two groups of COPD patients tested 
Values are log AU and either shown as mean (SD) or median (75th, 25th percentile). Significant of differences in the groups were calculated 
either using un-paired T test (T) or Mann-Whitney (MW) as the non-parametric alternative. Significance of difference is shown with p 
value. Mir-16 and miR-122 were chosen as non-muscle specific miRNA (and used as negative controls similar to the first cross-sectional 
study). Results were normalised to spiked in exogenous control C. elegans-39.  
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Figure 4-2 Muscle-specific plasma microRNA results compared between COPD patients admitted to hospital with an 
exacerbation of disease to stable COPD patients 
Comparison of plasma miRs between the stable COPD patients (open circles) and those admitted to hospital for an exacerbation of COPD 
(black dots). Differences are calculated either using T test or Mann-Whitney test as the non-parametric alternative. There was no 
difference in plasma a. miR-1, b. miR-499, c. miR- 206 and d. miR-133 e. miR-181 between the two groups tested. Individual data points 
are shown and error bars represent mean and standard error of the mean. 
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Figure 4-3 Non-muscle-specific plasma microRNA (used as controls) results compared between COPD patients admitted 
to hospital with an exacerbation of disease to stable COPD patients 
Comparison of plasma miRs between the stable COPD patients (open circles) and those admitted to hospital for an exacerbation of COPD 
(black dots). Differences are calculated either using T test or Mann-Whitney test as the non-parametric alternative. There was no 
difference in plasma levels of miR-122 and miR-16 used as non-muscle specific miRNA controls between the two groups tested. Individual 
data points are shown and error bars represent mean and standard error of the mean.  
 
 
4.3.3 Plasma miR levels and correlations with physiological parameters 
 
Plasma miR-1 levels, lung function and body composition 
We did not have baseline lung function or specifically FEV1 measurements for the AECOPD patients 
to classify the patients according to GOLD criteria. This is because the patients were admitted 
acutely to hospital. It is therefore not possible to comment on any relationship between GOLD 
stages of disease and plasma miR levels in the AECOPD patients.  
In the first study plasma levels of miR-1 negatively correlated with measures of fat-free mass in the 
COPD patients. In the current study, FFM was not measured by our collaborators as a clinical 
parameter and therefore again, it is not possible to draw any conclusions about the relationship 
between FFM and circulating miRs in COPD patients during an exacerbation.  Body mass index was 
measured, but this did not relate to miR-1 levels when the subjects were analysed as a group, nor 
when the stable patients or those admitted to hospital with an exacerbation of disease were 
analysed separately. 
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Plasma miR levels and quadriceps strength 
In the first study there were modest relationships between circulating miR levels and measurements 
of quadriceps strength.  Analysis of the results from the current study suggests that there are similar 
relationships between circulating miR-206 and miR-133 levels and measurements of quadriceps 
strength for the stable COPD patients in this cohort but not for the AECOPD patients.   
In respect of both miR-206 and miR-133, the study in chapter 3 showed a positive relationship with 
QMVC. These relationships were replicated in the current study for both miRs (figure 4.4). The 
relationship was however statistically weaker for miR-133 and the relationships were only present 
when analysing the un-corrected QMVC results.   
On another analysis, if the AECOPD patients are divided into quartiles based on their quadriceps 
strength, ANOVA testing did not shown any difference in muscle-specific miR levels between the 
quartiles and the stable COPD patients (for miR-1 p= 0.54, miR-499 p=0.34, miR-206 p=0.55, miR-133 
p=0.76, miR 181 p= 0.92 and for the negative controls tested miR-122 p=0.47 and miR-16 p=0.55).   
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Figure 4-4 Relationships between plasma miR-133 and miR-206 levels and measures of quadriceps strength 
Relationship between plasma a. miR-206 and b. miR-133 and quadriceps strength as measured by (uncorrected) QMVC. 
a1 and b1 are the results from the first study in chapter 3 of this thesis (blue dots ). a2 and b2 are the  relationship between strength 
(QMVC) and stable COPD patients in this study (open circles) a3 and b3 are the  relationships between strength (QMVC) and the AECOPD 
patients in this study  (black sqaures).  
 
If a composite score, is generated from the addition of all of the results for the muscle-specific 
miRNA per subject in the either the AECOPD patients or control patients, there are no improvements 
in the association with measurements of quadriceps strength.  For example, the association between 
such a composite score and QMVC in the stable patients demonstrates a weak relationship of r= 0.4 
and p=0.041, but there is no association with QMVC when corrected for weight.  There is also no 
association between this composite score in AECOPD patients and measurements of quadriceps 
strength.   
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4.4 Discussion  
 
The main result from this study is that muscle-specific miRNA levels in the blood of COPD patients do 
not differ between those admitted to hospital with an AECOPD compared to stable COPD patients. 
The data in this chapter provide some degree of support for the relationships between circulating 
miR-206 and miR-133 levels and quadriceps strength in stable COPD patients found in the first study. 
However, these relationships were not significant for miR-499 levels, nor maintained in the AECOPD 
patients.  A method for measuring miRNA from heparinised samples was developed and partially 
validated.  
 
4.4.1 Significance of findings 
 
Use of muscle-specific miRNA in the diagnosis of AECOPD and as biomarkers for skeletal muscle 
loss 
In this study the analysis showed that there was no difference in the muscle-specific miRNA plasma 
levels between the patients that had been admitted with AECOPD (samples taken within 24 hours of 
admission) and the stable COPD patients. This suggests that, despite the importance of worsening 
quadriceps function during an AECOPD, levels of muscle-specific miRs in the plasma on their own are 
not useful to either aid a diagnosis of an AECOPD or assess its impact on skeletal muscle.  
Specifically, the negative results in this study would suggest that plasma miRNA levels are poor 
biomarkers of quadriceps weakness associated with an AECOPD.  
In the first study in chapter 3, although there were significant differences in muscle-specific miR 
levels between COPD patients and controls, it was not possible to separate the two groups 
completely based on their plasma miR levels. In other words the overlapping results of the two 
groups meant that there was no specific value above which the tested subject could be identified as 
having COPD. The lack of any significant difference in the muscle-specific miR levels between the 
two groups in this study is surprising.  Some of the possible reasons for the lack of difference found 
between the groups are discussed in the following sections.  
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MiRNA and lung function during AECOPD 
The AECOPD patients in this second study were patients who had been acutely admitted to hospital. 
In the current study we do not have pre-admission or follow-up lung function data for those 
admitted with an AECOPD. The absence of this data potentially limits the interpretation of the 
results.  
In the first study we found that certain plasma miRNA levels related to GOLD stage severity. In this 
second study we do not know the baseline lung function (GOLD stage) of the exacerbator subjects 
outside of the AECOPD event which caused them to be admitted. We therefore do not know if there 
is a pre-existing difference between the plasma miRNA levels of the AECOPD patients when stable 
(i.e. pre AECOPD event) and the plasma miRNA levels of the control patients. Why this is important is 
explored further below. 
In the first study it was found that although muscle-specific miRNA levels were higher in the COPD 
patients compared to the controls, within the COPD patients the levels of miR-206, miR-499 and 
miR-133 were highest in the patients with the most preserved lung function (i.e. GOLD I and II) and 
lowest in those with the worst lung function (GOLD stages III and IV).  Specifically, patients with 
GOLD IV COPD had lower plasma miR-499 and miR-206 than those with GOLD II COPD (p=0.002, 
p=0.009 respectively). There were also modest positive correlations between plasma miR-499, miR-
206 and miR-133 and FEV1% predicted in just the COPD patients (miR-499 r=0.26, p=0.007, miR-206 
r=0.26, p=0.008; miR-133 r=0.24, p=0.018). We have speculated that this correlation may be 
explained by the loss of muscle bulk that occurs in the later stages of COPD which in turn results in a 
reduction in the source of circulating miRs.    
The AECOPD patients and the controls in this study could have been poorly matched in terms of 
baseline lung function during times of disease stability. The mean FEV1 % predicted in the stable 
COPD patients in this study was 56% predicted, which is in the GOLD II stage of severity.  There were 
3 GOLD stage IV patients, 6 GOLD stage III patients, 12 GOLD stage II and 3 GOLD stage I patients in 
the stable COPD group.  Because of the relatively low number of subjects in the study, it is not viable 
to remove the stable COPD GOLD I and II patients from the data analysis for comparison purposes as 
this would leave only 9 patients.  As a result the stable COPD patients as a group may have been 
unsuitable ‘controls’. Therefore, the results from cross-sectional comparisons made between the 
AECOPD patients and the controls may not necessarily be representative of the effects of an 
AECOPD on plasma miRNA levels due to the differences that can occur in miRNA levels across the 
GOLD stages of disease.  
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To summarise, if we were to assume that those COPD patients admitted to hospital had an increase 
in circulating miR-499, miR-206 or miR-133 in response to an AECOPD, but the magnitude of change 
was such that the increase in miR level would result in levels comparable to those of the stable COPD 
patients who are being used as controls, then no difference in the plasma miRNA levels would be 
detected at that particular point in time.  If more severe GOLD stage COPD patients had been used 
as controls, or if blood samples were collected from the patients at more than one point in time, for 
example during their recovery, this could remove or reduce these potential influences.  
 
MiRNA and quadriceps strength during AECOPD 
It was found that the patients who were admitted to hospital with AECOPD had significantly lower 
quadriceps strength compared to the stable COPD patients.  The cross-sectional nature of this study 
means it is not possible to make assumptions about changes in the patients’ muscle strength over 
time.  Thus it is difficult to ascertain the degree of muscle strength lost by AECOPD patients as a 
result of their hospitalisation for AECOPD because we do not have the data to identify whether their 
lower levels of muscle strength as compared with the stable COPD patients were as a result of a 
lower pre-admission baseline values or hospitalisation, or both.    
Although the first study was not able to discriminate between patients with different quadriceps 
strength using miR levels, there were some modest relationships demonstrated between miR levels 
and strength. In this second study, we also found that miR-206 and miR-133 levels related to 
measures of quadriceps strength in the stable COPD patients.  The correlations found in this study 
were weaker as compared with the first study which may have resulted from a smaller sample size. 
There was only a trend for levels of miR-499 to correlate with measures of quadriceps strength, 
specifically for QMVC/wt, r=0.35, p=0.09.  
Despite the possibilities these results suggest, it remains the fact that in the short term direct 
measurements of quadriceps strength (e.g. QMVC) to assess the severity of muscle dysfunction in 
COPD patients are quicker and cheaper to perform than miR analysis. The caveat is that strength 
measurements are not routinely performed by the hospital clinical teams and it may therefore be 
clinically more useful to use other tests of lower extremity function such as the 4 metre gait speed 
(Kon, Patel et al. 2013). 
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4.4.2 Limitations of the study 
 
 
Blood samples were taken at one time point only in the AECOPD patients 
 
The main limitation of this study is that blood samples were only analysed from one point in time 
from the patients admitted to hospital with an AECOPD (within 24 hours of admission).  It is 
therefore not possible to comment on whether levels of the miRNA tested are different between the 
AECOPD patients and the stable COPD controls at any other time points during an AECOPD and 
whether miRNA changes occur over time during an AECOPD.  If blood samples had been available for 
each patient prior to admission, on the day of admission and/or during convalescence then this 
study would have been strengthened and could have investigated whether miRNA levels can track 
disease status.  
 
Lack of muscle biology data  
 
It was not part of the study to investigate both muscle and blood, but this would have added to the 
current results. Muscle biopsies are invasive and more complex to perform in the in-patient setting. 
This is because patients who are immobile are often given prophylactic anti-coagulants so there is a 
higher risk of bleeding. They might have difficulty lying flat. These factors might have collectively led 
to poor tolerance of the procedure.  
The hypothesis of this study is based on an assumption that changes in circulating miRNA would 
reflect what is happening at a muscle level.  Furthermore, the hypothesis of this study makes the 
assumption that any change in muscle-specific miRNA would be as a result of the quadriceps 
changes that occur around the time of an AECOPD. It is currently not possible to confirm which 
muscle circulating muscle-specific miRNA originate from. However, the contribution of the 
quadriceps towards total muscle bulk is relatively low (13%) and miRNA can originate from other 
muscles (e.g. cardiac muscle).  Therefore, another limitation of this study is that because no muscle 
biopsies were taken from the patients I was not able to investigate what, if any, changes are 
occurring in the quadriceps and can only make informed assumptions. 
Even if muscle biopsy data were to be obtained, current knowledge on miRNAs and the method and 
timing in which they enter the circulation is limited.  Transport of miRs into the circulation is not 
completely understood.  It is possible that the release of miRNA are altered in AECOPD in an as yet 
unknown manner and which may affect circulating miRNA levels in this context.   
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Physical activity is proposed to be an important contributor towards skeletal muscle dysfunction 
during an AECOPD. But it is not possible to comment on physical activity levels in this study due to 
a lack of data.   
 
In this cohort of patients we did not have any measures of daily physical activity for either the 
AECOPD patients or the stable controls. It is well established that COPD patients admitted to hospital 
have lower levels of physical activity compared to stable patients, but the absence of any data on 
daily physical activity means we are unable to comment on the levels of physical activity associated 
with admission for the AECOPD patients participating in this study.  
  
This study assumes that the AECOPD patients were admitted to hospital after a period during which 
triggers for muscle atrophy are activated.  It also assumes that the admission would be at a point in 
time at which maximum muscle changes were occurring. However, an alternative hypothesis is that 
miRNA levels might change more significantly at the start of the muscle atrophy process, having 
been triggered by an initial decline in physical activity and the onset of increased inflammation, 
which could occur before being admitted to hospital.  
 
A third alternative hypothesis is that a change in circulating miRs could occur towards the end of an 
admission or a few days after any insult has started and blood taken outside of these time points 
would not reflect these changes. This is consistent with the largely negative results of this study.   
 
Longitudinal data and repeated blood samples may help to answer the question as to which of these 
three hypotheses is the more likely.  
 
 
This study does not consider the effect of medication on microRNA levels 
 
Patients admitted to hospital with an AECOPD are usually started on oral or intravenous steroids in 
combination with other additional medication, such as antibiotics, to treat symptoms and improve 
pathology.   Although it has been shown that short-term usage of corticosteroids does not cause 
muscle dysfunction (Hopkinson, Man et al. 2004), the effect (if any) of steroids on miRNA in the 
muscle and in the circulation remains unknown.  If steroids do affect muscle miRNA expression due 
to their suppressive function on inflammation, then conceivably their use during an AECOPD might 
have affected the results of this study. However, the design of this study and the lack of detailed 
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medication history for the patients mean it is not possible to comment on this and limits further 
speculation.  
 
4.5 Conclusion 
 
In summary, this study does not support the use of circulating muscle-specific miRNA as biomarkers 
for skeletal muscle dysfunction (specifically loss of quadriceps strength) during an AECOPD.  
Further studies are required to investigate the relationship between plasma miRNA and muscle 
miRNA during an AECOPD. The use of longitudinal data to investigate the role of miRNA in muscle 
dysfunction associated with an AECOPD is preferable for the reasons outlined in the discussion. 
 
The next chapter investigates the effects of acute exercise on the quadriceps in COPD patients and 
controls. That study will investigate the change in both muscle expression and plasma levels of 
miRNA with exercise. This will be done by performing biological sampling at two time points to 
address the concerns of the current study that the data is taken from one time point only and is not 
properly representative of the AECOPD event.   
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5 . The Effect of exercise on muscle and plasma microRNA 
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5.1 Introduction 
 
The main aim of this study was to investigate whether changes in miRNA expression in muscle can 
be detected in the blood; to make the experiment practical a model of acute exercise was chosen.  
Subsidiary questions were to be whether the miRNA changes with exercise are similar in COPD 
patients and controls; and whether there is a variation within the COPD subjects depending on 
patient phenotype.  Thus, the principal aim of the experiment was to evaluate whether circulating 
miRNAs are useful tools for monitoring the response of individuals to acute exercise, but it was 
appreciated that data from the subsidiary aims would indicate whether circulating miRNA had 
potential value to monitor the response of COPD patients to specific therapy to improve their 
exercise capacity, for example novel anabolic agents. 
  
The rationale for this study is as follows.  Firstly, miRNA are likely to be important in muscle 
adaptation to exercise. A number of researchers have reported that muscle miRNA expression can 
rapidly adjust to acute exercise in mice (Safdar, Abadi et al. 2009) and in healthy adults (Drummond, 
McCarthy et al. 2008; Nielsen, Scheele et al. 2010).  In mice, Safdar et al (Safdar, Abadi et al. 2009) 
studied the effect of acute endurance exercise. These authors found that quadriceps expression of 
miR-1, and miR-181 significantly increased after exhaustive exercise by 40% and 37% respectively, 
but there was no change in miR-133 expression. In man, quadriceps expression of miR-1 and miR-
133 has also been found to significantly increase one hour after exercise in healthy individuals 
(Nielsen, Scheele et al. 2010).  
Secondly, the concept that the response of COPD patients to exercise will be different to that of the 
healthy controls is suggested by the results of the study by Nielsen et al (Nielsen, Scheele et al. 2010) 
in which the quadriceps miRNA response of trained and untrained individuals to acute exercise was 
investigated (Nielsen, Scheele et al. 2010). As COPD patients are less physically active they could 
exhibit a similar miRNA response to exercise to the untrained individuals in that study.  Nielsen et al 
found that miR-1 and miR-133 expression significantly increased in untrained male individuals (n=10) 
in response to exercise. But, the increase in miR-1 and miR-133 observed in the untrained men did 
not occur in the same individuals after a period of 12 weeks of exercise training (Nielsen, Scheele et 
al. 2010).   If COPD patients behave similarly to untrained individuals, then it might be expected that 
they would have a greater increase in quadriceps miR-1 and miR-133 expression in response to 
exercise as compared to healthy trained controls. 
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Evidence to support the possibility that miRNA responses may be different within particular COPD 
patients can be found in the work of Davidsen et al who studied the increase in muscle mass in 
response to resistance training in healthy adults.  These authors found different quadriceps miRNA 
profiles can relate to the amount of gain in muscle mass or ‘responder status’ of the individual 
(Davidsen, Gallagher et al. 2011). Davidsen et al found that the quadriceps miRNA that differed 
between those with a greater resistance training-induced gain in muscle mass (n=9) and those who 
had less of an increase in muscle mass (n=9) in response to training, are predicted to target mTOR, 
one component of the muscle protein synthesis pathway.  
 
Lastly, studies have found that the components of miRNA biosynthesis pathway can be affected by 
exercise.  Components of this pathway are required for miRNA processing and transport to the 
cytoplasm where they function and include the enzymes Drosha and Dicer and the protein Exportin-
5.  Levels of Drosha, Dicer and Exportin-5 have all been found to be significantly up-regulated in 
muscle after exercise in young adults by 35%, 35% and 30% respectively (Russell, Lamon et al. 2013). 
 
This study aimed to test the following three hypotheses: 
 
5.1.1 Hypotheses 
 
1. Quadriceps muscle-specific miRNA expression will increase in response to an acute bout of 
exercise.  
This hypothesis was tested by comparing the expression of muscle-specific miRNA in 
quadriceps biopsy material taken before and one hour after exercise. The COPD patients and 
the controls were tested in the fasted state. The muscle biopsy analysis was performed using 
qPCR.  
 
2. The change in muscle-specific miRNA will be detected in plasma levels taken before and one 
hour after exercise.  
 
This hypothesis was tested by comparing levels of muscle-specific miRNA in plasma samples 
taken from the same COPD patients and the healthy controls before and one hour after 
exercise. Levels of muscle-specific miRNA were quantified using qPCR.  
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3. COPD patients will have a greater response to an acute bout of exercise compared to the 
healthy controls. 
 
This hypothesis was tested by comparing the change in miRNA response to exercise (in both 
the muscle and the plasma samples) between the COPD patients and controls.  
 
 
5.2 Methods 
 
Patients and healthy controls were recruited and tested (in the fasted state) as detailed in the 
methods chapter.  All subjects gave written informed consent and the protocol was approved by the 
National Research Ethics Service Committee in London, Bloomsbury ethics number 11/ LO/0711. 
 
Biological sample collection, muscle miRNA expression and plasma miRNA level quantification are 
also detailed in the methods chapter. Pre-amplification of RT products, as described in chapter 4, 
was performed prior to quantification of miR levels in the plasma to increase detection. 
  
 
5.2.1 Patient recruitment  
 
Study inclusion criteria for the COPD patients were a diagnosis of COPD (Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) criteria: post bronchodilator forced expiratory volume in one 
second (FEV1)/forced vital capacity (FVC) <70%) confirmed with spirometry in stable clinical 
conditions.  Patients were either current or ex-smokers with a smoking history equivalent to at least 
10 pack years (1 pack year = 20 cigarettes smoked per day for 1 year), had to be able to read and 
write and to use electronic devices and a physical activity monitor.  Aged-matched healthy controls 
were included if they had no spirometric evidence of obstructive airways disease and either had 
never smoked or had a smoking history equivalent to less than 10 pack years.  
 
Patients were not included in the study if they had any orthopaedic, neurological or other 
complaints that significantly impaired normal biomechanical movement patterns or if they had any 
other respiratory diseases other than COPD (e.g. asthma) and/or cognitive impairment as judged by 
the investigator. Patients were also excluded if they were on warfarin (to avoid bleeding risk with 
muscle biopsy) or had a bleeding diathesis. Aspirin was stopped for 5 days before biopsy in those 
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taking it if this was deemed safe by the Chief Investigator. Patients with other obvious 
contraindication to cardio-pulmonary exercise testing (for example ischaemic cardiac disease) were 
not included in the study.  
 
20 COPD patients and 11 healthy controls underwent exercise testing with quadriceps muscle 
biopsies and blood sampling. A further 13 COPD patients and one healthy control underwent 
exercise testing with only blood sampling, i.e. no muscle biopsy. 
 
5.2.3 Physiological and molecular methods 
 
All of the patients and the healthy controls had physiology testing on a day prior to the incremental 
cycle test and the muscle biopsies. The tests were performed by the researchers in the group 
(including me) and are described in detail in chapter 2. To summarise, they included measurements 
of body composition (FFM), quadriceps strength (QMVC), daily activity and pulmonary function tests. 
The patients and the controls also performed a six-minute walk test.  
On a separate day, the patients and the controls attended the lab in a fasted state. They then had 
blood and quadriceps muscles samples taken before undergoing a symptom limited incremental 
exercise test. Further blood samples and muscle biopsies were taken one hour after the end of 
exercise.  
Expression of muscle-specific miRNA and levels of muscle-specific miRNA were measured in the 
biological samples obtained using qPCR. Samples were analysed for expression of miR-1, miR-133, 
miR-499, miR-206 and miR-181. In the plasma samples, levels of miR-16 and miR-122were quantified 
as non muscle-specific negative controls.  
 
5.2.3 Statistical analysis  
 
Power calculation and sample size 
 
Muscle miR-1 expression has been shown to increase significantly in response to exercise in the 
literature after one hour of exercise (Nielsen, Scheele et al. 2010). It has also been shown to increase 
by 429% in blood taken from young men three hours after exercise (Nielsen, Akerstrom et al. 2014).  
It was the most down-regulated (2.5 fold) miRNA in the quadriceps of COPD patients compared to 
144 
 
controls (Lewis, Riddoch-Contreras et al. 2012) and in the first study of this thesis, it was found that 
plasma miR-1 levels were the most significantly increased in COPD patients compared to controls 
(2.5 fold). For these reasons, sample size calculations were performed using previous data on 
quadriceps miR-1 expression and plasma miR-1 levels.  
 
To detect a two fold increase in muscle miR-1 expression after exercise in the COPD patients, with an 
80% power at the 5% significance level, power calculations indicated that a minimum of 8 subjects 
with muscle biopsies taken before and after exercise would be required. This was calculated using 
miR-1 expression data taken from (Lewis, Riddoch-Contreras et al. 2012); mean (SD) COPD muscle 
miR-1 expression = 0.0012AU (0.0023).  
 
For plasma samples, to detect the same fold increase, it was calculated that 19 COPD patients with 
paired results would be required, again at 80% power at the 5% significance level. This was 
calculated using unlogged plasma miR-1 level results from the first study in this thesis, with mean 
(SD) COPD plasma miR-1 level= 7.8256E-07 AU (1.3956E-06). Therefore 20 COPD patients were 
recruited for the study and 11 controls studied for comparison purposes.   
 
13 additional COPD patients and one healthy control underwent cycle ergometry testing but had 
blood sampling only before and after exercise. Their data is only included in the analysis of the 
paired plasma samples (i.e. before and after exercise) and a table of characteristics for these 
subjects is given in the appendix, table 8.1.  The data for these patients and controls is not included 
in any other analysis unless stated.  
 
Data analysis 
 
Data from this study has been analysed and figures constructed using GraphPad Prism Version 5.0 
(GraphPad Software, San Diego, California, USA). 
 
To detect differences in muscle miRNA expression and plasma miRNA levels one hour before 
exercise and one hour after exercise two statistical tests were performed.  
i) Firstly fold changes were calculated for the COPD patients and the controls and the 
difference between the groups was then tested using an un-paired analysis.  
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This analysis was performed on normalised qpCR data (see methods section for 
normalisation method), where the miRNA expression per subject after exercise was 
expressed as a ratio of the miRNA expression before exercise. This ratio was then log 
transformed and the average ratio calculated for the COPD group of patients and the 
controls for each miRNA. The difference between the average ratios of the COPD 
patients and the controls was assessed with an un-paired analysis (either T Test or 
Mann-Whitney). This analysis was undertaken to assess whether there was a change in 
absolute miRNA expression after exercise and whether this change (if any) differed 
between the COPD patients and the controls. 
 
ii) A second type of analysis was undertaken to assess whether the spread of data points 
would have an effect on the results (i.e. how miRNA expression changes after exercise 
within an individual relative to its expression before exercise) and therefore whether 
analysing the change in miRNA expression within an individual was more likely to 
identify small changes in miRNA expression. This analysis was undertaken using paired 
analysis where the differences in mean or median miRNA expression before and one 
hour after exercise were calculated within a group for the COPD patients and the 
controls. Due to the multiple analyses performed, it should be noted that there was an 
increased risk of type II statistical error.  
 
When corrections have been made for multiple comparisons using a Bonferroni 
correction, this has been noted in the text.   
Correlation analyses between miRNA levels and physiological data or quadriceps data were 
performed assuming linearity using Pearson correlation coefficient. To interpret the correlation data 
I have taken p<0.05 as an indicator of association to allow investigation of the likely relationships 
within the data.  
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5.3 Results 
 
5.3.1 Patient characteristics and muscle phenotypes  
 
Patient characteristics 
 
The characteristics of the patients and controls who underwent incremental symptom-limited cycle 
ergometry with quadriceps biopsy and blood sampling before and one hour after are shown in table 
5.1.  
 
Consistent with a diagnosis of COPD, the patients had significantly impaired lung function with a 
reduced FEV1 expressed as % predicted (see appendix table 8.2). It was not possible to compare 
other respiratory parameters between groups at baseline, as the control subjects did not have full 
pulmonary function tests. 
 
Compared to the control subjects, the COPD patients had a reduced exercise capacity as measured 
by six minute walk distance (6MWD) and physical activity monitoring (time spent in walking, time 
spent in activity and step count).  Cycle ergometry results further demonstrated a reduced exercise 
capacity in the COPD patients.  The COPD patients had a significantly lower workload expressed in 
Watts (W) as % predicted and lower oxygen consumption at maximum workload expressed as % 
predicted.  
 
The COPD patients and controls cycled with different increases in load per minute; 10 W per minute 
for COPD patients and 20 W per minute for controls.  The cycle ergometry results are therefore 
expressed either as values at maximum exercise (i.e. at time maximum load was achieved) or as % 
predicted.  
 
Capillary blood gas data is shown at rest and after exercise. Paired analysis was performed for the 
change in gas tensions for the COPD and control group, the difference between these changes is also 
shown in the table. 
 
There was no difference in age, body mass index, fat-free mass index or quadriceps strength 
between the groups.  
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Baseline characteristics COPD Control significance of difference, p value 
Number of paired samples 20 11  
Male (female) 13 (7) 6 (5)  
Age (years) 66 (9) 63 (7) 0.35 (T) 
Height (cm) 171.7 (9.1) 168.4 (9.0) 0.34 (T) 
Weight (kg) 80.1 (17.1) 68.5 (12.6) 0.06(T) 
BMI (kg/m
2
) 27.1 (5.4) 24.1 (3.6) 0.102 (T) 
FFFMI (kg/m
2
) 18.2 (2.7) 17.9 (3.1) 0.620 (T) 
Normal (low) FFMI (<16 m, <15 f) 16 (4) 8 (3) 0.61 (T) 
Pack year smoking 51 (60,31) 0 (0,0) 0.0001 (MW) 
FEV1 (% pred) 57 (22) 104 (14) <0.0001 (T) 
6MWD (m) 462.5 (121.8) 646.1 (81.1) 0.0001 (T) 
mMRC score 1 (3,1) 0 (0,0) 0.0001 (MW) 
Best QMVC (kg) 31.9 (9.5) 31.0 (6.5) 0.90 (T) 
QMVC/wt (kg/kg) 0.4 (0.1) 0.5 (0.1) 0.154 (T) 
QMVC/BMI 1.1 (1.4,0.9) 1.3 (1.5,1.1) 0.34 (MW) 
 
 
Activity data    
time spent walking (mins/day) 57 (33) 107 (29) 0.0003 (T) 
time spent standing (mins/day ) 136 (53) 162 (28) 0.14 (T) 
time spent in activity (mins/ day ) 75 (41) 135 (34) 0.0004 (T) 
average step count/day  4721 (6421,2453) 9140 (12635, 5682) 0.003 (MW) 
    
 
Cycle Ergometry results 
Resting HR before exercise test (bpm) 78 (13) 65 (9) 0.007 (T) 
Max HR during exercise (bpm) 129 (22) 152 (14) 0.004 (T) 
Max HR during exercise as % pred 84 (15) 97 (6) 0.011 (T) 
    
V'E L/min max exercise 42.9 (54.7, 40.8) 56.4 (95.0,45.6) 0.025 (MW) 
V'E L/min max exercise % pred 58.7 (15.9) 86.1 (24.1) 0.001 (T) 
Maximum workload, (watt) 77.5 (28.5) 161.8 (60.3) <0.0001 (T) 
Maximum workload, (watt, % predicted) 69.9 (28.8) 146.0 (34.1) <0.0001 (T) 
V'O2 L/min max exercise    1.4 (1.6,1.0) 1.8 (2.3,1.5) 0.035 (MW) 
V'O2 L/min max exercise (% pred) 76.0 (21.6) 110.5 (16.9) <0.0001 (T) 
VO2/kg max exercise (ml/min/kg) 16.5 (3.5) 27.5 (6.9) <0.0001 (T) 
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Baseline characteristics COPD Control significance of difference, p value 
delta PaO2 per subject:    
After exercise PaO2 (kpa) 11.1 (2.5) 13.1 (1.1)  
paired analysis p= 0.113 (PT) p= 0.065 (W)  
delta PaO2 (% change COPD vs control) 7.6 (20.0) 11.0 (14.3) 0.64 (T) 
 
 
Resting PAO2 (kpa) 14.0 (14.3, 13.4) 13.4 (14.4,12.9) 0.73 (MW) 
 delta PAO2  per subject:    
After exercise  PAO2 (kpa) 14.6 (15.4, 13.8) 15.1 (16.3,14.5)  
paired analysis p= 0.025 (W) p= 0.020(W)  
delta PAO2 (% change COPD vs control) 5.3 (7.2) 9.9(10.3) 0.16 (T) 
    
Resting PaCO2 (kpa) 5.2 (0.5) 5.0 (0.7) 0.51 (T) 
delta PaCO2 per subject (kpa):    
After exercise PaCO2 (kpa) 5.4 (0.8) 4.8 (1.1)  
paired analysis p= 0.039 (PT) p= 0.790(PT)  
delta PaCO2 (% change COPD vs control) 10.2(16.7,-1.7) -2.7 (11.4,-11.5) 0.23 (MW) 
    
    
Resting SpO2 (%) 96.1 (1.4) 97.3 (0.8) 0.014 (T) 
delta SpO2 per subject (%):    
                           After exercise  sats (%) 94.5 (4.7) 97.4 (0.7)  
                          paired analysis p= 0.076 (PT) p= 0.678 (PT)  
delta SpO2 (% change COPD vs control) 0.2 (2.6,-0.7)  0 (0.2,-0.5) 0.26 (MW) 
    
End Dyspnoea, Borg units 4 (5, 3) 4 (5,3) 1 (MW) 
End Leg discomfort Borg units 4 (6,3) 4 (7,3) 0.68 (MW) 
    
    
 
    
Table 5-1 Summary of characteristics of patients who underwent cycle ergometry with both blood tests and muscle 
biopsy before and one hour after   
GOLD IV, n=3, GOLD III, n=4, GOLD II, n=9, GOLD I, n=4.  Statistical difference of groups is shown as p value. Testing was performed using 
either un-paired T test (T) or Mann-Whitney test (MW) as the non-parametric alternative.  
Paired testing was performed using paired T Test (PT) or Wilcoxon matched pairs test (W) as the non-parametric alternative.  
Bold indicates those which are statistically significantly different. Values are expressed either as mean (SD) or median (75th, 25th 
percentile). See abbreviation table at start of thesis for abbreviations.  
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Muscle phenotypes  
 
In contrast to published literature, myosin heavy chain (MHC) mRNA analysis did not show a 
significant difference between the groups (table 5.2). The lack of difference found could be due to 
relatively low patients numbers studied in both groups and/ or that the COPD patients in this study 
do not represent the spectrum of disease with regards to loss of FFM or quadriceps strength.  These 
two measurements were not different between the groups analysed.  
 
 
Muscle myosin heavy chain mRNA 
expression COPD (n=20) Control (n=11) 
significance of difference, 
p value 
MHCI mRNA ( log AU) 1.1 (0.4) 1.3 (0.2) 0.20 (T) 
MHCIIa mRNA (log AU) 0.4 (0.2) 0.2 (0.2) 0.10 (T) 
MHCIIx mRNA (log AU) 0.9 (0.3) 0.7 (0.4) 0.23 (T) 
 
Table 5-2 Quadriceps muscle myosin heavy chain expression 
Data are presented as mean (SD) and significance of difference of difference as shown by p value. MHC expression levels 
were determined by qPCR and normalised to RPLPO. 
 
 
On analysis of the MHC data, a negative correlation was found between MHCIIx mRNA expression 
and maximum load achieved % predicted for the COPD patients (r=-0.5, p=0.015).  
 
Relationships between MHCIIa expression and exercise capacity differed between COPD patients 
and controls.  Specifically, the relationship between MHC IIa mRNA and oxygen consumption (VO2) in 
L/min as % predicted and maximum load in watts achieved during the cycle ergometry test.  
 
In the COPD patients, there were negative relationships between MHCIIa mRNA expression and 
maximum load (r=-0.44,p=0.049) and VO2 in L/min at maximum load as % predicted (r=-0.48, 
p=0.036). However, in the control subjects, there were positive correlations between MHCIIa mRNA 
expression and maximum load achieved (r= 0.64, p=0.031) and VO2 L/min % predicted (r= 0.74 and 
p=0.009).  
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5.3.4 Muscle miR expression and changes with exercise 
 
To answer the first hypothesis of this study, fold changes in miRNA expression with exercise for the 
COPD patients and the controls and the difference between the two groups was calculated. The raw 
data for the analysed miRNA used in the fold change analysis is shown in table 8.3 in the appendix 
and significance of difference in fold changes in table 5.3 below.  
Data in table 5.4 shows the difference in mean or median muscle expression before and one hour 
after exercise (i.e paired analysis of results).  
 
Muscle miR-1, miR-133, miR-206 and miR-499 expression with exercise  
 
There were no differences in fold changes of miR-1 (upon which the study was powered), miR-133, 
miR-206 or miR-499 expression between the COPD patients and controls (table 5.3).  A corrected p 
value of <0.01 was taken as significant to account for multiple testing. 
 
 
miRNA p value to indicate significance of 
difference in fold change in 
miRNA expression after exercise 
between COPD patients and 
controls 
miR-1 0.74 (T) 
miR-133 0.76 (T) 
miR-181 0.22 (T) 
miR-206 0.47 (MW) 
miR-499 0.50 (T) 
 
 
Table 5-3 Analysis of muscle miRNA expression fold change differences between the COPD patients and the controls 
For full data see appendix table 8.3. Fold changes in muscle miRNA expression were calculated using un-logged, raw data for the COPD 
patients and controls. The fold changes were then logged and the difference between the two groups calculated using either un-paired T 
test (T) or Mann-Whitney as the non-parametric alternative (MW). It can be seen that there were no significant difference in the fold 
change in miRNA expression between the COPD patients and the controls.  Group median values for fold changes with inter-quartile 
ranges and mean values of fold changes with SD and SEM are shown in table 8.3 in the appendix.  
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Using a paired analysis, there were also no changes found in quadriceps expression of miR-1, miR-
133 or miR-499 one hour after exercise within the COPD patients or controls. The results of muscle 
biopsy analysis for quadriceps miRNA expression are summarised in table 5.4.  
 
 
miR tested COPD before COPD after 
COPD paired 
analysis (before 
and 60 mins) 
miR-1 1.4 (1.5, 1.3) 1.4 (1.6, 1.3) 0.72 (W) 
miR-133 1.5 (1.7, 1.4) 1.5 (1.6, 1.3) 0.70 (W) 
miR-181 0.7 (0.2) 0.9 (0.1) 0.017 (PT) 
miR-206 0.5 (0.9, 0.4) 0.7 (0.9,0.6) 0.07 (W) 
miR-499 0.6 (0.8, 0.3) 0.6 (0.7, 0.5) 0.90 (W) 
    
    
miR tested Control before Control after 
Control paired 
analysis (before 
and 60 mins) 
miR-1 1.5 (0.3) 1.4 (0.1) 0.86 (PT) 
miR-133 1.5 (0.2) 1.5 (0.2) 0.97 (PT) 
miR-181 0.8 (0.2) 0.9 (0.3) 0.83 (PT) 
miR-206 0.5 (0.3) 0.5 (0.2) 0.65 (PT) 
miR-499 0.9 (1.0, 0.7) 0.8 (1.0, 0.6) 0.90 (W) 
 
 
 
Table 5-4 Summary of muscle miRNA results before and after exercise with paired analysis results 
Summary of muscle miRNA expression in muscle biopsies before and one hour after exercise. miRNA values are log normalised in AU and 
either shown as mean (SD) or median (75th percentile, 25th percentile). D’Agostino and Pearson omnibus test was used to test whether the 
data were normally distributed. Significance of difference before and after exercise in the groups is shown as p value using either paired t 
test if both groups were normally distributed data (PT), or Wilcoxon matched pairs test (W) as the non-parametric alternative.  There was 
no significant difference in expression of gene used for normalisation, i.e. 5S expression (analysed using raw Ct value paired T test p= 0.34, 
1/2ct values paired T test p=0.674,) before and after exercise. It can be seen that miR-181 increased in the COPD patients after exercise 
(p=0.017), but this increase is not significant if an adjusted p value of <0.01 is used to take into account to correct for multiple testing.  
COPD patients n=20, control n=11. 
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Muscle miR-181 and change with exercise 
There was no difference in quadriceps miR-181 expression between the COPD patients and controls 
before exercise (p= 0.330). When comparing group mean fold change, there was no difference found 
between the fold change in miR-181 expression after exercise between the COPD patients and 
controls (table 5.3).  
 
However, when muscle miR-181 expression was analysed using a paired analysis, in which mean 
miRNA expression was compared before and one hour after exercise, group mean expression of 
miR-181 was noted to increase 1.4 fold  (p=0.017) in the quadriceps after an acute bout of exercise 
in the COPD patients. It should be noted that if corrections are made for multiple testing, then this 
just fails to reach significance at p<0.01. Mean (SD) muscle miR-181 expression was 0.7 (0.2) log AU 
before exercise and 0.9 (0.1) log AU after exercise.  
 
This change in expression is thought to be a true finding, rather than an effect of sample size, due to 
the fact that miR-181 expression did not change in the quadriceps of the control subjects after 
exercise.  If miR-181 were to increase in both the COPD patients and the controls with exercise, but 
this study was likely underpowered to detect such a change, it would be expected that the 
significance would be strengthened by combining the results of the two groups tested.  The changes 
in miR-181 expression for all of the subjects, the COPD patients and the controls are shown in figure 
5.3 a.  
 
Within the COPD patients, muscle miR-181 expression after exercise correlated with MHCI mRNA 
expression (r=0.54, p=0.02) (figure 5.3 b). 
 
Also within the COPD patients,  the change in quadriceps miR-181 expression positively  correlated 
with maximum oxygen uptake per kg expressed in ml/min/kg at maximum exercise, r= 0.67, p=0.002 
(figure 5.3c ).  
 
In keeping with the above finding, if the COPD patients were divided into those whose miR-181 
expression increased compared to those whose miR-181 expression decreased, oxygen consumption 
at maximum watts was significantly higher in those whose miR-181 expression increased (p=0.014). 
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b       c 
 
 
 
 
 
 
 
Figure 5-1 Changes of muscle miR-181 with exercise 
a. Changes of muscle miR-181 expression with exercise in all of the subjects, in the COPD patients and in the control subjects. Significance 
of difference before and one hour exercise in the groups is shown as p value. Testing was performed using either paired t test if both 
groups were normally distributed data (PT), or Wilcoxon matched pairs (W) as the non-parametric alternative. COPD patients alone 
demonstrated a x1.4 increase in miR-181 one hour after exercise. (Fold change performed on non-logged data). b. Mir-181 expression 
after exercise correlates with MHC I mRNA expression in the quadriceps of the COPD patients.  c. shows correlation between change in 
miR-181 expression and maximum oxygen uptake expressed as VO2 ml/min/kg at maximum exercise in the COPD patients in this study.  
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5.3.5 Muscle miR-499 levels were lower in COPD patients compared to controls and 
correlated with disease status, physical activity and exercise ability  
 
MiR-499 expression was lower in the quadriceps of COPD patients than in controls (figure 5.7). 
Consistent with our previous observations (Lewis, Riddoch-Contreras et al. 2012), relationships were 
found between muscle miR-499 expression and measures of muscle biology and smoking history 
(figure 5.8), physical activity and exercise capacity (figure 5.9). 
 
Figure 5-2 Muscle miR-499 is suppressed in the quadriceps of COPD patients compared to controls 
Muscle miR-499 expression in the COPD patients compared to controls. COPD patients were found to have statistically significantly less 
miR-499 at baseline in muscle biopsies compared to controls. Individual data points are shown with error bars showing mean and standard 
error of the mean (SEM). COPD median baseline miR-499 median (75th, 25th percentile)= 0.6 (0.8,0.3). Control subjects median baseline 
miR-499 median (75th, 25th percentile)= 0.9 (1.0, 0.7) log AU. As per the methods section, qPCR data is not included in the results if the 
testing failed or experimental duplicates did not produce the same results.  
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Figure 5-3 Relationships between miR-499 levels in muscle and MHC1 mRNA and smoking history in the COPD patients 
Relationship between baseline miR-499 in muscle biopsies from the COPD patients and a.  MHC1 mRNA content in muscle biopsies (log 
AU) and b. smoking history as pack year history. Correlations determined by Pearson’s testing; r and p value are shown indicating 
statistical significance.  
 
 
 
 
 
Figure 5-4 Relationship between muscle miR-499 and physical activity and exercise ability in the COPD patients 
Correlations between muscle miR-499 levels and measurements of daily activity. Correlations determined using Pearson’s testing; r and p 
value of significance shown a. Correlations between muscle miR-499 levels before exercise and measurements of time in activity b. 6 
minute walk distance   
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5.3.6 Plasma miR levels and changes with exercise 
To answer the second hypothesis of this study (i.e. whether any changes in muscle expression of 
miRNA could be detected in plasma), fold changes in levels of miRNA were calculated for the COPD 
patients and the controls and then compared using an un-paired analysis, (see table 5.5 and 
appendix table 8.4). 
Changes in mean miRNA levels were also calculated for the COPD patients and controls using a 
paired analysis and this data is shown in table 5.6.  
 
There were no significant changes in plasma levels of miR-1, miR-133, miR-181, miR-206 or miR-499 
one hour after an acute bout of exercise in either analyses, using a corrected p value of <0.007 to 
account for multiple testing.  
 
miRNA p value to indicate 
significance of difference 
in fold change in plasma 
levels of miRNA after 
exercise between COPD 
patients and controls 
miR-1 0.52 
miR-133 0.28 (MW) 
miR-181 0.23 
miR-206 0.79 
miR-499 0.13 
miR-16 0.012 
miR-122 0.34 
 
Table 5-5 Analysis of plasma miRNA level fold change differences between the COPD patients and the control  
For full data see appendix table 8.4.  Fold changes in plasma miRNA levels were calculated using un-logged, raw data for the COPD patients 
and controls. The fold changes were then logged and the difference between the two groups calculated using un-paired T test (T) or 
Mann-Whitney as the non-parametric alternative (MW) for miR-133. It can be seen that there were no significant difference in the muscle-
specific fold change in miRNA expression between the COPD patients and the controls.  Group median values for fold change with inter-
quartile ranges and mean fold change values with SD and SEM are shown in table 8.4 in the appendix.  
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miR tested COPD before COPD after 
COPD paired analysis 
(before and 60 mins) 
miR-1 2.2 (2.3, 1.9) 2.0 (2.3, 1.9) 0.45 (W) 
miR-133 1.7 (1.8,1.4) 1.6 (1.9,1.2) 0.92 (W) 
miR-181 2.3 (2.6, 1.9) 2.2 (2.5,2.0) 0.46 (W) 
miR-206 4.5 (4.8,3.2) 3.7 (4.6,3.2) 0.53 (W) 
miR-499 0.5 (0.5) 0.4 (0.5) 0.12 (PT) 
miR-16 3.5 (3.7, 3.2) 3.4 (3.6,3.2) 0.21 (W) 
miR-122 1.8 (0.6) 1.7 (0.5) 0.19 (PT) 
    
    
miR tested Control before Control after 
Control paired analysis 
(before and 60mins) 
miR-1 2.5 (0.3) 2.4 (0.5) 0.25 (PT) 
miR-133 1.8 (0.3) 1.7 (0.4) 0.36 (PT) 
miR-181 2.5 (0.7) 2.8 (0.4) 0.23 (PT) 
miR-206 4.1 (0.9) 4.1 (0.8) 0.65 (PT) 
miR-499 0.6 (0.4) 0.8 (0.4) 0.09 (PT) 
miR-16 3.2 (0.5) 3.6 (0.4) 0.089 (PT) 
miR-122 1.8 (0.5) 2.1 (0.5) 0.57 (PT) 
 
   
    
 
  
Table 5-6 Summary of plasma miR results before and after exercise with paired analysis results 
Plasma miRNA values are log AU and either shown as mean (SD) or median (75th percentile, 25th percentile). D’Agostino and Pearson omnibus test was used to 
test whether the data were normally distributed. Significance of difference before and one hour after exercise  in the groups is shown as p value using either 
paired t test if both groups were normally distributed data (PT), or Wilcoxon matched pairs test (W) as the non-parametric alternative.  All values are included 
in this analysis, therefore COPD patients n=33, controls n=12. 
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5.3.7 Plasma miR-1 levels were (in contrast to previous study) elevated in the controls 
compared to COPD patients 
 
In the first study of this thesis (chapter 3), it was shown that skeletal muscle specific miRs were 
elevated in the plasma of COPD patients compared to controls.  MiR-1 was the most significantly 
increased miR between the two groups.  Results from this current study, demonstrate that miR-1 
plasma levels were, in contrast, significantly higher in the control subjects compared to the COPD 
patients before exercise (figure 5.10) and numerically higher, but not statistically significantly after 
exercise (p=0.066).  
 
 Figure 5-5 Fasted plasma miR-1 levels were elevated in controls compared to COPD patients 
There was a significant difference between the groups tested using an un-paired t test; p value is shown. This is in contrast to the results 
found in the cross-sectional cohort, where the patients and subjects were not fasted. Individual data points are shown with error bars 
showing mean and SEM.  
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5.3.8 Plasma miR-181 levels were different between COPD patients and controls after 
exercise  
 
There was no significant difference between plasma miR-181 levels in the COPD patients when 
compared with healthy controls in the first study of this thesis (chapter 3). In this study however, 
median plasma miR-181 levels were lower before exercise in the COPD patients compared to 
controls, albeit this difference was not statistically significantly.  Although plasma mir-181 levels did 
not change on an individual level upon exercise in either group (figure 5.11 a), after exercise the 
COPD patients had significant lower levels of plasma miR-181 compared to the controls (figure 
5.11b).  
 
 
 
Figure 5-6 Changes in plasma miR-181 with exercise 
a. miR-181 did not change with statistical significance in the plasma of all subjects, COPD subjects alone or control subjects alone with 
exercise, analysis performed using paired analysis. b. Plasma levels of miR-181 were not significantly different between the two groups at 
baseline prior to exercise in fasted.  There was a significant difference in mean group values after exercise between the COPD patients and 
controls.  Data are shown with black dots representing COPD patients and open circles representing control patients. Individual data 
points are shown with error bars showing mean and SEM.  
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5.4 Discussion 
 
There were no changes noted in the quadriceps expression of miR-1, on which the study was 
powered, miR-133 or miR-499 one hour after an acute bout of exercise in either the COPD patients 
or controls.  It was however found that using a paired analysis approach quadriceps mean miR-181 
expression increased in the COPD patients one hour after an acute bout of exercise. If a corrected p 
value of <0.01 is used which takes into consideration multiple testing, then this just failed to reach 
significance as p=0.017. Levels of muscle-specific miRNA in the plasma levels did not change with 
exercise. Therefore testing the specific plasma miRNA analysed here one hour after exercise cannot 
be used to mark a trajectory of change in the muscle of COPD patients or controls.  This last point is 
in keeping with the observation that has been made in other studies: for example those studies of 
DMD patients and discussed in the Introduction chapter, in which there was found to be a complex 
relationship between muscle miRNA expression and circulating miRNA levels.  
 
The results of this study confirmed the results of previous data from my research group on muscle 
miRNA expression in a separate cohort of patients. Quadriceps miR-499 expression was reduced in 
the COPD patients and correlated with their MHCI mRNA expression, smoking history, and measures 
of daily physical activity. In addition, this study showed contradictory miR-1 plasma results to those 
found in the first study (see chapter 3).   
 
 
5.4.1 Significance of findings in muscle 
 
It was not an aim or a hypothesis of this study to investigate the mechanisms behind miRNA changes 
(if any) associated with exercise. This study was primarily designed to investigate muscle-specific 
miRNAs as biomarkers of miRNA changes that occur in muscle with exercise and the results were 
mainly negative. The fact that there was an increase in expression of miR-181 with exercise in COPD 
patients can lead to some interesting speculation about how this miRNA might be a physiological (or 
pathological) mediator of the effects of exercise, which is expanded on below, but this is theoretical 
and remains to be proven by other studies.  
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Change in quadriceps miRNA expression with acute exercise   
 
MiR-181 in the quadriceps of COPD patients may increase after acute exercise to function in a 
network of signals to regulate a key process associated with exercise: inflammation. This response 
may not have been seen in the healthy trained individuals, who are more physically active, because 
the relative impact of the acute exercise on locomotor muscles would have been less.  These 
theories are beyond the scope of this relatively small study and need to be confirmed in a separate 
cohort of patients, but the rationale (which remains quite hypothetical at present) behind these 
hypotheses is discussed briefly below for miR-181 with reference to its regulation and proposed 
down-stream targets.   
 
MiR-181 regulation 
 
The molecular mechanisms regulating miR-181 are not yet fully understood. They continue to be the 
subject of investigation: in vitro experiments studying cancer stem cells have led to the hypothesis 
that miR-181 may be up-regulated by transforming growth factor β (TGF-β) (Wang, Yu et al. 2011).   
Although TGF-β can act in a tissue-specific manner, in adult muscle, TGF-β1 (one isoform of TGF-β) 
can negatively affect skeletal muscle regeneration by inhibiting satellite cell proliferation, myofibre 
fusion, and the expression of some muscle-specific genes (Kim and Svendsen 2011). TGF-β1 can also 
induce the transformation of myogenic cells into fibrotic cells after injury (Nam, Won et al. 2011).  
 
Specifically in relation to its role in exercise-induced muscle injury, TGF-β is known to be 
physiologically increased in regenerating skeletal muscle after injury and exercise and is thought to 
play a role in a short-term transient inflammatory response to muscle damage (Serrano and Munoz-
Canoves 2010). TGF- β1 can induce an immune response but can also act as an anti-inflammatory 
mediator and an immunosuppressive (Yang, Zhang et al. 2012).  
 
As discussed above, it is assumed that more muscle injury occurs in the quadriceps of COPD patients 
with exhaustive exercise as compared to the controls. This assumption is made because in this study 
the COPD patients are less physically active than the controls (differences in activity data between 
the groups are highlighted in table 5.1). Therefore when the COPD patients undertake the tested 
exercise the load and duration of exercise is greater as compared to their normal levels of daily 
activity than controls. This theory is supported by the study of Menon (Menon, Houchen et al. 2012) 
colleagues who  studied the inflammatory response to exercise in 12 COPD patients and 7 healthy 
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controls. There was no difference in the FFMI between the COPD patients and the controls in their 
study, but they found a greater statistically significant inflammatory response in the quadriceps of 
COPD patients after exercise when compared to the controls, despite a lower exercise intensity.  
 
The proposed mechanisms for the regulation of miR-181 by TGF-β and the findings of Menon et al., 
might suggest the increase in miR-181 found in the COPD patients in this study could have resulted 
from more significant injury and inflammation in quadriceps of COPD patients caused by exercise (as 
compared to controls) increasing TGF-β signalling. That increased quantity of TGF-β could 
consequently lead to an increase in miR-181 expression. However it should be noted that this study 
did not assess the degree of muscle damage sustained from the exercise nor the degree of 
inflammation that occurred as a result of the exercise.  
 
This hypothesis should be treated with caution since it is based on limited literature and studies 
which did not involve muscle cell lines and this study was not designed to investigate mechanisms of 
disease. The response of miR-181 to inflammation in muscle cell lines is the subject of ongoing 
investigation by other investigators in the research group.  
 
 
Down-stream response to miR-181 
 
An increase in miR-181 expression will have an effect on its down-stream (predicted) targets. One 
such target which miR-181 is thought to inhibit is importin-α3, a protein that is required for nuclear 
translocation (and therefore function) of the transcription factor NFκB. 
 
As a result of miR-181 inhibiting the translation of importin-α3, miR-181 is thought to down-regulate 
NF-κB targeted genes that are associated with inflammation, such as inflammatory mediators, 
adhesion molecules, chemokines and their receptors (Sun, Icli et al. 2012). Physical inactivity has 
been shown to activate the non-canonical NFκB pathway (that utilises NFκB p50 and BCl3) as 
demonstrated by transgenic mouse models (Lee, Yu et al. 2011). The increase in miR-181 in response 
to exercise activity in COPD patients could therefore function to regulate (or turn off) the negative 
effects of NFκB on muscle mass and the associated muscle phenotype transition that are associated 
with inactivity.   
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The second relevant predicted target of miR-181 is the homeobox protein Hox-A11.  Hox-A11  is a 
repressor of muscle cell differentiation that acts by inhibiting the action of the transcription factor 
MyoD (Yamamoto and Kuroiwa 2003).  It would appear that an increase in miR-181 expression will 
reduce the inhibitory effect of HoX-A11 on MyoD. The release of the inhibition of MyoD that results 
from an increase in miR-181 would allow an increase in muscle cell differentiation.  
  
In the light of the results of this study, it would seem possible that if quadriceps MyoD expression is 
increased in response to an increase in miR-181 expression in the COPD patients, this would mean 
that quadriceps of COPD patients are able to respond to exercise with an adaptive response which 
promotes muscle repair, regeneration and remodelling after exercise.  That this response may be 
more sensitive in patients than in controls is consistent with the observation that the patients are 
sedentary compared to the controls as illustrated by physical activity data.  
 
 
MiR-206 
Although there was no difference in fold change expression in miR-206 between the COPD patients 
and the controls, it was found that median (75th percentile, 25th percentile) muscle miR-206 
expression before exercise was 0.5 (0.9, 0.4) log AU and increased to 0.7 (0.9, 0.6) log AU one hour 
after exercise in the COPD patients (paired analysis p=0.07).   
 
The trend towards an increase in quadriceps miR-206 expression in the COPD patients in this study 
on paired analysis suggests that the quadriceps of COPD patients might respond to the stimulus of 
exercise with an miRNA response that is involved in regeneration and fibre type transition.  Similar 
to the increase in miR-181 expression in the COPD patients, the trend towards an increase in 
quadriceps miR-206 expression in COPD patients and not controls might also imply it is a disease or 
inactivity related phenomenon.  
 
 
Different muscle miRNA responses to acute exercise within the COPD patients  
 
There were only 4 COPD patients and 3 control patients classified as having a low fat-free mass. As a 
result of the low numbers of patients, the changes in miRNA responses to exercise were not 
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analysed in such a way to compare responses in those with normal fat-free mass to those with low 
fat-free mass.  
 
In the COPD patients, quadriceps miR-181 expression after exercise correlated with MHCI mRNA 
expression. Therefore, within the COPD patients, those with the greater quantity of MHCI mRNA had 
the greatest miR-181 expression in their quadriceps after exercise.   
 
If the change in miR-181 expression is calculated for the COPD patients, it can be seen that within 
this group the greatest change in quadriceps miR-181 expression was also found in those with the 
greatest exercise ability as measured by oxygen uptake at maximum workload. In an untrained 
group of individuals such as the COPD patients in this study, it therefore appears that those who 
have higher MHCI mRNA expression are able to exercise to a greater degree on the cycle ergometry 
test and have a greater change (increase) and higher absolute levels of quadriceps miR-181 
expression.   
 
The lack of correlations between miR-181 and other patient physiology further limits interpretation 
of muscle miRNA response to exercise within the COPD patient group. 
 
If the COPD patients were grouped into those with reduced quadriceps strength (n=10) compared to 
those with preserved quadriceps strength (n=10), where quadriceps weakness was defined as a 
QMVC in kilograms less than 120% of the patient’s body mass index (Swallow, Reyes et al. 
2007), there was a trend for muscle expression of miR-206 to increase one hour after exercise 
(p=0.02), from a mean expression before exercise of (SD)= 0.5 (0.29) to 0.75 (0.13) log AU).  Using 
the unlogged muscle miR-206 data, this was calculated to be a 1.5 fold increase in expression.  
 
There were no other changes for any other muscle miRNA analysed using this sub group analysis.  
 
Confirmation of previous results on muscle miRNA expression in COPD patients 
 
The results of this study confirmed some of the results of our previous data on muscle miRNA 
expression in a separate cohort of patients. 
 
In this study, quadriceps miR-499 expression was reduced in the COPD patients and correlated with 
MHCI mRNA expression, smoking history, and measures of daily physical activity.   
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MiR-499 is known to be co-expressed with MHC I and regulates type I fibre gene expression. It is 
therefore expected that correlations between quadriceps miR-499 expression and MHCI mRNA 
should exist.  
 
A correlation between miR-499 expression and daily activity would be predicted to exist due to the 
biological function of type I fibres in endurance activities, such as walking.  Data to support the 
relationship between % type I fibres in the quadriceps and exercise ability (6 minute walk distance 
and peak oxygen consumption as % predicted) has been published by Natanek and colleagues 
(Natanek, Gosker et al. 2013).   
 
5.4.2 Significance of findings in plasma 
 
Change in plasma miRNA levels with acute exercise  
 
This study found that there was no difference in circulating muscle-specific miRNA levels in the 
plasma of the COPD patients or controls one hour after an acute bout of exercise. In line with the 
largely negative plasma results for this study, there were no significant miRNA changes in the plasma 
of patients with reduced quadriceps strength compared to those with preserved quadriceps 
strength.   
 
There is a relative paucity of literature surrounding circulating miRNA and changes with exercise, 
especially in diseased patients.  One study has measured levels of miRNA which are thought to 
function in angiogenesis, inflammation, skeletal and cardiac muscle contraction and hypoxia 
adaptation in the circulation of healthy young male rowers and found some changes occur with 
exercise (Baggish, Hale et al. 2011).   
 
Specifically, the work of Baggish et al demonstrated that levels of miR 146a, miR-222, miR-21 and 
miR-211 significantly increased in the blood samples of 10 young male athletes immediately after 
exercise (mean fold changes 3, 2.46, 1.89 and 3.58 respectively) and the levels of these miRNA then 
returned to baseline values after one hour of rest.  The only muscle-specific miRNA they studied was 
miR-133. Levels of miR-133 did not change in response to acute exercise.  It is difficult to draw 
comparisons of their results with the results of the current study as they studied younger individuals, 
who were trained athletes. 
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The fact that changes in miR levels were found in that study may be attributable to the greater 
degree of exercise (load or duration) that the trained athletes were able to perform. Such a degree 
of exertion may be necessary to cause a change in miR levels, or enable any change in miR levels to 
be sufficiently significant so as to be measured in plasma. 
 
To date, there have been no studies on the simultaneous effect of exercise on both muscle and 
plasma miRNA in either healthy or diseased individuals.  This study would therefore appear to be the 
first study undertaken that analyses the effect of exercise on both muscle and blood.  
 
The samples analysed in this study were taken from COPD patients and controls with mean ages of 
66 and 63 years respectively. Whilst this analysis did not show a difference in circulating miRNA 
levels in the plasma, it would be interesting to see whether in younger healthy individuals their 
levels of muscle-specific miRNA would change in the circulation in response to an acute exercise. 
Such a finding of changes in plasma miR levels might indicate that this response is dependent upon 
age, the likely greater degree of exercise (either in load or duration) of younger subjects, or a 
combination of the two.  
 
Plasma miR-1 results 
 
In this study we found that plasma miR-1 levels were higher in the control patients as compared to 
the COPD patients, both before (p=0.02) and after exercise (p=0.066). This is contradictory to the 
results found in the first study of this thesis in chapter 3 which showed that stable COPD patients 
had higher plasma miR-1 levels as compared to healthy controls.  
 
The difference in the miR-1 results between the two studies could either be due to: (i) the reduced 
number of patients studied and therefore simply the effect of sample size; or (ii) the study design 
and therefore the effect of fasting on the muscle (and origin of circulating miR-1) of the subjects; or 
a combination of the two. It is also possible that differences in the control groups or the size of the 
control groups contributed to the apparent difference. 
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The number of subjects 
 
The patients in this study had a mean FEV1 predicted of 56% and were categorised into GOLD IV, 
n=3, GOLD III, n=4, GOLD II, n=9, GOLD I, n=4. Therefore the COPD patients represent a relatively 
mild form of COPD. MiR-1 plasma levels in the first study in this thesis negatively correlated with 
FEV1% predicted in all of the subjects, and the levels in the milder patients were similar to those 
measured in the control patients.  It could simply be that there were not enough severe COPD 
patients in this study to find increased levels in the COPD patients as a group compared to the 
controls.   
 
The effect of fasting 
 
If the increase in miR-1 in the control patients was not an effect of sample size, the findings in this 
current study might be explained on the basis that miRNA export into the circulation could be 
altered by fasting. This would entail a difference in the muscle response to glucose and insulin 
between COPD patients and controls.   
 
However as no changes in muscle miR-1 expression were apparent between the two groups before 
exercise, the effect of fasting on miR-1 expression in the muscle is unlikely to fully explain the 
findings in the blood.  
 
Therefore the changes in circulating miR-1 could be explained by the effects of fasting on other 
molecular pathways which, for example, affect miRNA export. As miRNAs can circulate bound to 
lipoprotein particles, as such the difference may reflect changes in lipid profiles in patients and 
controls that may occur in response to fasting. These findings and hypotheses of the effect of 
starvation, reduced glucose and altered insulin sensitivity on plasma miRs of COPD patients are 
currently being investigated by another researcher in the group (Dr M. Baz).  
 
 
5.4.2 Limitations of the study 
 
Although this study found miR-181 expression increased in response to exercise using a paired 
analysis approach in COPD patients, the mechanism by which miRNA do so and the resultant effects 
can only be hypothesised. That is because up-stream regulators and down-stream targets of miR-181 
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in exercise were not investigated in this study.   These are the focus of ongoing in vitro studies, but 
were not an aim or hypothesis of this current study.  
 
It should also be noted that the subjects in both the COPD and control group in this study were 
relatively elderly compared to other studies, which have already been referred to, in the literature. 
This study found that exhaustive cycle exercise had only limited effects on inducing muscle-specific 
miR expression one hour after exercise termination in this age group. It is highly plausible that if by 
comparison younger patients muscle samples were studied, the results of this study might have 
differed due to the more sedentary lifestyle that often occurs in the older population.  
 
This study investigated the effects of acute exercise on plasma and muscle miR expression at only 
one time point: one hour after acute exercise. This time point was chosen, as explained in the 
introduction, because other studies have found changes in miRNA expression one hour after 
exercise. However, it may be that miRNA responses to exercise are more significant at later time 
points. This could potentially explain the lack of change seen in miR-1 and miR-133. It would have 
been useful to analyse more time points in a fewer number of patients at first, to confirm that there 
was no change with exercise.  
 
The relevance of the chosen time point is illustrated by the study of healthy subjects by Russell and 
colleagues who analysed muscle taken at a later time point after exercise. The authors of that study 
used a pure endurance cycle protocol (as compared to the incremental symptom-limited cycle test 
used in this study) where subjects cycled for 60 minutes at 70% of VO2 peak and the samples were 
taken from the subjects’ quadriceps 3 hours after exercise. The results showed that miR-1, miR-133 
and miR-181 expression increased significantly by 60%, 35% and 35% respectively (Russell, Lamon et 
al. 2013). 
 
Studies in the literature have also investigated muscle miRNA responses at later time points: 6 hours 
after exercise (Drummond, McCarthy et al. 2008) and 48 hours after exercise (Davidsen, Gallagher et 
al. 2011); but the feasibility of this with COPD patients is questionable. Drummond and colleagues 
measured primary miRNA expression (pri-miR) changes with exercise in young (n=6) and older men 
(n=6). They found that at 6 hours after exercise Pri-miRNA-1-2, -133a-1, and -133a-2 were 
significantly reduced only in the young men compared with baseline, whereas pri-miRNA-206 was 
elevated at 3 hours and 6 hours after exercise in older and young men. Compared with baseline, 
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mature miR-1 was reduced (50%) only in the young men at 3 and 6 hours after exercise (Drummond, 
McCarthy et al. 2008).  
 
Davidsen and colleagues studied subjects classed as ‘high responders’ and ‘low responders’ with 
regards to muscle mass gain after exercise. After a 12 week resistance training programme, these 
authors found that quadriceps expression of miR-378, miR-26a and miR-29a reduced by a relative 
change of 0.4, 0.6 and 0.4 respectively compared to baseline, and levels of miR-451 increased with a 
relative change of 4 compared to baseline. There were no changes in these miRNA expression before 
the exercise programme. In this study biopsies were taken 48 hours after a final training session 
(Davidsen, Gallagher et al. 2011).  
 
Whilst the inclusion of later time points may have potentially revealed other miRNA responses that 
occurred later with exercise, these changes might not in any event be a true response to the acute 
exercise. This is because confounding factors, such as the unknown effects of feeding, might be 
introduced as a result of the interim period between further biopsies. The effects of potential 
confounding effects might have been exacerbated had further biopsies been taken in this study 
because all subjects had fasted prior to being assessed.  
 
The primary aim of this study was to investigate miRNA responses to acute exercise. Therefore 
muscle biopsy tissue was prioritised for this analysis. Because of the limited amount of muscle tissue 
obtained, it was not possible to analyse the fibre type proportions in the muscle biopsies for all of 
the subjects in this study. Therefore fibre type analysis and analysis for histological evidence of 
inflammation was not performed.  The reason for the limited tissue from some of the muscle 
biopsies was that the automated method (Magnum device system) used to obtain the muscle 
samples in the subjects did not always provide enough tissue to be processed for histological 
analysis.  
 
The COPD patients and controls included in this study had similar fat-free masses and quadriceps 
strength. It may be that miRNA response to exercise would differ in a more wasted and/or severe 
COPD group. However, this study cannot comment on this.  
 
Despite the relatively large number of COPD patients and controls taking part in this study (20 COPD 
patients and 11 controls) as compared to published studies, the absolute size of the study may limit 
the plasma result findings and it might be that the study was underpowered to detect the 
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anticipated change in miR expression/ miR levels. It should be noted that the first study in this thesis 
had, by contrast, 103 COPD patients and 25 controls and therefore the results of that first study 
might be more representative of the general COPD population.  
 
5.4.3 Conclusions 
 
Although this study is not able to offer any evidence on the mechanistic roles of miRNA in an 
adaptive response to exercise, the data presented nevertheless show that mean muscle miR-181 
expression increases in the COPD patients in response to acute exercise.  
The difference in the response of miR-181 expression to exercise is consistent with COPD patients 
possibly having a greater inflammatory response to exercise stimulus as compared to the controls. 
The trend towards an increase in muscle miR-206 expression suggests that the quadriceps of COPD 
patients might mount an injury or insult response to acute exercise which may be implicated in the 
regulation of fibre type.    
This study has also found that plasma levels of several muscle-specific miRNA do not change one 
hour after exercise. This implies that the increase in plasma muscle-specific miRNA in COPD patients 
(as compared to the controls) that was observed in the first study of this thesis is unlikely to be an 
acute phenomenon, or one which could change on a short term basis. These findings would be 
consistent with the largely negative results from the previous chapter (chapter 4), in which no 
changes were found in plasma levels of skeletal muscle-specific miRs associated with an AECOPD.  
The next study of this thesis expands the investigation of miRNA in the COPD population to those 
miRNA which are not necessarily muscle-specific but their levels might differ between COPD patients 
with particular phenotypes.   The design of the next study specifically allows investigation of miRNA 
associated with a loss of fat-free mass in the more severe COPD patients. The design of this current 
study meant that it was not possible to examine the effects of exercise in the more wasted or severe 
COPD patients.  
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6 . Identification of plasma microRNA associated with severe COPD 
and the loss of fat-free mass  
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6.1 Introduction 
 
In the first study in this thesis I showed that levels of muscle specific miRNA are higher in the plasma 
of COPD patients compared to controls. As the quadriceps are the main group of muscles affected in 
COPD patients and for reasons proposed in chapter 3, the increased levels of muscle-specific miRNA 
were hypothesised to reflect the greater amount of muscle turnover that occurs or has occurred in 
the quadriceps of COPD patients. The results of the first study also showed that plasma miR-1 levels 
were associated with fat-free mass and miR-499 levels with the presence of quadriceps type I fibre 
shift.   
However, so far in this thesis no one individual skeletal-muscle specific miRNA or combination of 
skeletal-muscle specific miRNAs measured in the plasma has been shown to be diagnostic of 
quadriceps muscle fibre atrophy or fibre shift.  Furthermore, plasma levels of muscle-specific miR-1, 
miR-133, miR-181, miR-206 or miR-499, did not change with exercise or during an acute 
exacerbation of COPD. It therefore remains the case that there is no method to monitor or detect 
quadriceps atrophy and/or fibre shift without analysing muscle biopsy material. 
The aim of this study was to investigate a larger number of plasma miRNAs that are not necessarily 
muscle-specific but which might prove to be better markers of severe COPD and a low fat-free mass 
index. Specifically, this study was planned to identify plasma miRNAs that might be associated with a 
diagnosis of LFFMI in severe COPD patients and might therefore be useful in monitoring the 
response of COPD patients to treatments that target muscle mass. It was hoped that identification of 
miRNA in the plasma associated with a LFFMI would also allow identification of potential 
mechanisms contributing to the presence of a LFFMI in COPD patients.   
Loss of muscle mass has important prognostic implications, such as reduced survival and increased 
morbidity, but not all COPD patients are affected equally and factors regulating susceptibility to loss 
of muscle mass in COPD remain under investigation. Therefore this study was also carried out to 
investigate any potential factors that could increase the susceptibility of an individual with COPD to a 
LFFMI. 
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6.1.1 Aims and hypothesis of the study 
 
A screening study will identify: 
1.  Those circulating miRNA that have not been previously investigated in this thesis which are not 
necessarily muscle-specific, but which differ between COPD patients compared to controls. 
2. The circulating miRNA patterns that are associated with the presence of a low fat-free mass index 
in a subset of GOLD stage III and IV COPD patients.  
3. Plasma miRNA that are associated with a loss of type I fibres in corresponding quadriceps muscle 
biopsies and a reduction in quadriceps strength. 
 
The hypothesis of this study is that there will be markers of disease and muscle wasting detectable in 
the plasma of the patients with COPD. 
This hypothesis was tested by using an array approach to quantify 754 miRNAs in plasma samples 
taken from 8 COPD patients with a normal fat-free mass, 8 patients with a low fat-free mass and 8 
healthy controls. The results were then compared between (i) the COPD patients and the controls 
and (ii) between the COPD patients with a NFFMI and those with a LFFMI. Experiments were 
performed to validate the findings from the latter analysis.    
 
6.2 Methods  
 
6.2.1 Patient recruitment and study design 
 
The design of the study is outlined in the Methods chapter.  
Briefly, plasma samples from three selected groups of male subjects were tested in this study: GOLD 
stage III-IV COPD patients with a LFFMI; GOLD stage III-IV COPD patients with a normal FFMI; and 
aged-matched healthy controls. Some of the subjects tested in this study were excluded from the 
final analysis because a high proportion of the plasma miRNA levels for that subject were below 
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levels of detection. Therefore, of the 24 subjects tested, 7 COPD patients with an NFMMI, 8 COPD 
patients with an LFFMI and 4 healthy controls were included in the final analysis.   
All subjects were male and the samples used were from the same cohort used in chapter 3 for which 
physiological data and biological specimens obtained were by Dr. A. Natanek. A low FFMI was 
defined as FFMI <16kg/m2 in males and <15kg/m2  in females (Schols, Broekhuizen et al. 2005). 
 
6.2.2 Molecular methods 
 
I performed all of the molecular experiments. To identify any differences in circulating miRNA 
between the subjects in this study, I performed a miRNA Taqman® PCR array, hereafter referred to 
as the “screen”.  These commercially available arrays are designed to measure 754 known miRNAs in 
one sample. The experiment therefore quantified miRNAs that had not been investigated in the 
previous chapters of this thesis.   
MiRNA that were found to be significantly different between the groups (i.e. hits from the screen) 
were then validated in a larger cohort of patients and controls. The levels of miRNA were quantified 
using individual Taqman assays in 21 COPD patients with LFFMI, 17 with a NFFMI and 12 healthy 
controls.  
 
Samples tested in validation experiments 
Due to the limited number of samples available, it was necessary to include samples from the 
patients that had been included in the screen study in the validation experiments.  Therefore in the 
validation experiments 7 out of the 17 NFFMI patients had previously been included in the screen 
study, 8 of the LFFMI patients had been in the screen study and 4 of the controls had previously 
been tested in the screen study. This is a weakness of the study, but these samples were included so 
that a greater number of patients could be included in the analysis. Further validation of these 
miRNAs is therefore still required in a separate cohort of patients.  
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Choice of miRNA tested in validation experiments 
MiRNA were validated if they were reliably detected in all samples tested in the screen and were 
considered to be miRNA representative of chromosomal regions suggested to be dysregulated in 
those with a LFFMI.  It should be noted that, due to these reasons, the miRNAs chosen to be 
validated were not necessarily those with the most significant difference between the NFFMI 
patients and those with a LFFMI. 
 
6.2.3 Statistical analysis 
 
Power calculation 
Calculation of the appropriate sample size in planning a microarray or screen study is not 
straightforward because the number of genes is far larger than the number of samples meaning that 
traditional methods of sample-size calculation cannot be directly applied.  
In performing a sample size calculation, assumptions have to be made. For example, it is assumed 
that the expression of each gene is normally distributed on the log scale and that the variance is the 
same in the groups. Therefore in the groups tested, the only difference between the groups is the 
mean of the gene of interest. The calculation also assumes that gene expression measurements are 
independent.  
The power calculation indicated that to detect a three-fold increase in plasma miR-1 levels in COPD 
patients with a LFFMI compared to COPD patients with a NFFMI, using an 80% power and a standard 
deviation of the gene intensity measurements on the base-two logarithmic scale of 0.7, a minimum 
of 7 subjects in the NFFI and LFFMI groups would be required. This number of subjects would be 
required to detect the stated difference in samples with a normal distribution. 
(http://bioinformatics.mdanderson.org/MicroarraySampleSize/). 
The study was powered on plasma levels of miR-1 as it was found that levels of miR-1 negatively 
correlated with the FFMI of the COPD patients in the first study of this thesis. No other miRNA was 
associated with measures of FFM in that study. Although in that cohort, it was not possible to 
separate the NFFMI COPD patients from those with a LFFMI based on the results obtained, as this 
current study had a more distinct patient groups with regards to FFM,  it was expected that a 
significant difference would be observed in levels of miR-1.   
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The acceptable number of false positives (n=1) was divided by the number of genes to generate a 
per-gene significance level alpha that would be expected to produce that number of false positives; 
in these experiments it was 0.00133.  
 
Data analysis  
All gene expression data was log transformed to stabilize variance and produce a normal distribution 
prior to analysis.  
Differences in gene expression between the groups were tested for using an unpaired T test. Gene 
expression for those that were found to be different between the COPD patients compared to the 
controls (“COPD-associated plasma miRNA”) were then expressed as a median ratio of COPD 
patients:controls and for those miRNA that were reduced in the COPD patients compared to 
controls, as a fold reduction. The genes that were found to be different between the COPD patients 
and controls were further compared between the subgroups of COPD patients, i.e. those with a 
LFFMI and those with a NFFMI, and the controls.  
Gene expression data for plasma miRNA that were different between the LFFMI COPD patients and 
the NFFMI COPD patients were handled in the same manner. 
A p value of <0.05 was taken as significant for differences in gene expression; there were no 
corrections made for multiple testing.   
Volcano plots were constructed to illustrate the fold change in miRNA levels (x axis) between COPD 
patients and controls, and between LFFMI COPD patients and NFFMI COPD patients, compared to 
the statistical significance of the change (y axis).  
Correlation analyses in this study were performed using Pearson’s correlations and a p<0.05 taken to 
indicate statistical significance. ROC curves were constructed to investigate where miRNA levels 
could predict the presence of a LFFMI.  
 Data from this study have been analysed and the figures constructed using Microsoft Excel and 
GraphPad Prism Version 5.0 (GraphPad Software, San Diego, California, USA). 
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6.3 Results 
6.3.1 MiRNA Taqman® PCR array 
Patient characteristics 
The COPD patients and controls in this study form part of the larger cohort tested in chapter 3. The 
full table of characteristics for the whole cohort is shown in table 3.1 in chapter 3. An abbreviated 
table of characteristics with the key physiological measurements for only those patients and controls 
included in this study is shown in table 6.1.   
 NFFMI LFFMI controls 
NFFMI vs LFFMI 
p value 
Number 7 8 4  
GOLD III (IV) 3(4) 4(4) n/a  
Age (years) 62 (4) 68(6) 66 (11) 0.19 
BMI (kg/m2) 25.1 (1.6) 22.5 (5.3) 27.0 (4.8) 0.23 
FFMI (kg/m2) 16.9 (0.8) 14.3 (0.9)** 17.3 (0.8) <0.0001 
Smoking pack 
year history 
57 (26)* 59 (31)* 13 (26) 0.88 
Current smokers 1 2 0  
FEV1 (%pred) 30 (11) 31 (7) 114 (17) 0.71 
6MWD (m) 396.1 (142.8)** 348.8 (150.2)** 687.8 (92.7) 0.54 
Best QMVC (kg) 31.3 (7) 26.6 (8.5)* 39.6 (7.6) 0.29 
Best TwQ (kg) 8.4 (3.5) 6.2 (1.1)*** 12.3(2.4) 0.18 
QMVC/wt (kg/kg) 0.4 (0.1) 0.4(0.1) 0.5(0.1) 0.98 
QMVC/BMI 1.2(0.3) 1.2(0.3) 1.5 (0.4) 0.68 
Table 6-1 Table of characteristics for the patients and the controls in the screen array 
Physiological results are shown for the two groups of COPD patients (NFFMI and LFFMI) and the controls. All physiology results collected 
by Dr. A. Natanek. Data shown as mean (SD).  *(p < 0.05) ** (p = <0.01) ***(p= <0.001) LFFMI or NFFMI vs control. Statistical significance 
was determined using T test for the data shown. See  list at start of thesis for abbreviations.  
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From the table of characteristics it can be seen that the COPD patients in both the NFFMI and LFFMI 
groups had characteristics typical of severe COPD patients. The COPD patients had (by definition) a 
reduced FEV1 % predicted, and in line with the design of this study, the COPD patients in the LFFMI 
had a significantly lower FFMI compared to the NFFMI patients and the controls.  
 
The COPD patients had a reduced exercise capacity (as measured by a 6 minute walk distance) and 
lower measures of quadriceps strength, both volitionally (QMVC) and non-volitionally (quadriceps 
twitch), compared to the controls. The measurements of quadriceps strength were only significantly 
lower in the LFFMI group compared to controls. The NFFMI and LFFMI COPD patients were well 
matched for age, lung function and smoking history.  
 
 
Analysis of plasma miRNA levels using the TaqMan® Array MiRNA Cards 
 
As discussed in the methods chapter, the miRNA qPCR results expressed as Ct values were 
normalised to the geometric mean U6 and RNU48 using the ΔΔ Ct method. The normalised values 
were then log transformed for further analysis. If miRNA levels were not detectable in a sample 
within the threshold set, the sample was assigned the threshold Ct value so that they were included 
in the analysis. 
 
The results for the screen experiments in this chapter focus on miRNA levels that: (i) differed in 
COPD patients and controls, (ii) differed in NFFMI COPD patients and LFFMI COPD patients or (iii) 
differed between patients with a normal or a shifted distribution of fibre-types in the quadriceps. 
 
Plasma miRNA levels that differed in the COPD patients and the controls in the screen:  COPD-
associated miRNA 
The miRNA profiles showed high inter-individual variation and the NFFMI COPD patient and the 
LFFMI COPD patient groups could not initially be separated by principal component analysis.  
Therefore to identify the COPD-associated miRNA, the entire COPD cohort was compared to the 
controls and no further filtering was applied.  
In total, 21 miRNAs were found to be significantly different in the plasma of the COPD patients when 
compared to the controls at p=<0.05 level (‘the COPD-associated miRNAs’). It was found that there 
179 
 
were 18 miRNA that were reduced at the p=<0.05 level in the COPD patients when compared to the 
controls and 3 miRNA that were increased in the COPD patients when compared to the controls.  
Taking a significance value of p= <0.01, it was found that only 3 miRNA were significantly reduced in 
the COPD patients compared to the controls. The miR that was most significantly different between 
the COPD patients and controls was miR-30d# which was suppressed 1.7 fold in the COPD patients 
compared to the controls when using median values (table 6.2 and figure 6.1).  
MiR-483, was represented twice in the COPD associated miR group (by both -3p and -5p forms) 
increasing the likelihood of it representing a true difference between the populations. MiR-483 is 
from chromosome 11 and expressed as part of the IGF-2 gene, a genetically imprinted locus 
associated with growth. Of the 21 COPD-associated miRNA changes, 5 miRNA are shown to be 
mapped to (or within 500Kbp of) locations known or suspected to be genetically imprinted 
(www.geneimprint.com), including miR-30d. These are shown in the table with a * next to the 
genomic locus. 
The miRNA within these genetically imprinted regions are considered further in the discussion.  
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miRNA COPD compared to controls 
NFFMI compared to 
controls 
LFFMI compared to 
controls 
Id Genomic locus p value 
Median 
ratio 
COPD: 
controls 
Fold 
reduction 
in COPD 
patients 
p value 
Median 
ratio 
NFFMI: 
controls 
p value 
Median 
ratio 
LFFMI: 
control 
miR-30d# 8q24.22 * 0.005 0.58 1.73 0.122 0.69 0.007 0.55 
miR-548E 10q25.2 0.006 0.11 8.89 0.586 0.44 0.00002 0.07 
miR-198 3q13.33 0.009 0.09 11.24 0.024 0.09 0.094 0.12 
miR-483-3p 11p15.5* 0.011 0.34 2.96 0.093 0.37 0.012 0.21 
miR-1253 17p13.3 0.012 0.46 2.20 0.017 0.46 0.045 0.43 
miR-511 10p12.33 0.017 0.06 16.05 0.209 0.54 0.019 0.044 
miR-27a# 19p13.13 0.027 0.53 1.90 0.230 0.67 0.026 0.47 
miR-331-5p 12q22 0.031 0.23 4.42 0.032 0.11 0.088 0.28 
miR-483-5p 11p15.5* 0.032 0.52 1.92 0.361 0.52 0.016 0.49 
miR-501-3p Xp11.23 0.033 0.76 1.32 0.345 1.01 0.010 0.49 
miR-139-3p 11q13.4 0.034 0.59 1.69 0.106 0.76 0.029 0.58 
miR-345 14q32.2 0.040 0.68 1.47 0.179 0.96 0.021 0.65 
miR-1270 19p12 0.040 0.44 2.26 0.070 0.55 0.059 0.39 
miR-28-3p 3q28 0.042 0.72 1.39 0.300 0.90 0.016 0.65 
miR-184 15q25.1* 0.044 0.60 1.66 0.123 0.41 0.084 0.64 
miR-221 Xp11.3 0.045 0.65 1.55 0.413 0.83 0.009 0.58 
miR-10b# 2q31.1 0.045 0.52 1.91 0.119 0.52 0.080 0.41 
miR-425# 3p21.31 0.048 0.69 1.44 0.329 1.11 0.031 0.63 
miR-603 10p12.2 0.011 7.17 - 0.199 2.06 0.004 7.45 
miR-138 3p21.32 0.029 1.86 - 0.018 2.21 0.070 1.65 
miR-216b 2p16.1* 0.038 1.54 - 0.429 1.15 0.029 18.09 
 
Table 6-2 COPD-associated plasma miRNA 
MiRNAs that were suppressed in COPD patients compared to controls are shown above the line in order of statistical significance; those 
increased in COPD patients compared to controls are shown below the line in order of statistical significance.  
Ratios are calculated using non-logged data and median average values for each of the groups as unlogged data was not normally 
distributed. All ratios are expressed relative to healthy controls, where controls=1. Fold changes are given for those miRNA that were 
reduced in the COPD patients compared to controls. Genomic loci were identified using the Ensembl genome browser. p values were 
calculated by t-test and significance cut of p<0.05 was set to indicate statistical significance. * indicates miRNA from a genetically 
imprinted region.  
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Figure 6-1 Volcano plot analysis of plasma miRNA levels of the COPD patients compared to the controls 
Volcano plot analysis of plasma miRNA levels of COPD patients compared to controls for both the LFFMI patients and NFFMI patients.  
MicroRNAs were quantified and normalised for each individual to U6, and RNU48 as described in Methods.    
Horizontal lines represent p=0.01 and p=0.05 
 
 
On further analysis of all of the COPD-associated miRNAs, the miRNAs that were found to be 
reduced in the COPD patients when compared to the controls, i.e. the down-regulated COPD-
associated miRNAs, were then compared between the LFFMI COPD patients and the controls, and 
the NFFMI COPD patients and the controls. Of the 18 miRNAs, 3 were reduced in the NFFMI COPD 
patients compared to the controls and 13 were reduced in the LFFMI patients compared to the 
controls at p=<0.05 level.  Moreover, there appeared to be a co-ordinated pattern of change 
(although not significant for all miRNA at the p=<0.05 cut off) in which the miRNA levels increased or 
decreased in both patient groups compared to the controls. This pattern of change is shown in figure 
6.2, which also includes the COPD-associated miRNAs that were increased in the two groups of 
COPD patients when compared to the controls. 
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Figure 6-2 The COPD-associated miRNA: Significant miRNA changes between the NFFMI and LFFMI COPD patients 
compared to the controls 
Comparison of fold change of the miRNAs different at p<0.05 in LFFMI patients compared to NFFMI patients, between LFFMI patients and 
controls and the NFFMI patients compared to the controls. The COPD-associated miRNA that were increased in the two COPD patient 
groups compared to the controls are also shown.  
 
 
Plasma miRNA levels that differed between the LFFMI COPD patients and the NFFMI COPD 
patients in the screen: FFMI-associated miRNA 
Comparing miRNA levels between the NFFMI and the LFFMI COPD patients identified only one 
miRNA that was significantly different between LFFMI and NFFMI patients at p<0.01 and 23 miRNA 
that were different at p<0.05 level (table 6.3 and figure 6.3). These miRNA are therefore considered 
to be FFMI-associated miRNA and will be referred to as such for the remainder of this chapter.  
Amongst these 23 miRNAs, 9 were found to be derived from a single cluster present on chromosome 
14 in the delta-like homolog 1 - type III iodothyronine deiodinase region (DLK1-DIO3) and 4 from a 
cluster on chromosome 19, known as the chromosome 19 microRNA cluster (C19MC). These two 
clusters are known to be genetically imprinted regions. In addition to these two miRNA clusters, 3 of 
the other LFFMI-associated miRNA were found to be derived from chromosomal regions that are 
known to be or predicted to be imprinted regions (table 6.3 where * in genomic locus indicates 
miRNA from a genetically imprinted region).   
Only one miRNA was found to be increased in the LFFMI compared to the NFFMI patients (figure 
6.4), however, given the low stringency of this statistical cut–off in the absence of a statistical 
correction it may not be a true difference and needs to be confirmed in an additional cohort.  
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Furthermore, the miR concerned is derived from the C19MC and such an increase does not 
correspond with the pattern of miRNA change found in the LFFMI COPD patients for the rest of that 
cluster, namely that miRNA from the C19MC were found to be reduced in the LFFMI COPD patients.  
 
miRNA LFFMI compared to NFFMI 
NFFMI compared to 
controls 
LFFMI compared to controls 
Id 
Genomic 
locus 
P 
value 
Median ratio 
LFFMI:NFFMI 
Fold 
reduction in  
LFFMI 
patients 
p value 
Median ratio 
NFFMI:control 
p value 
Median ratio 
LFFMI:control 
miR-539 14q32.31* 0.002 0.33 3.00 0.025 3.18 0.891 1.06 
miR-548E 10q25.2 0.015 0.15 6.63 0.586 0.44 0.00002 0.07 
miR-520h 19q13.42* 0.019 0.10 10.14 0.117 6.08 0.283 0.60 
miR-559 2p21* 0.021 0.01 105.60 0.993 5.06 0.016 0.05 
miR-668 14q32.31* 0.024 0.38 2.62 0.218 2.04 0.629 0.78 
miR-485-3p 14q32.31* 0.024 0.45 2.20 0.124 2.61 0.682 1.19 
miR-135b 1q32.1 0.025 0.21 4.75 0.381 1.73 0.159 0.36 
miR-580 5p13.2 0.026 0.06 18.06 0.033 5.41 0.549 0.30 
miR-409-3p 14q32.31* 0.027 0.43 2.35 0.637 2.13 0.354 0.91 
miR-518e 19q13.42* 0.028 0.08 12.10 0.153 5.25 0.510 0.43 
miR-487b 14q32.31* 0.029 0.41 2.46 0.059 2.34 0.581 0.95 
miR-550 7p14.3 0.030 0.18 5.66 0.608 1.63 0.149 0.29 
miR-30d 8q24.22* 0.031 0.66 1.53 0.465 1.22 0.085 0.80 
miR-519d 19q13.42* 0.032 0.06 16.22 0.486 6.29 0.072 0.39 
miR-30a-3p 6q13 0.036 0.58 1.72 0.116 1.28 0.112 0.75 
miR-485-5p 14q32.31* 0.038 0.05 19.91 0.612 3.40 0.362 0.17 
miR-210 11p15.5* 0.040 0.44 2.28 0.398 1.29 0.074 0.57 
miR-623 13q32.3 0.041 0.21 4.78 0.183 4.77 0.919 0.10 
miR-422a 15q22.31 0.043 0.37 2.71 0.099 2.18 0.926 0.81 
miR-655 14q32.31* 0.045 0.55 1.82 0.062 2.58 0.898 1.42 
miR-543 14q32.31* 0.046 0.49 2.06 0.150 2.33 0.922 1.13 
miR-134 14q32.31* 0.049 0.49 2.03 0.366 1.43 0.405 0.70 
miR-520g 19q13.42* 0.049 4.52 - 0.254 0.30 0.747 1.34 
 
 
Table 6-3 Plasma miRNA that were different between the LFFMI COPD patients and the NFFMI COPD patients 
MiRNAs that were suppressed in LFFMI patients compared to NFFMI patients are shown above the line in order of statistical significance.  
MiRNA increased in LFFMI patients compared to LFFMI patients are shown below the line in order of statistical significance.  
Ratios are calculated using non-logged data and median average values for each of the groups as unlogged data was not normally 
distributed. LFFMI to NFFMI ratio is expressed relative to NFFMI (where NFFMI =1). The NFFMI and LFFMI to control ratios are expressed 
relative to controls (controls=1). Fold changes are given for those miRNA that were suppressed in the LFFMI patients compared to the 
NFFMI COPD patients. Genomic loci were identified using the Ensembl genome browser. p values were calculated by t-test and 
significance cut of p<0.05 was set to indicate statistical significance.  * indicates miRNA from a genetically imprinted region.  
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Figure 6-3 Volcano plot analysis of plasma miRNA levels of LFFMI COPD patients compared to NFFMI COPD patients 
Volcano plot analysis of plasma miRNA levels of LFFMI patients and NFFMI patients.   MicroRNAs were quantified normalised for each 
individual to U6, and RNU48 as described in Methods.  Average miRNA expression in LFFMI patients was then normalised to NFFMI, 
horizontal lines represent p=0.01 and p=0.05 
 
The difference in miRNA levels of the 23 miRNA identified as different between the plasma of the 
LFFMI COPD patients and the NFFMI COPD patients could arise for two reasons. 
Firstly, it is possible that the LFFMI COPD patients are at the extreme end of the patient spectrum. If 
this were the case, the significantly reduced FFMI associated-miRNA (i.e. those that were found at 
significantly lower levels in the LFFMI COPD patients compared the NFFMI COPD patients) would be 
reduced in both the LFFMI COPD patients and NFFMI COPD patients (but to a lesser degree) when 
compared to the controls but not different between the whole patient cohort and controls. 
However, the miRNA levels would have to be reduced further or to a greater extent in the LFFMI 
group relative to the controls, compared to the any reduction in the NFFMI group in order to explain 
the difference between the two groups observed in this study.   
When the data were analysed to compare the FFMI-associated miRNA further between the two 
COPD patient groups compared to the controls, the above explanations were found not to be true.  
It was found that 17 of the 22 reduced FFMI-associated miRNAs were present at a lower median 
level in LFFMI patients, but at a higher median level in the NFFMI patients when compared to 
controls (table 6.5). However, as it can be seen from the table, few of the miRNA differences 
reached statistical significance when comparing the median levels in controls with those in the 
LFFMI patients or the NFFMI patients.  
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 An alternative explanation for the difference in the direction of change of the plasma miRNA levels 
between the LFFMI COPD patients and the NFFMI COPD patients when compared to the controls 
could be that other factors such as genetics differ between the COPD patient groups. Although the 
differences were generally not significant between the two COPD patient groups and the controls, 
the findings that the levels of the majority of the LFFMI-associated miRNA were reduced in the 
plasma of the LFFMI patients compared to the controls but were increased in the plasma of the 
NFFMI patients compared to controls would support this second hypothesis. 
 
 
 
 
 
 
 
 
Figure 6-4 Significant miRNA changes between the NFFMI and the LFFMI COPD patients compared to the controls 
Comparison of fold change of the miRNAs different at p<0.05 in LFFMI patients compared to NFFMI patients between the LFFMI patients 
and the controls and the NFFMI patients and the controls 
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6.3.2 Validation of the plasma screen 
 
Patient characteristics in the validation of screen 
Table 6.4 shows the characteristics of the COPD patients and the controls included in the validation 
of the screen study.  Inclusion criteria for the COPD patients and controls were the same as for the 
screen study (i.e male and GOLD III or IV for the COPD patients). 
The main differences in characteristics to highlight from the table are: 
The COPD patients compared to the controls 
The COPD patients in the NFFMI and LFFMI groups had significantly lower FFMI compared to the 
controls.  The two groups of COPD patients were less physically active with a reduced locomotion 
time compared to the controls and had significantly reduced exercise capacity as measured by their 
6-minute walk distance.  
The NFFMI and LFFMI COPD patients had reduced measures of quadriceps strength compared to the 
controls and a lower SGRQ score which reflects the lower health status of the COPD patients.  
Consistent with the fibre shift that has been found to occur in the quadriceps of COPD patients, the 
COPD patients in this study had a reduction in quadriceps % type I fibres and an increase in % type 
IIa fibres when compared to the controls.  Also consistent with known muscle fibre changes in COPD,  
the average type IIx fibre cross-sectional areas was reduced in the quadriceps of the COPD patients. 
 
The NFFMI COPD patients compared to the LFFMI COPD patients 
The main difference between the COPD patients in the NFFMI group and the LFFMI group were 
measures of FFMI, BMI and weight as per the study stratification. These two groups of COPD 
patients were also found to have significantly different quadriceps strength, where QMVC was 
reduced in the LFFMI patients.  
  
187 
 
 
 NFFMI LFFMI controls NFFMI vs LFFMI 
p value 
Number 17 21 12  
GOLD III (IV) 8 (9) 13 (8) n/a  
Age 64 (6) 67 (8) 67 (10) 0.160 (T) 
Height (cm) 173.4 (7.3) 171.2 (7.2) 174.7 (7.5) 0.354 (T) 
Weight (Kg)# 67.8 (77.8, 60.4) 54.0 (63.0, 48.0)*** 73.6 (78.0, 59) 0.005 (MW) 
BMI (kg/m2)# 24.9 (28.3, 23.7) 21.7 (22.4,19.4)** 26.25 (29.1, 24.7) 0.0001 (MW) 
FFMI (kg/m2)# 16.9 (18.0,16.5)  14.5 (15.2,14.3) 19.0 (20.6, 17.2)  
Pack year 60 (27)*** 49 (26)*** 14 (21) 0.208 (T) 
FEV1 (%pred) 30 (9) 34 (9) 111 (14.) 0.238 (T) 
RV/TLC (%) 61 (8)*** 60 (8)*** 35.1 (3.6) 0.811 (T) 
TLCO (% pred) 39(14)*** 40 (20)*** 94 (15) 0.826 (T) 
PaCO2 (kPa) 5.4 (0.6) 5.1 (0.6) 5.4 (0.4) 0.223 (T) 
PaO2 (kPa) 8.8 (1.4)** 9.7 (1.7) 10.9 (1.7) 0.089 (T) 
Current smokers 2 3 0  
6MWD (m) 380.6 (120.4)*** 396.0 (137.4)*** 638.2 (9.6) 0.720 (T) 
locomotion time (min/12h)# 37 (60, 19)** 47 (71, 20)** 86 (122, 61) 0.270 (MW) 
SGRQ* 52.0 (66.5,45.5)*** 56.0 (66.0,43.0)*** 2.5 (8.0,0.0) 0.768 (MW) 
Best MVC (kg) 34.0 (8.6)* 27.7 (6.9)*** 41.8 (8.9) 0.017 (T) 
Best TwQ (kg)# 8.7 (10.3, 6.3)* 7.1 (8.7, 5.8)*** 10.7 (14,9) 0.073 (MW) 
MVC/wt (kg/kg)# 0.5 (0.6, 0.4) 0.4 (0.5, 0.4) 0.5 (0.6, 0.4) 0.883 (MW) 
MVC/BMI 1.3 (1.6,1.0) 1.2 (1.4,1.1) 1.6 (1.8,1.2) 0.849 (MW) 
% type I fibres 28.5 (12.3)*** 24.7 (13.4)*** 51.1 (17.1) 0.366 (T) 
% type I/IIa fibres# 1.0 (3.5, 0.0) 3.0 (10.5, 0.5) 4.5 (6.0, 0.3) 0.228 (MW) 
% type IIa fibres# 66.0 (69.0, 60.0)*** 62.0 (70.0, 57.0)*** 45.0 (53.0, 32.5) 0.724 (MW) 
% type IIx fibres# 4.0 (8.0, 0.5) 5.0 (10.5, 2.0) 4.0 (6.8, 0.3) 0.301 (MW) 
CSA type I fibre um2# 5036 (5732, 4329) 5363.60 (5886, 4251) 5771.0 (6224, 5096) 0.883 (MW) 
CSA type I/II fibre um2# 5312.0 (6229.0, 4359.0) 5437.0 (6123.0, 4665.0) 6027.0 (6896.0, 4857.0) 0.982 (MW) 
CSA type IIa fibre um2# 4222.0 (5055.0, 3746.0) 4138.0 (5040.0, 3320.0) 4483.0 (6244.0, 4068.0) 0.463 (MW) 
CSA type IIx fibre um2 2740.0 (848.2)*** 4345.0 (1515.0)*** 5434.0 (2170.0) 0.359 (T) 
 
 
Table 6-4 Table of characteristics for the COPD pateints and the controls in the validation study 
Physiological results are shown for the two groups of COPD patients (NFFMI and LFFMI) and the controls. For abbreviations see main text. 
All physiology results collected by Dr. A. Natanek. Data shown as median (75th, 25th percentile) or mean (SD) 
# indicates data is not normally distributed. *(p < 0.05) ** (p = <0.01) ***(p= <0.001) LFFMI or NFFMI vs control. Due to limited samples, 
the patients included in the array were also tested in the validation experiments.  
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Results from the plasma screen validation  
The aim of the validation experiments were to confirm the findings from the screen study, that 
miRNA derived from certain genetic imprinted regions were dysregulated in COPD patients with a 
LFFMI.  
Therefore to validate the screen, plasma levels of miR-518e and miR-519a (representatives of the 
miRNA located within the C19MC) and miR-483-5p, along with miR-210 were measured in samples 
from 17 NFFMI COPD patients, 21 COPD LFFMI COPD patients and 12 controls.  
Although levels of miR-210 had not been found to be different in the plasma of the COPD patients 
compared to the controls in the screen, expression of miR-210 had been found to be reduced in the 
plasma of the LFFMI patients compared to the NFFMI patients; miR-210 is located in the same 
genomic region as miR-483 (mir-210 is located 1.5Mbp closer to the chromosome end). For these 
reasons, miR-210 was tested in the validation study and included in the analysis.  
Plasma levels of miR-655, miR-543 and miR-422 were also tested as these miRs had been found to 
be significantly different between the LFFMI and NFFMI COPD patients in the initial experiments 
(table 6.3). Importantly for this validation study involving single Taq man assays, these miRs had 
been reliably detectable in all samples, which was not necessarily the case for other significantly 
different miRNAs.   
Experiments were performed using individual Taqman® qPCR reactions for the relevant miRNA. 
Results for these experiments are shown in table 6.5 and figure 6.5.  
miRNA  tested  
LFFMI COPD 
patients miR level 
NFFMI COPD 
patients miR level 
controls miR 
level p value NFFMI vs LFFMI  
miR-210  2.3 (0.8) *  2.5 (0.7)  2.9 (0.6)  0.279 (T)  
miR-483-5p  1.7 (0.5)*  1.9 (0.6)  2.2 (0.5)  0.437 (T)  
miR 485-3p  2.2 (0.9)  2.6 (0.8)  2.7 (0.7)  0.437(T)  
miR-519a  0.1 (0.7)*  0.7 (0.9)  1.0 (0.9)  0.035 (T) #  
miR-655  1.8 (0.4)  1.9 (0.7)  1.9 (0.7)  0.572 (T)  
miR-542  1.8 (0.7)  2.0 (0.6)  2.2 (0.6)  0.327 (T)  
miR-422  1.0 (0.6)  1.0 (0.7)  0.7 (1.0)  0.752 (T)  
Table 6-5 Results for miRNA levels in the validation of screen 
Plasma miRNA levels in the NFFMI COPD patients, the LFFMI COPD patients and controls are shown. * indicates p<0.05, ** p<0.01 and 
***p<0.001 for miRNA levels in LFFMI or NFFMI COPD patients when compared to controls. # indicates p<0.05, ## p<0.01 and ### p<0.001 
for miRNA levels compared between LFFMI COPD patients and NFFMI COPD patients.  Mean (SD) values are shown. Data is normalised 
and log transformed expressed as AU prior to analysis as described in the methods section. MiR-518e results are not shown in table as was 
poorly detected in the majority of samples and therefore excluded from analysis.  
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Plasma miRNA levels that were different between the COPD patients and the controls in the 
validation study 
 
Median levels of miR-210 had a tendency to be lower in the plasma of COPD patients compared to 
the controls but this difference did not reach statistical significance (p=0.09) (figure 6.5a).  
Consistent with the plasma screen results, plasma miR-210 levels were significantly reduced in the 
LFFMI COPD patients relative to the controls (p=0.04). There was no difference in plasma miR-210 
levels between the NFFMI COPD patients when compared to the controls p=0.11. 
Mir-483 levels were found to be reduced in the validation cohort of COPD patients when compared 
to the controls, p=0.02 (figure 6.5b).  This difference was driven primarily by the LFFMI COPD 
patients who had significantly lower miR-483 levels when compared to the controls (p=0.013).  MiR-
483 levels in the NFFMI COPD patients was not reduced when compared to the controls (p=0.09).  
Levels of miR-210 and miR-483 showed a strong association with each other (r=0.632, p<0.001).  
 
 
0
1
2
3
4
5
P
la
sm
a 
m
iR
-2
10
 (
lo
g 
A
U
)
Controls NFFMI  LFFMI  
* 
-2
-1
0
1
2
3
P
la
sm
a 
m
iR
-5
19
a 
(l
og
 A
U
)
Controls NFFMI  LFFMI  
* # 
0
1
2
3
4
P
la
sm
a 
m
iR
-4
83
 5
p
Controls NFFMI  LFFMI  
* 
a 
b 
c 
190 
 
Figure 6-5 Comparison between the three groups: Results for miRNA levels in the validation of screen 
Plasma levels of miR-210, miR-483 and miR-519a were quantified in plasma from the subjects in the validation cohort.  Plasma levels of 
miR-210 (a) and miR-483 (b) were lower in LFFMI COPD patients than controls but not different between patients with different FFMIs. 
MiR-519a (c) was lower in the plasma of LFFMI patients compared to both NFFMI patients and controls.  As per the methods section, 
results were not included in this analysis if the miR tested either failed to be detected or the duplicate experiments were poor replicates.  
 * indicates p<0.05, ** p<0.01 and ***p<0.001 for miRNA levels in LFFMI or NFFMI COPD patients when compared to controls. # indicates 
p<0.05, ## p<0.01 and ### p<0.001 for miRNA levels compared between LFFMI COPD patients and NFFMI COPD patients. Values are log 
normalised in AU as described in the methods. Error bars show mean and SEM. 
 
 
IGF-2 plasma protein levels in COPD patients compared to controls 
To expand the validation experiment findings of reduced plasma miR-210 and miR-483 in the COPD 
patients compared to the controls further and to see if other associated genes in that locus were 
reduced in the plasma of the COPD patients compared to the controls, Human Insulin-like Growth 
Factor-II (IGF-2) protein levels were quantified.  Working with Dr A. Lewis, IGF-2 protein was 
quantified using ELISA in the plasma samples taken from a larger number of COPD patients (n= 36) 
and controls (n= 11). This experiment included some patients from the screen study. No difference 
was found in IGF-2 levels between the COPD patients and the controls (p=0.574), figure 6.6. 
 
 
 
 
 
 
 
Figure 6-6 Plasma IGF-2 protein in COPD patients compared to controls 
There was no difference in IGF-2 plasma levels between COPD patients and controls (p=0.574), and within the COPD patients between 
NFFMI patients compared to LFFMI patients (p=0.820). Error bars showing mean and SEM. 
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6.3.2.5. Plasma miRNA levels that were different between the NFFMI COPD patients and the LFFMI 
COPD patients in the validation study 
 
MiRNA from the C19 cluster 
MiR-518e was poorly detected in the majority of samples so no conclusion could be drawn about the 
relative miR-518e levels between the COPD groups in the validation cohort. This was not an 
expected finding after performing the array experiments in which it was readily detectable; it may 
have been that the pre-amplification or reverse transcription stages in the experiments did not work 
as efficiently, but it is not possible to confirm this without repeating the validation experiments.  
However, consistent with the screen study, miR-519a levels were higher in the NFFMI patients than 
in the LFFMI COPD patients (p=0.035), figure 6.5c, and there was a direct correlation between miR-
519a levels and fat-free mass index in the COPD patients (r=0.37, p=0.043), figure 6.7.  
 
Figure 6-7 Relationship between plasma miR-519a levels patient characteristics 
A correlation can be seen between plasma levels of miR-519a and FFMI kg/m2. a. Open circles represent the controls, red circles are those 
with a NFFMI, and orange circles are the LFFMI COPD patients.  For the COPD patients, p= 0.04, r= 0.37.  Plasma miR-519a was measured 
as per the methods section and expressed as log normalised value in AU. 
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Receiver operating characteristic curve analysis to detect presence of LFFMI in COPD patients in 
the validation study 
 
ROC curve analysis of the plasma miRNA levels that were found to be different between the LFFMI 
COPD patients and the NFFMI COPD patients was performed to determine whether these miRNA 
levels were able to predict whether the patient had a low LFFMI. ROC analysis revealed a moderate 
AUC of 0.74 for miR-519a, an AUC of 0.64 for miR-210 and an AUC of 0.63 for miR-483. Combining 
the three miRNA levels did not improve the AUC (0.72). These analyses are shown in figure 6.8. 
 
Figure 6-8 ROC analyses for the presence of LFFMI in COPD patients according to plasma miRNA levels 
ROC analysis for a. Plasma miR-519a,  b. Plasma miR-210, c. Plasma mir-483-5p and d. sum of 519a, -210 and 483-5p and the presence of 
LFFMI in COPD patients.  
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6.3.3 Plasma miRNA levels in those with loss of type I muscle fibre proportions in 
quadriceps biopsy compared to those with preserved type I fibre proportion 
 
To answer the third aim of the study, plasma miRNA levels in those with loss of type I muscle fibre 
proportions in quadriceps biopsy were compared to those with preserved type I fibre proportion in 
those patients included in the screen study (COPD n=15, with 7 NFFMI, and 8 LFFMI).  
Quadriceps fibre type proportion was analysed in biopsies of the subjects of this study (by Dr. A. 
Natanek) and results published with the reference ranges for normal fibre type proportions 
(Natanek, Gosker et al. 2013).  Using the fibre type data from that study, the 15 COPD patients from 
the screen study were ranked in ascending order according to the % of type I fibres in their 
quadriceps biopsy. The patients were then divided into tertiles from this ranking.  In the top tertile 
the range of % type I fibres was 30-47%, and in the bottom tertile % type I fibres range was between 
2 and 22% of total fibres.  
Analysis of the miRNA levels that differed between the COPD patients who were in the bottom 
tertile of quadriceps % of type I fibres were then compared to those in the top tertile (table 6.6). It 
was decided that although this classification is not used clinically, it was used in this study to identify 
those miRNA that might be important in the identification of fibre type extremes. In addition, it 
provided more equally weighted groups of patients (5 patients in each) as compared with using the 
type 1 % fibre cut-offs described  by Natanek et al (Natanek, Gosker et al. 2013) which would have 
classified 11 patients as having evidence of type 1 fibre shift, and 4 patients as having no evidence of 
type I fibre shift.  
Analysis of the plasma miRNA levels compared between these two tertiles found that some of the 
miRNA which differed between these two groups of patients (specifically miR-376a ,miR-496 and 
miR-367b), are genomically located in imprinted regions which had previously been found to differ 
between the LFFMI COPD patients and the NFFMI COPD patients. This is shown in table 6.6 where 
the miRNA are marked with an *.   
When plasma levels of miR-450a (taken as the most significantly reduced miR between the two 
groups analysed in this fibre type analysis) were analysed across all 15 COPD patients in this study, 
there was a trend for there to be a negative correlation with % type I fibres in quadriceps biopsy as 
seen in figure 6.9. 
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miRNA 
Id 
miRNA 
genomic 
locus 
p value median ratio 
lower 1/3 :higher 
1/3 type 1 fibres 
fold reduction in 
low 1/3 compared 
to higher 1/3 
 
miR-450a Xq 26.3 0.007 0.06 17.48  
miR-376a 14 q 32.31 0.015 0.12 8.25 *same region 
reduced in LFFMI 
patients compared 
to NFFMI patients 
miR-337-5p 14 q32.2 0.016 0.16 6.24  
miR-376b 14 q 32.31 0.026 0.010 112.09 *same region 
reduced in LFFMI 
patients compared 
to NFFMI patients 
miR-449b 5q 11.2 0.034 0.04 23.26  
miR-374b# X q 13.2 0.039 0.05 18.55  
miR-124 8 p23.1 0.039 62.00 0.03  
miR-29b 7q 32.3 0.040 0.25 3.96  
miR-26a-2# 12q14.1 0.041 0.09 11.77  
miR-496 14 q 32.31 0.043 0.04 25.44 *same region 
reduced in LFFMI 
patients compared 
to NFFMI patients 
miR-661 8 q24.3 0.043 0.06 17.09  
miR-429 1 p36.33 0.046 0.05 19.76  
miR-450b-
5p 
X q26.3 0.012 8.96   
miR-672 X D 0.015 3.70   
miR-486-5p 8 p11.21 0.017 6.15   
miR-223# X q12 0.017 2.36   
miR-489 7 q21.3 0.024 5.89   
miR-1243 4 q26 0.024 7.67   
miR-636 17 q25.1 0.035 1.78   
miR-623 13q32.3 0.042 5.02  *same region 
reduced in LFFMI 
patients compared 
to NFFMI patients 
miR-523 19q13.42 0.044 13.09   
 
Table 6-6 Plasma miRNA that were different between the COPD patients with or without quadriceps type 1 fibre shift 
MiRNAs that were suppressed in the COPD patients in the bottom tertile of type I % in quadriceps biopsy compared to COPD patients in 
the highest tertile of % of type 1 fibres are shown above the line in order of statistical significance.  MiRNA increased in the respective 
groups are shown below the line in order of statistical significance. p values were calculated by t-test and significance cut of p<0.05 was 
set to indicate statistical significance. Ratios are calculated using non-logged data and median average values for each of the groups as 
unlogged data was not normally distributed. Genomic loci were identified using the Ensembl genome browser. 
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Figure 6-9 Relationship between plasma miR-450a levels and quadriceps % type 1 fibres 
Figure shows there is a trend for a negative correlation between plasma levels of miR-450 and % type 1 fibres in quadriceps biopsy, 
p=0.095, r= -0.45. Plasma levels of miR-450a were measured as in the methods section and expressed as log values in AU.  
 
 
Plasma miRNA that were different in COPD patients with preserved quadriceps strength compared 
to those with loss of quadriceps strength 
The 15 COPD patients included in the screen were divided into those with preserved quadriceps 
strength (n=6) and those with reduced quadriceps strength (n=9). Differences in miRNA levels 
between these two groups were determined. Quadriceps weakness was defined as a QMVC in 
kilograms less than 120% of the patient’s body mass index (Swallow, Reyes et al. 2007). 
The results for this analysis are shown in table 6.7.  
It can be seen that there are only 4 miRNA that are significantly reduced at the p<0.05 level and that 
two of these, miR-422a and miR-518 were reduced in the LFFMI patients compared to the NFFMI 
COPD patients.  
There are 13 miRNA that are significantly increased in the plasma of patients with a loss of muscle 
strength. None of these overlap with miRNA that differ between COPD patients and controls, or 
those that differed between COPD patients with a LFFMI and COPD patients with a NFFMI.  
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Table 6-7 Plasma miRNA that were different between the COPD patients who had reduced quadriceps strength 
compared to those with preserved quadriceps strength 
MiRNAs that were suppressed in the weak COPD patients compared to COPD patients with preserved quadriceps strength are shown 
above the line in order of statistical significance.  MiRNA increased in the respective groups are shown below the line in order of statistical 
significance. p values were calculated by t-test and significance cut of p<0.05 was set to indicate statistical significance. Ratios are 
calculated using non-logged data and median average values for each of the groups as unlogged data was not normally distributed. *also 
found to be dysregulated or originate from same cluster of miRNA that were found to be dysregulated in those with LFFMI (see table 6.3) 
  
 
 
 
 
 
COPD patients with reduced quadriceps strength (“weak”) compared to COPD patients 
with preserved quadriceps strength (“strong”) 
  
  
MiRNA p value median ratio weak:strong 
fold reduction in weak 
patients 
miR-1275 0.035 0.29 2.12 
miR-891a 0.014 0.30 15.24 
miR-422a* 0.011 0.33 2.65 
miR-518d-3p* 0.043 0.49 2.03 
miR-573 0.010 6.04   
miR-378 0.016 5.83   
miR-125b 0.018 10.34   
miR-1179 0.020 3.54   
miR-1262 0.021 2.208   
miR-190b 0.024 2.50   
miR-587 0.028 3.65   
miR-1182 0.029 12.19   
miR-597 0.031 1.84   
miR-1267 0.036 2.82   
miR-569 0.041 3.16   
miR-335# 0.042 7.37   
miR-571 0.042 6.72   
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6.4 Discussion 
 
Although there are a number of limitations to this study, and only small number of patients were 
studied, this study has found that there are distinct plasma miRNA profiles associated with the 
presence of severe COPD and the presence of a LFFMI in a subset of severe COPD patients. This 
study has also identified miRNA that are different in the plasma profiles of those with a loss of 
quadriceps type I muscle fibre proportion and a reduction in quadriceps strength, some of these 
miRNA overlap with those identified as FFMI-associated miRNA. The significance of the other 
dysregulated miRNA in the latter two analyses remains unclear at present. The study was based 
upon levels of miR-1 being different between NFFMI and LFFMI, however no such difference was 
found.  
 
Potentially the most important finding that will be discussed first is the observation that a significant 
proportion of the LFFMI-associated plasma miRNA are derived from genetically imprinted regions.  
Whilst there may be epigenetic control of miRNAs that are derived from such imprinted regions 
(including those that were found to be different between the COPD patients with a NFFMI and those 
with a LFFMI), the design of this study means it is not possible to comment as whether this occurs in 
COPD patients who have lost fat-free mass and if so, to what extent.   
 
Genomic imprinted regions are chromosomal regions which encode genes that are expressed in a 
parent-specific manner (Ferguson-Smith 2011). The process of genomic imprinting is erased in germ 
cells and established and maintained in an individual after fertilisation (Walter and Paulsen 2003) 
and genes expressed from imprinted regions are not only allele-specific but can also be tissue-
specific or developmental stage-specific. 
 
Gene expression within imprinted regions is controlled by epigenetic modifications; these are 
inherited alterations in gene expression patterns that do not change the DNA sequence (i.e. parent-
specific modifications). DNA methylation is an epigenetic method by which imprinted gene 
expression can be modified resulting in transcriptional silencing of genes by chromatin condensation 
(Portela and Esteller 2010). DNA methylation involves the addition of a methyl group to cytosine by 
the enzymes DNA methyltransferases.  
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Imprinted genes occur in clusters and are usually associated with genomic regions with different 
methylation states called differentially methylated regulatory regions (DMRs).  Only some of these 
DMRs are subject to DNA methylation prenatally and these are known as germline DMRs.   An 
example of a germline DMR can be found in a chromosomal region called an imprinting control 
region. This imprinting control region controls the transcription of imprinted genes within somatic 
cells.  An imprinting control region can also contain binding sites for transcription factors (Kim, 
Ekram et al. 2012).  
 
During the process of epigenetic remodelling, it is thought that DNA methylation can be influenced 
by certain environmental factors.  One example of this is where in utero exposure to cigarette smoke 
has been shown to affect levels of DNA methylation.  Maternal smoking has been associated with 
increased levels of DNA methylation at the imprinting control region which regulates the expression 
of growth hormone IGF-2. In addition, methylation profiles have been demonstrated to link the 
association between maternal smoking and low-birth weights (Murphy, Adigun et al. 2012).  
 
By studying elite athletes, DNA methylation has also been shown to be affected by polymorphic 
variants of enzymes required in the methylation process. A higher prevalence of particular 
polymorphisms of enzymes has been found in elite athletes when compared to controls and these 
polymorphisms are associated with a reduced DNA methylation capacity.  In vitro studies by the 
same group of authors support the hypothesis that the reduced DNA methylation associated with  
the enzyme polymorphisms found is associated with the higher levels of myogenic proteins that are 
required for the muscle mass and function of an athlete (Terruzzi, Senesi et al. 2011).  
 
Of particular relevance to this study, abnormal DNA methylation has also been shown to occur in 
promoter regions of stem-cell specific genes including those that encode pluripotency transcription 
factors (Bibikova, Laurent et al. 2008). 
 
The majority of imprinted genes function during embryonic growth and development. In adults, 
genes (and miRNA) expressed from imprinted clusters are predominately expressed in 
undifferentiated cells.  Therefore, plasma miRNA which are derived from genetically imprinted 
regions are presumed to originate from undifferentiated cells or stem cells throughout the body. 
Levels of these plasma miRNA might therefore reflect the regenerative capacity of an individual or 
the reserve of undifferentiated cells in that individual which have potential for growth and cell 
regeneration.   
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Although gene expression from imprinted regions and the potential epigenetic regulation of such 
expression is of relevance and of interest, this study was not designed to investigate the epigenetic 
control of miRNA expression and its regulation in COPD patients.  
 
The following sections in the discussion will in turn discuss miRNA that were different in the plasma 
of COPD patients with a LFFMI compared to COPD patients with a NFFMI, followed by the miRNA 
that were different in the plasma of GOLD stage III and IV COPD patients compared to controls.  
 
6.4.1 Significance of findings 
 
FFMI-associated miRNA in severe COPD patients 
There was a trend for the median levels of FFMI-associated miRNA to be suppressed in the plasma of 
the LFFMI patients and increased in the plasma of the NFFMI patients when compared to the 
controls, however this difference was only statistically significant for two of the miRNA using an un-
corrected p value of <0.05 (table 6.3). The FFMI-associated miRNA which had reduced median levels 
in those with a LFFMI might reflect the reduced ability of individuals with a LFFMI to maintain 
skeletal muscle mass. As the median levels of FFMI-associated miRNA were increased in the NFFMI 
patients when compared to the controls, although again only statistically significant for two miRNA 
(table 6.3), this might suggest these patients have preserved ability or increased need/ability with 
reference to the controls to maintain muscle mass.  
One possible explanation for the higher FFMI-associated miRNA levels detected in the NFFMI 
patients when compared to the controls (and as previously discussed in chapter 5), could be that the 
COPD patients, whose muscle are typically deconditioned, suffer from a greater level of muscle 
damage relative to the controls at the same level of physical activity. Muscle damage, which could 
occur for example during activities of daily living, is therefore hypothesised in NFFMI individuals to 
lead to an increase in detectable levels of miRNA in the circulation, whose function is to restore 
muscle mass or respond to stress.  The higher miRNA levels might therefore reflect a higher reserve 
pool of these particular miRNA when compared to controls and LFFMI individuals and could be a 
result of genetic influences.  
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The importance of the location and function of the certain miRNA of interest in this study will be 
considered in the following section. 
 
 Chromosome 11 miRNA: miR-483 and mir-210 
(i) MiR-483  
MiR-483 is located on chromosome 11p15.5 within an intron of the IGF-2 gene, a growth promoting 
hormone with which miR-483 is co-transcribed.  In normal individuals, the IGF-2 gene is expressed 
from the paternal chromosome and its expression is reciprocal with that of H19, a large non-coding 
RNA expressed from the maternal chromosome.  
In humans, Beckwith-Wiedmann syndrome is an example of a disease in which changes to the 
imprinted genes expressed on chromosome 11 result in an increase in IGF-2 expression. 
Consequently musculoskeletal overgrowth occurs and patients with this condition have embryonic 
and placental overgrowth, a large tongue, protruding eyes in addition to an increase tendency 
towards childhood tumours (Walter and Paulsen 2003).  
IGF-2 is produced in the liver, widely expressed during embryonic development and down-regulated 
shortly after birth, except in skeletal muscle (Arney 2003). Animal studies have proposed that IGF-2 
has a role in adult skeletal muscle and functions in the response of muscle to injury. Firstly, IGF-2 has 
been shown to act in conjunction with IGF-1 to stimulate myoblast differentiation via increased 
expression of the transcription factor myogenin (Florini, Ewton et al. 1991) and secondly it has been 
considered to be necessary for myoblast proliferation (Stewart and Rotwein 1996).   
In respect to H19 expression, it has been shown to be induced by hypoxia (Matouk, Mezan et al. 
2010).  H19 is a precursor to or generates miR-675 (Cai and Cullen 2007) and together with miR-675 
H19 has been shown to oppose the biological effects of IGF-2, and via miR-675 to regulate IGF-1 
receptor protein expression.   
In view of the reduced levels of miR-483 in COPD patients compared to controls and in particular in 
LFFMI patients compared to controls (table 6.2), it was hypothesised that there would be a 
reduction in circulating IGF-2 protein levels in the LFFMI COPD patients. However we were not able 
to demonstrate reduced IGF-2 protein levels or any relationship between IGF-2 levels, FFMI and 
levels of miR-483 or miR-210.  This could be because circulating IGF-2 is heavily bound to various 
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binding proteins in the circulation and this would affect measurements of ‘free’ IGF-2 made by the 
ELISA method chosen in this study.  
(ii) MiR-210  
MiR-210 is a hypoxia sensitive miRNA and its expression increases in response to hypoxia via the 
transcription factor hypoxia-inducible factor-1 alpha (Ivan, Harris et al. 2008) and NFκB, which is also 
known to be a  hypoxia-sensitive transcription factor (Cummins and Taylor 2005).  
Various functions have been proposed for miR-210 in response to hypoxia to include: inhibition of 
cell proliferation, cell differentiation and angiogenesis, and in combination with chronic hypoxia, 
arrest DNA repair mechanisms and induce genetic instability (Chan, Banerjee et al. 2012). In 
addition, miR-210 can act to decrease mitochondrial function (Chen, Li et al. 2010).  
Of particular relevance to this study, miR-210 has been shown to support stem-cell survival (Kim, 
Haider et al. 2009). Reduced circulating miR-210 levels in those with a LFFMI compare to patients 
with a NFFMI (table 6.3), could therefore be consistent with a reduced stem cell population in the 
LFFMI individuals. But as COPD patients can suffer from chronic hypoxia, acute hypoxia or acute on 
chronic hypoxia, if hypoxia was a greater stimulus for miR-210 expression, it would be expected that 
there would be an increase in miR-210 levels rather than a decrease.   
It might therefore be considered paradoxical that miR-210 levels were reduced in the plasma of the 
LFFMI COPD as the quadriceps of these patients might be relatively more hypoxic compared to the 
controls due to the loss of capillarity that has been observed in the literature alongside the loss of 
muscle mass.  
One possible explanation for the reduced plasma miR-210 levels could be that patients with chronic 
hypoxia have adapted to persistent low oxygen levels and in this respect they may respond to 
hypoxia in a different manner when compared to healthy individuals; they may respond poorly to 
hypoxia, or mount an abnormal response.  However, it should be noted that levels of miR-210 were 
only just significantly reduced in COPD patients with a LFFMI compared to those with a NFFMI using 
a p<0.05 and it is beyond this study to speculate on further mechanistic explanations for the miR-
210 findings. 
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Chromosome 14 miRNA; DLK-DIO3 region 
9 out of the 23 FFMI-associated miRNA found in the plasma are derived from chromosome 14 in the 
DLK-DIO3 region. This region of miRNA is one of the largest clusters known in the human genome 
(Benetatos, Hatzimichael et al. 2013) but their function and/or role in genes regulation remains 
poorly studied.  It has however been found that both the DLK and DIO3 genes encoded within the 
same imprinted regions are paternally expressed, and the miRNAs appear to be maternally 
expressed (Seitz, Royo et al. 2004).  
 
There also appears to be a relationship between plasma levels of chromosome 14 miRNA and type I 
fibre shift. This is because levels of 2 miRNA derived from chromosome 14 cluster (miR-376b and 
miR-496) were found to be reduced in those with a lower % type I fibres when compared to those 
with higher % type I fibres. This is a preliminary finding and one which would need to be confirmed 
in a separate, larger cohort of patients.  
 
Evidence that genes in this region in humans are imprinted is suggested by maternal and paternal 
uniparental disomy 14 syndromes in which significant growth anomalies occur (Kamnasaran and Cox 
2002). Since the imprinted gene cluster on chromosome 14 is associated with growth, a change in 
circulating miRNA that are located within chromosome 14q32 would therefore be an expected 
finding in patients with a loss of muscle mass.   
 
The DLK-1 gene has been associated with muscle precursor cells. Functionally, DLK is thought to be 
implicated in the commitment and proliferation of myoblasts, as well as increasing postnatal 
myofibre size and muscle mass (White, Vuocolo et al. 2008).  This is of particular interest in sheep, 
where the callipyge locus is homologous to human 14q32 and where genetic mutations in this locus 
lead to an increased DLK-1 gene expression (White, Vuocolo et al. 2008). As a result sheep 
demonstrate a Callipyge phenotype in which muscular hypertrophy occurs alongside a decrease in 
fat mass of the hind quarter muscles (Lewis and Redrup 2005).  Only heterozygous sheep with the 
callipyge mutation express the phenotype when the mutation is inherited from their sire 
(Kamnasaran and Cox 2002). 
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Chromosome 19 miRNA cluster:  C19MC 
Perhaps one of the most interesting findings from the experiments in this study is that miRNA 
derived from the chromosome 19 miRNA cluster, C19MC, were reduced in the COPD patients with a 
LFFMI when compared to the NFFMI COPD patients.  
As with the cluster on chromosome 14, the C19MC is also one of the largest human miRNA gene 
clusters, which comprises approximately 8% of all known human miRNA genes (Donker, Mouillet et 
al. 2012). C19MC is primate-specific and studies examining tissue expression of miRNA from C19MC 
have shown that high levels of miRNA derived from this cluster are found in placental tissue and 
undifferentiated cells (Bentwich, Avniel et al. 2005). As such C19MC derived miRNA have been 
implicated in embryonic development and the maintenance of an undifferentiated cell population. 
The C19MC is expressed from the paternally inherited allele and gene expression has been shown to 
be regulated by DNA methylation (Noguer-Dance, Abu-Amero et al. 2010).  In line with this, some 
miRNA from this cluster have been found to be epigenetically controlled and silenced (Tsai, Kao et al. 
2009).   
Work performed by Li et al (Li, Lee et al. 2009) has given an insight into possible biological functions 
of the miRNA from C19MC.  C19MC derived miRNA are thought to promote cell growth and drive 
oncogenesis, as demonstrated by increased miRNA levels in brain tumours. MiRNA from C19MC are 
also thought to promote cell survival. Furthermore, these authors found an up-regulation of stem 
cell markers in cell lines containing C19MC miRNA, suggesting that these miRNA have a role in 
promoting stem cell phenotypes (Li, Lee et al. 2009). In support of this proposed biological role in 
maintaining cell pluripotency, a functional role for miRNA derived from the C19MC has also been 
demonstrated in human embryonic stem cells where cell differentiation has been shown to lead to a 
differentially expressed C19MC cluster (Laurent, Chen et al. 2008). 
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MiR-30d as the most down-regulated miRNA in the plasma of the COPD patients and reduced in 
the LFFMI patients when compared to the controls 
Plasma levels of miR-30d were the most significantly reduced plasma miRNA in the COPD patients 
compared to the controls.   
MiR-30d is a member of the miR-30 miRNA family, and has been shown to be associated with 
inflammation. Levels of miRNA from the miR-30 family have been found to be reduced in the muscle 
of Duchenne Muscular dystrophy patients (Eisenberg, Eran et al. 2007).  
The function of miR-30 is thought to be cell context dependent.  MiR-30 has been shown to function 
in the regulation of cell death by affecting both autophagy and apoptosis and with this, has been 
shown to act both as an oncogene and as a tumour suppressor.   
As an oncogene, miR-30d has been shown to target and regulate multiple genes in the autophagy 
pathway in human (ovarian and breast) cancer cell lines (Yang, Zhong et al. 2013). But in the context 
of renal cell carcinoma cells, miR-30d is pro-apoptotic and therefore acts as a tumour suppressor 
(Wu, Jin et al. 2013).  
The reduced plasma levels of miR-30d could therefore be in keeping with the greater level of 
systemic inflammation that is thought to occur in COPD patients.  It may be that miR-30d is in some 
way related to regulation of cell survival in these patients, but this would need to be confirmed by 
further experimental studies  
 
The following section will discuss the COPD-associated miRNA found in this study. Although it was 
the first aim of this study to identify those circulating miRNA that are different between GOLD stage 
III and IV COPD patients compared to controls, the results generated from the study with regards to 
this aim were less cohesive and impressive compared to those already discussed above (possible 
reasons for this are covered in the limitation of the study section 6.4.2). Important miRNA 
differences are however discussed in the following section. 
  
Severe COPD-associated miRNA: Down-regulated COPD-associated miRNA 
Mir-30d, miR-483-3p and -5p and miR-184 were found to be reduced in the plasma of the COPD 
patients compared to the controls.  However, all of these were in the group of miRNA in the screen 
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study that were only reduced in the LFFMI patients compared to the controls, and not in the NFFMI 
COPD patients compared to the controls. This might suggest that levels of these miRNA are 
associated with a loss of muscle mass or an inability of the muscle to regenerate rather than the 
presence of COPD itself.  
Indeed, this idea is supported by the FFMI-associated miRNA findings (already discussed in section 
6.4.1.1) where levels of miR-30d, miR-210 and miR-485 (which is chromosomally located in the same 
region as miR-483) were significantly reduced in the LFFMI patients compared to the NFFMI patients.    
MiR-1253 was one COPD-associated miRNA that was reduced significantly in both the LFFMI COPD 
patients and the NFFMI COPD patients when compared to the controls. There were 2 COPD-
associated miRNA that trended towards being reduced in both groups (p<0.09), miR-331-5p and 
miR-1270.  There is a lack of data in the literature on miR-1253 and miR-1270.  It is not definitively 
known where these miRNA are expressed, what the regulators of their expression are, and what 
their down-stream targets are.  It is therefore difficult to draw conclusions about why these specific 
miRNA were reduced in the plasma of the COPD patients and conclude whether these observations 
are true biological findings or false positives detected in the study.  
 
Severe COPD-associated miRNA: Up-regulated COPD-associated miRNA 
MiR-138 was up-regulated in both the LFFMI and the NFFMI COPD patients when compared to the 
controls. It is therefore possible that this might be a true COPD-associated miRNA. Mir-603 and miR 
216b were up-regulated in only the LFFMI COPD patients compared to the controls. Once more a 
lack of detailed data on the function and role of these miRNA limits the interpretation of these 
findings.  
 
Loss of fat-free mass in COPD patients 
 
This small study has identified that patients with a LFFMI have a miRNA profile that could be 
associated with an overall reduced cellular regenerative capacity and those with a NFFMI could 
maintain their regenerative capacity or have an increased regenerative capacity compared to 
controls, as reflected by the number of circulating miRNA derived from undifferentiated cells.  
However, it was not an aim of this study to assess the function and control of the miRNA studied, 
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likewise, as this study is cross-sectional and not longitudinal, the kinetics of muscle loss over time 
associated with a LFFMI can only be hypothesised.   
 
In the UK, COPD usually occurs as a direct result of smoking. The loss of fat free mass or skeletal 
muscle in those with COPD only occurs in approximately one third of patients (Schols, Broekhuizen 
et al. 2005) but has important implications. Myofibre number is established during fetal growth and 
although genetic factors can account for 50-80% of variation in post-natal skeletal muscle mass, 
epigenetic factors may similarly influence post-natal muscle mass and structure (Xiang, Ghanipoor-
Samami et al. 2013).  Epigenetic regulation of post-natal muscle mass is becoming increasingly 
recognised and proposed to play an important role in the regulation of adult stem cells proliferation 
and differentiation. It would be interesting to investigate this further in the COPD population as it 
can only be hypothesised that this might be the case for patients with COPD in whom there is 
evidence of skeletal muscle dysfunction. 
 
The significance of epigenetic regulation has been demonstrated in genetic porcine studies. For 
example, IGF2 alleles have been shown to account for up to 30% of the variation in post-natal 
muscle mass (Van Laere, Nguyen et al. 2003).  
 
Importantly, and with relevance to this study, the role of miRNA from genetically imprinted regions 
in regulating the number and maintenance of undifferentiated cells remains to be fully understood. 
 
6.4.2 Limitations of the study 
 
This study was cross-sectional by design and therefore it is only possible to hypothesise on miRNA 
changes over time.  Longitudinal sample analysis may only partially negate this limitation as miRNA 
kinetics themselves are poorly understood, and therefore the time at which further biological 
specimens should be analysed to provide greatest information is debatable. The cross-sectional 
nature of this study also means the differences in plasma miRNA cannot be concluded to be 
causative, rather than associated with either COPD and/or the presence of a LFFMI.  
 
This study did not investigate the responsible mechanisms of the COPD-associated or LFFMI-
associated miRNA or targets that might be affected. This is a particularly difficult aim to fulfil when 
analysing plasma samples as miRNA levels will reflect the whole body miRNA reserve, not just one 
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body compartment (e.g. quadriceps). In addition, although potential targets were discussed, many 
miRNA targets remain unknown and they are likely to be numerous and could be cell context-
dependent.  Furthermore, as discussed in the Introduction chapter, the biological function of 
circulating miRNA remains unclear. Specific targets of interest could be investigated further using in 
vitro cell culture experiments or in vivo manipulation of miRNA, but it was outside the remit of this 
current study to perform such time intensive experiments.   
 
It was not an aim to investigate miRNA profiles of healthy smokers and therefore a control group of 
healthy smokers was not included in this study. It may be that (some of) the changes noted in the 
COPD population are related to smoking. Investigating smokers would obviously address the 
aforementioned question and indicate whether smoking affects miRNA profiles which might reflect 
stem cell maintenance in adult life.  
 
As the LFFMI COPD patients had all been previous smokers, the results of this study cannot therefore 
be extrapolated to another subset of individuals with a LFFMI. For example, it is not possible to 
comment on whether healthy LFFMI individuals would have similar miRNA changes or whether 
individuals with cardiac disease and a LFFMI would have similar miRNA profiles. Further screening 
studies would need to be performed to make these comparisons.  
 
Finally, due to technical and sample limitations within this study, there were fewer controls studied 
than planned for in the initial screen study and the sample selection for the validation study included 
patients that had been tested in the screen experiment.  With regards to controls, it is possible that 
the reduced number of controls in some way affected the results or limited the COPD-associated 
miRNA findings. With regards to the patients that were included in both the screen and the 
validation study, the validation study would need to be repeated in a separate cohort of patients to 
confirm the findings.  
 
The results of this study have highlighted miRNA profiles associated with a loss of FFMI in COPD 
patients and possible future directions of study will be addressed in the overall discussion - the final 
chapter of this thesis.   
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7.  Discussion  
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7.1 Summary of findings 
 
The four results chapters of this thesis have investigated circulating miRNA in COPD patients with 
the aim of assessing muscle-specific miRNA as biomarkers of skeletal muscle dysfunction.  Although 
the experiments in this thesis were not designed to explore molecular mechanisms responsible for 
such muscle dysfunction, it is hoped that the results of the experiments can be used to suggest 
future areas of investigation into the mechanistic pathways involved in fibre shift and loss of muscle 
mass.  
 
Chapter 3: Increased skeletal muscle-specific microRNA in the blood of COPD patients  
The increased levels of muscle-specific miRNA, namely miR-1, miR-133, miR-206 and miR-499 found 
in the first study of this thesis suggest that muscle wasting might occur even in the stable COPD 
patient. Distinct plasma miRNA profiles were observed according to disease severity and muscle 
fibre composition.  For example, levels of miR-499 were found to positively correlate with the 
percentage of type I fibres in quadriceps biopsies in the COPD patient and levels were also higher in 
those without the presence of muscle fibre shift.  
The results of this study lead to the proposition that physical inactivity is an important driver of loss 
of type I muscle fibres in the early stages of the disease, whereas systemic inflammation appears to 
be more important in causing muscle wasting in the more severe stages of the disease.  
Despite the large number of samples included in this study and the panel of miRNA quantified in the 
blood, it was not possible to identify one or more miRNA measurements to enable individuals with 
either fibre shift or loss of muscle mass to be detected with any confidence.  
 
Chapter 4: The effects of an acute exacerbation of COPD on circulating microRNA levels 
This second study found that the measured circulating miRNA did not change in patients admitted 
with an AECOPD when compared to stable COPD patients. The results of the experiments provide 
limited support for the associations found in the first study between levels of miR-133 and miR-206 
with quadriceps strength.  
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Chapter 5: The effect of exercise on muscle and plasma microRNA 
The main finding from this third study was that miR-181 increased in the muscle of the COPD 
patients one hour after exercise, albeit with a p value of 0.017. It might be that this is an activity-
dependent miRNA in the COPD patients, but as miRNA function within vast molecular networks, the 
importance of an increase in miR-181 can only be speculated upon at this stage. That is because the 
study was not designed to assess molecular mechanisms and because of the limitations of the 
current literature on this issue. 
The kinetics of miRNA expression are complex. MiRNA function in combination with other miRNA to 
affect levels of mRNA and protein turnover.  Thus, although the possible functions of miR-181 (and 
miR-206) have been hypothesised, they are unlikely to be as straightforward as simple on/off 
switches.  Furthermore, the down-stream effects from the changes in miRNA concentration are not 
only likely to be influenced by the concentration of a miRNA but also on the affinity for each binding 
site and their prevalence.  
The plasma miRNA analysed were found not to track the change in quadriceps muscle expression of 
miRNA after an acute bout of exercise, which suggests limited biomarker potential in this acute 
setting.  
 
Chapter 6: Identification of plasma microRNA associated with severe COPD and the loss of fat-free 
mass  
The last study in this thesis has perhaps generated the most questions out of all of the studies about 
the significance of non-muscle-specific miRNA in COPD and the need for further investigation. 
A significant proportion of circulating miRNA that were found to differ between the COPD patient 
with a preserved FFM and those with a LFFMI are derived from genetically imprinted regions. For 
example from chromosome 14 in the DLK-DIO3 region, from chromosome 19 in the C19MC cluster 
and from chromosome 11, from which miR-483 and miR-210 originate. These are all known growth 
associated regions. This suggests that there may be a theme in which COPD patients with a LFFMI 
have a reduction in miRNAs associated with growth or stem cell pluripotency and therefore a 
reduced regenerative capacity. 
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A significant problem with this study is that the validation experiments will need to be repeated to 
confirm the findings, as only a small number of samples were available for testing, and ideally it 
should be repeated in a separate cohort of patients.  
 
7.2. Blood based biomarkers in COPD 
 
There are no established blood-based biomarkers for the muscle fibre type changes that occur in 
skeletal muscle dysfunction in COPD. A biomarker is needed since quadriceps strength does not 
accurately predict those COPD patients who have evidence of muscle fibre shift and/or muscle 
atrophy and therefore cannot replace a muscle biopsy to predict quadriceps morphology during 
times of disease stability (Natanek, Gosker et al. 2013). The results from the studies in this thesis 
suggest that at present the measured miRNA in isolation are poor candidate biomarkers for skeletal 
muscle dysfunction in a stable patient.  
Other published studies have made more headway in investigating blood markers which might be 
useful to predict those who are likely to suffer from an exacerbation of COPD. However, these 
markers do not relate to, or have not been compared with, the skeletal muscle (composition) of a 
patient.  
At the time of writing I did not have access to the relevant follow-up data for the AECOPD patients in 
chapter 4 of this thesis. The lack of follow-up data for these patients limits any comment regarding 
the predictive value of the current results. If circulating miRNA levels were in any way able to predict 
clinical outcome, for example those patients whose quadriceps strength does not return to pre-
AECOPD levels or who have high readmission rates, then this could potentially lead to modification 
of treatment practice by allowing stratification of resource.   
In COPD, the most reliable predictor of a future exacerbation is the patient’s exacerbation history 
(Hurst, Vestbo et al. 2010). However, over 50% of previous exacerbations are not reported to 
clinicians (Wilkinson, Donaldson et al. 2004) and it is not known which patients fall into the category 
of those who are likely to suffer from an AECOPD, nor which patients fall into the category of 
needing re-admission with 90 days of an AECOPD (Donker, Mouillet et al. 2012).  It is for these 
reasons that investigators have sought to identify biomarkers which may predict future 
exacerbations. Furthermore, as early pulmonary rehabilitation after an AECOPD can have significant 
beneficial effects (Man, Polkey et al. 2004) and reduce subsequent re-exacerbation rates and rates 
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of re-admission to hospital (Seymour, Moore et al. 2010), it would also be useful to be able to 
identify those individuals at higher risk so as to be able to deliver prompt treatment preventative of 
further decline (and early PR) and/or introduce new targeted treatments (Rosenberg and Kalhan 
2012). 
The use of blood inflammatory markers as potential biomarkers for an AECOPD has been 
investigated. One large (n=2138) longitudinal study (Hurst, Vestbo et al. 2010) has found that using a 
multinomial regression model, an increased leucocyte count in COPD patients was independently 
associated with an increase in exacerbation frequency during the first year of follow up (with an 
odds ratios of  1.08 95% CI (1.03-1.14), p=0.002 in the group of COPD patients who had greater than 
two exacerbations). Other parameters associated with an increase in exacerbation frequency in this 
study were worsening lung function, worsening health status and a history of reflux.  
Elevated fibrinogen levels have also been shown to be an independent risk factor for an AECOPD 
(Groenewegen, Postma et al. 2008).  
Recently, a study by Thomsen et al (Thomsen, Ingebrigtsen et al. 2013) has measured leucocyte 
count and levels of CRP and fibrinogen in a large group of COPD patients (n=6574) and found that 
simultaneously elevated levels of CRP, fibrinogen, and leukocytes were associated with an increased 
risk of frequent exacerbations in those with stable COPD, including those with a mild disease and 
those in whom there was no history of an AECOPD.  In individuals who had high levels of all three 
mediators, the risk of having frequent exacerbations was increased by four fold in the first year and 
by three fold at maximum follow up time compared to those who had no elevated inflammatory 
markers.  
One disadvantage with measuring inflammatory markers is it is not known whether such 
measurements relate in any way to the state of peripheral muscles and it is not known whether the 
data can be extrapolated to other clinical conditions such as exercise.  
In support of a possible future application for circulating muscle-specific miRNA as biomarkers or 
predictors of morbidity and mortality (rather than just skeletal muscle dysfunction) in diseases 
associated with cancer cachexia, Hu et al have identified a panel of circulating miRNAs, which 
include miR-499 and miR-1 (Hu, Chen et al. 2010) that were associated at lower levels with a poorer 
outcome.   Although Hu and co-workers did not measure muscle bulk or strength, they found that 
the cancer patients who were at a higher risk of death had the lowest levels of muscle specific miR-1 
and miR-499 (Hu, Chen et al. 2010). Those end-stage cancer patients may well have been those with 
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cachexia or loss of muscle mass.  If it is assumed that the end-stage patients have lost muscle bulk, 
then this might be comparable with the data in chapter 3 of this thesis in which the most severe 
COPD patients (GOLD stage IV) had the lowest FFMI and lowest levels of miR-499.  This would need 
to be confirmed in a longitudinal study.  
 
7.3 Quantifying miRNA in plasma 
 
Reproducibility and normalisation of miRNA data 
For any biomarker to show promise, it needs to be easily measured in a robust manner with high 
sensitivity, specificity and the data needs to be reproducible.   
The way the miRNA experiments are currently conducted, including those in this thesis and those in 
the field of cardiac ischaemia and neuromuscular conditions, means that the raw data or results are 
not directly comparable between studies. This is because it is not possible to compare results from 
experiments that use different reverse transcription reactions, as the enzyme efficiency for each 
reaction is not identical. Further numerical comparisons between the studies of blood miRNA are 
limited due to the fact that relative qPCR (as opposed to absolute) quantification of miRNA is 
performed and therefore data are presented as a relative fold change with respect to control 
samples. For example in the paper by (D'Alessandra, Devanna et al. 2010), miR data are presented as 
fold change in patients who have had an acute MI with reference to the control subjects. Similarly in 
studies assessing miRNA differentially expressed in blood or tissues of DMD patients or in the animal 
models of disease, the data are at large presented as fold changes with respect to controls (Mizuno, 
Nakamura et al. 2011).  Different normalisation methods can also limit experimental comparisons.  
The results of this thesis suggest that the relative miRNA measurements carried out are reproducible 
for the following reasons: 
Firstly, I have demonstrated in chapter 5 that two control miRNAs quantified in plasma (miR-16 and 
miR-122) do not change in samples taken from the same person before and one hour after exercise, 
This indicates that at least within this timescale the relative quantity of these measurable miRNA, 
which serves as a negative controls, are stable and do not change in response to exercise, which may 
indicate reproducibility of results. 
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Secondly, I have demonstrated there are similar trends in miRNA associations across two cohorts of 
COPD patients. In the COPD patients studied in chapter 3, there were weak associations between 
levels of miR-133, miR-206 and miR-499 and measures of quadriceps strength. Although, they were 
less statistically significant, these relationships were still partially supported by the findings in 
chapter 4 of this thesis. In chapter 4, levels of miR-133 and miR-206 were associated with quadriceps 
strength in samples from stable COPD patients taken by our collaborators.  
Thirdly, it is usual for arrays to be validated by individual qPCR reactions to demonstrate 
reproducibility of results.  Data from the last set of experiments in chapter 6, in which miRNA in the 
same samples were measured twice, gave consistent group results for miR-210, miR-519 and miR-
483. Although it is not ideal or usual for validation experiments to include samples that were used in 
the initial screen, this was necessary in chapter 6 due to limited sample availability. It does however 
mean that repeat validation of my experiments is necessary.  
Finally, throughout conducting the experiments in this thesis there have been occasions when it was 
necessary to repeat miRNA analysis for the samples for a study. For example if there was a concern 
about the negative control on a qPCR plate then the experiment would be repeated to ensure the 
sample results were valid. The repeat experiments showed a high degree of correlation between 
results suggesting consistency. One such example is in chapter 5 of this thesis, where the plasma 
analysis of miR-499 was run twice for the samples taken at 60 minutes after exercise.  One set of 
samples had been pre-amplified (as described in chapter 4) prior to testing and the others had not. 
The normalised raw data for the COPD patients measured on those two occasions from the same 
sample or cDNA showed a high degree of correlation with a p<0.001 and r value of 0.9.   
The consistency between results suggests that the limited findings in this thesis are likely to be true 
biological findings, although due to the reasons above it is not possible to combine data sets and 
make comparisons between studies.  
The fact that it is not possible to combine results from different studies is a major limitation for the 
development of a biomarker. Techniques will need to be developed to measure absolute miRNA 
quantification per ml of blood (currently not performed) and develop reference or normal ranges for 
each miRNA of interest. RT reactions will also need adapted so that they are more robust, but at the 
moment it is not clear how this could be achieved. Normalisation methods will also need to be 
standardised.  
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Choice of normalising gene  
The work in this thesis used both Sybr-based and Taqman based qPCR reactions to quantify miRNA 
in the plasma samples. Although these are commercially available kits for experimental use, handling 
of the generated data is not standardised.  Particular consideration in this thesis was given to how 
the data was normalised and the choice of normalising gene prior to analysis.  
There is currently no standardised way to normalise miRNA levels in blood and to choose a suitable 
internal control to account for biological variability.  Normalisation of gene expression using an 
endogenous control gene is performed using a gene that is uniformly expressed in all samples in 
order to limit measurement errors which can occur by technical variation, and obtain absolute 
values. This is difficult in plasma or blood samples as factors affecting miRNA levels (other than the 
condition of interest) remain incompletely understood, therefore spiked in controls have been used 
which allow analysis based on relative expression.  Some studies do not normalise plasma data, but 
this may potentially lead to false results as RNA extraction for each sample may vary. 
Some groups have used miR-16 or miR-223 to normalise plasma miRNA data, as these miRs are 
thought to be stable and easily detectable. However, this is not the case in all clinical circumstances, 
for example levels can differ between some (ovarian cancer) patients and controls (Resnick, Alder et 
al. 2009).  
U6 small nuclear RNA (RNU 6B) or 5S ribosomal RNA are often used to normalise tissue miRNA 
expression (5S was used in this thesis for muscle miRNA analysis) and have been used to normalise 
quantified miRNA levels in blood samples. But again, there is controversy regarding their use as 
normalising genes in serum as it has been shown that they are not uniformly stable and hence may 
not serve to normalise correctly (Cortez and Calin 2009). 
To account for technical variability in RNA extraction in plasma samples and presence of any PCR 
inhibitors that may be co-purified with the RNA in the samples, a synthetic non-human exogenous 
spike (C. elegans) miRNA was added at the onset of RNA extraction in each sample, after the 
addition of the denaturing solution.  The C. elegans spike was measured at the RT-qPCR stages and 
used for normalisation process.  This method has been previously used and validated by Kroch et al 
(Kroh, Parkin et al. 2010) and similarly described in (Mitchell, Parkin et al. 2008; Heegaard, Schetter 
et al. 2012). Other non-human artificial spikes such as cel-lin2 and cel-lin 4 and ath-miR-159a have 
been used in the literature (Cacchiarelli, Legnini et al. 2011). 
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In studies assessing the use of biomarkers in cardiac ischaemia, several endogenous circulating 
miRNAs (i.e. miR-17-5p, miR-1249, miR-454, U6, 5SrRNA, and RNU6b) and spiked-in miRNAs (i.e. 
synthetic C. elegans miR-39, -54, and -238) have been used for normalisation purposes. However, 
the choice of normalisation method is once more not consistent throughout the literature; for 
example miR-17-5p expression levels in one study have been shown to be significantly higher in 
patients with non-acute coronary syndrome (ACS) than in those with ACS and miR-454 and miR-1249 
are not always reliably detected (Kuwabara, Ono et al. 2011) therefore it is questionable if these 
miRNA should be used and whether it is experimentally more robust to use spiked in controls.  
Normalisation of miRNA plasma array data such as that performed in chapter 6 of this thesis remains 
equally controversial and is not standardised.  Previous groups undertaking blood microRNA arrays 
based on the Taqman® method have used spiked-in exogenous controls (Soeda, Ohyashiki et al. 
2013).  The array method used in this thesis follows the commercially available TaqMan® Array 
MicroRNA Cards which contain four control assays; there are three selected candidate endogenous 
control assays and one negative control assay. Two of these controls were expressed uniformly in 
the plasma samples tested (RNU48 and U6) and thus used for normalisation of the data obtained. 
This method is similar to other studies of miRNA using an array approach in the field of 
cardiovascular disease where results have been normalised to small artificial RNA internal calibrators 
and other small RNAs such as  U6 (Adachi, Nakanishi et al. 2010; Kuwabara, Ono et al. 2011). 
 
7.4 Future studies 
 
Future studies should firstly confirm the findings in this thesis in a larger, separate cohort of 
patients. Studies thereafter should be directed towards an understanding of the mechanisms 
responsible for dysregulated miRNA.  
The data from the first study in this thesis raises the possibility that NF-κB p50 drives or promotes 
nuclear export of miR-499 in a selective manner from type I fibres. As discussed in the chapter, NF-
κB p50 in this context might function in the complex regulation of fibre type via the non-canonical 
pathway. To investigate this hypothesis further, in vitro muscle cell line studies investigating the 
effect(s) of NF-κB p50 on miR-499 expression are required, furthermore, in vitro studies on export of 
muscle-specific miRNA, might be superior in their ability to refute or confirm this theory.  
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Following on from in vitro mechanistic studies, one could envisage that future studies investigating 
the function or role of muscle-specific miRNA in muscle atrophy conditions may involve mice or man. 
Such experiments are likely to include assessment of the therapeutic potential of certain miRNA by 
manipulation, to either increase or block their action systemically or more locally at the muscle level, 
and may involve monitoring the clinical response by measuring circulating miRNA.  
 
Indeed miRNA are already exploited as therapeutic targets in non-muscle wasting diseases, for 
example in chronic hepatitis C infection. Recently, a 15-nucleotide locked nucleic acid–modified 
antisense oligonucleotide called Miravirsen has shown therapeutic effects in a phase 2a study for 
the treatment of chronic hepatitis C virus  (HCV) in humans (Janssen, Reesink et al. 2013). This drug 
binds to and inhibits the actions of miR-122 (a liver specific microRNA required for viral stability and 
propagation) by forming a heteroduplex complex.   At the end of the study HCV load was reduced in 
a dose-dependent manner in the patients studied.  Similarly, experimental work in mice has shown 
that intramyocardial injection of miR-210 precursor (a miR induced by hypoxia) within a vector can 
improve angiogenesis, inhibit apoptosis, and improve cardiac function in one murine model of 
myocardial infarction (Hu, Huang et al. 2010). However, neither of these studies investigated the 
impact of treatment on circulating miRNA levels and therefore whether circulating miR-122 or miR-
210 levels in these conditions could act as biomarkers.  
 
There have been limited studies in the literature in which muscle-specific miRNA have been 
manipulated in animals but none in any COPD model. One study has studied the effects of local 
injection of double-stranded miR-1, miR-133 and miR-206 on injured rat tibialis anterior muscle 
(Nakasa, Ishikawa et al. 2010).  These authors found that the combination of injected miRNA not 
only significantly increased the size of myofibres in the injured muscle compared to the control 
group at one week (size 60.3 ± 2.4µmm compared to 44.7 ± 3.5 µmm), but also after the injection of 
the miRNAs, the injured muscle in the treatment group had significant improvement in functional 
ability as measured by measurements of strength (fast twitch and tetanus strength). In addition to 
these findings, the authors further demonstrated that some genes associated with myogenesis were 
significantly increased in the miRNA group compared to controls. Specifically, gene expression of 
MyoD, myogenin and Pax7 were significantly (p<0.05) increased at day 3 and 7 after miRNA 
injection.   
However, it remains the case that manipulation of muscle-specific miRNA has not been widely 
performed.  It would be interesting to assess whether local administration of miRs had any effect on 
218 
 
longer-term muscle miRNA levels and whether this was detectable in the circulation and what the 
specific timeframes in which these happen might be.  
To take the results of the last study in this thesis further, firstly my findings will need to be validated 
in another cohort of patients. Then, assuming the findings are validated, appropriate studies would 
be those that investigate the mechanisms behind the altered circulating miRNA profiles in COPD 
patients with a LFFMI. 
It is known that imprinted regions are controlled by DNA methylation and altered DNA methylation 
is one mechanism by which an individual may become more susceptible to a loss of muscle mass. If 
an individual was already genetically pre-disposed to loss of muscle-mass, then altered DNA 
methylation (for example by smoking) might impair muscle regeneration in that person. This 
proposition is supported by the finding that repeated cigarette smoking has been shown to 
reversibly alter plasma miRNA profiles in healthy adults (Takahashi, Yokota et al. 2013). The resulting 
effect of epigenetic programming in the presence of a pre-existing susceptibly would be an increased 
loss of muscle mass, and an alteration in circulating miRNA levels. Studies investigating DNA 
methylation status in COPD patients may help answer this proposition. DNA methylation can be 
measured in both blood and tissue.  
Investigation of the LFFMI associated miRNAs under different clinical conditions, for example during 
an AECOPD or pulmonary rehabilitation, might further add to our understanding of the mechanisms 
of muscle regeneration in certain individuals during times of stress and exercise. If changes in these 
miRNAs are identified, these miRNAs may ultimately prove to be more suitable biomarkers of muscle 
dysfunction for use in the clinical treatment of COPD patients.  
It would also be of value to study patients with other chronic diseases associated with muscle 
wasting, for example patients with heart failure. Such a study would aim to ascertain whether similar 
miRNA differs found in the final study of this thesis between patients with and without loss of FFM 
occurs in other chronic conditions. If similar miRNA patterns were detected, i.e. those associated 
with growth regions, then this might suggest the process of muscle wasting, or the involvement of 
genetically imprinted regions in limiting muscle regenerative capacity, is potentially comparable in 
different types of diseases, and is not disease or COPD-specific. Likewise, the study of miRNA 
expression profiles in older patients who have lost muscle mass due to ageing rather than being 
disease-related (termed sarcopenia) may provide answers as to whether the loss of muscle mass due 
to ageing results in a similar miRNA plasma profile to COPD patients with LFFMI.   
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7.5 Conclusion 
 
The results discussed in this thesis indicate that circulating muscle-specific miRNAs are different in 
COPD patients when compared to healthy controls and, to some extent reflect the underlying 
muscle pathology of an individual. However, the results of the four studies would suggest that 
measured circulating miRNAs are not currently able to replace a quadriceps biopsy as a determinant 
of the presence of skeletal muscle fibre type changes.  
At the time of writing this thesis no biomarker has been identified or is already available whose use 
would include monitoring the response of a patient to treatment intervention (whether it be 
pulmonary rehabilitation or future molecular targeted drugs) or identification of COPD patients at 
risk of loss of muscle mass (for whom preventative treatment could be proscribed). Nevertheless, 
based on the results of this thesis it would seem likely that if miRNA is to have a role in the clinical 
treatment and management of COPD then it will be need to be combined with clinical 
measurements of COPD disease rather than in isolation.  
Future studies in COPD should be guided towards investigating other miRNA as potential biomarkers 
of muscle atrophy such as those discussed in the final results chapter of this thesis, e.g. those 
derived from the C19MC, in longitudinal studies. Validation of results is then required in a separate 
cohort of patients. In addition, if muscle-derived miRNA are to be considered as clinically useful 
biomarkers or for future therapeutics, then a greater understanding of their mechanism of action 
and mechanisms and timing of export into the circulation and factors that can affect this, is required.   
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8. Appendix  
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8. 1 Additional data tables for Chapter 5: The Effect of exercise on muscle and plasma 
microRNA 
 
    Characteristic COPD Control significance of difference, p value 
Number 33 12 
 Male (female) 22 (11) 7 (5) 
 Age years 68 (9) 63 (7) 0.05 (T) 
Height (cm) 170.2 (8.9) 169.3 (9.1) 0.77 (T) 
weight (kg) 79.0 (16.9) 68.3 (12.0) 0.05 (T) 
BMI (kg/m
2
) 27.3 (5.8) 23.8 (3.6) 0.06 (T) 
FFFMI (kg/m2) 18.5 (2.9) 17.8 (2.9) 0.49 (T) 
high (low) FFMI ( <16 m, <15 f) 26 (7) 9 (3) 
 Pack year smoking 40 (59,19.5) 0 (1,0) <0.0001 (MW) 
current smokers (number) 1 0 
 FEV1 (% pred) 59 (23) 121 (13) <0.0001 (T) 
6MWD (m) 454 (110.1) 642.5 (78.3) <0.0001 (T) 
mMRC score 0.5 (2,1 ) 0 (0,0) <0.0001 (MW) 
Best MVC (kg) 30.3 (10.1) 31.0 (6.2) 0.84 (T) 
MVC/wt (kg/kg) 0.39 (0.1) 0.46 (0.1) 0.07 (T) 
 
   
    
Table 8-1 Characteristics of those who only had blood samples taken before and after exercise 
Characteristics of the subjects who underwent cycle ergometery with blood tests before and one hour after testing.  (i.e. no muscle biopsy 
performed). GOLD 4, n=4, GOLD 3, n=9, GOLD 2, n=13, GOLD 1, n=7. Statistical difference of groups is shown as p value. Testing was 
performed using either un-paired T test (T) or Mann-Whitney test (MW) as the non-parametric alternative.  Values are expressed either as 
mean (SD) or median (75th, 25th percentile). For abbreviations see text in chapter.  
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 Mean Std. Deviation 
FEV1 (% pred) 57 22.4 
FVC (L) 3.4 0.8 
FVC (% pred) 97 16 
FEV1/FVC 44.9 15.4 
TLCOc (%) 62 27 
KCOc (%) 72 26 
TLC 7.24 1.58 
TLC (% pred) 115 16 
RV 3.73 1.21 
RV (% pred) 159 53 
RV%TLC 51.1 8.7 
FRC 4.67 1.43 
FRC (% pred) 140 37 
PaO2 10 1.3 
PaCO2 5.2 0.5 
 
Table 8-2 Pulmonary function test results for the COPD patients only in Chapter 5  
N=20. Mean and standard deviation values are shown for measured values. See abbreviation list for abbreviations. 
223 
 
           
Group 
COPD 
miR-1 
Control 
miR-1 
COPD 
miR-
499 
Control 
miR-499 
COPD 
miR-
133 
Control 
miR-133 
COPD 
miR-
181 
Control 
miR-181 
COPD 
miR-206 
Control 
miR-206 FOLD CHANGE 
DATA 
           
Minimum -0.81 -0.44 -0.75 -0.53 -1.19 -0.40 -0.41 -0.76 -1.06 -0.55 
25% Percentile -0.23 -0.24 -0.14 -0.29 -0.27 -0.24 -0.06 -0.19 -0.11 -0.14 
Median 0.07 -0.10 0.03 0.01 0.05 -0.07 0.22 -0.04 0.16 0.00 
75% Percentile 0.23 0.19 0.52 0.21 0.28 0.29 0.38 0.53 0.26 0.27 
Maximum 0.91 0.76 1.10 0.77 1.50 0.57 0.85 0.62 0.63 0.57 
           
Mean 0.03 -0.02 0.11 -0.01 0.06 0.00 0.19 0.03 0.10 0.05 
Std. Deviation 0.38 0.34 0.47 0.38 0.56 0.30 0.30 0.43 0.37 0.32 
Std. Error 0.09 0.10 0.11 0.11 0.13 0.09 0.07 0.13 0.08 0.10 
D'Agostino & Pearson omnibus normality test         
Passed normality 
test (alpha=0.05)? 
Yes Yes Yes Yes Yes Yes Yes Yes No Yes 
 
          
 
 
 
 
        
           
Table 8-3 Data for muscle miRNA fold change analysis in the COPD patients and the controls  
Fold changes in muscle miRNA expression were calculated using un-logged, raw data for the COPD patients (n=20) and controls (n=11). The fold changes were then logged and the difference 
between the two groups calculated using either un-paired T test (T) or Mann-Whitney as the non-parametric alternative (MW). There were no significant difference in the fold change in 
muscle-specific miRNA expression between the COPD patients and the controls.  Group median fold change values with inter-quartile ranges and mean fold change values with SD and SEM 
are shown in the table. 
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GROUP 
miR-1 
COPD 
miR-1 
control 
miR-499 
COPD 
miR-499 
control 
miR-133 
COPD 
miR-133 
control 
miR-181 
COPD 
miR-181 
control 
miR-206 
COPD 
miR-206 
control 
miR-16 
COPD 
miR-16 
control 
miR-122 
COPD 
miR-122 
control 
FOLD CHANGE DATA              
Minimum -0.70 -0.77 -1.18 -0.27 -0.65 -0.57 -0.82 -0.35 -1.35 -1.93 -0.64 -0.53 -0.94 -0.54 
25% Percentile -0.35 -0.41 -0.30 -0.09 -0.27 -0.33 -0.24 -0.10 -0.36 -0.85 -0.29 0.09 -0.27 -0.24 
Median -0.06 -0.21 0.03 0.07 0.01 -0.16 0.00 0.08 -0.01 -0.18 -0.12 0.30 -0.06 0.05 
75% Percentile 0.19 0.27 0.25 0.61 0.35 0.02 0.25 0.41 0.28 0.68 0.15 0.85 0.20 0.38 
Maximum 0.95 0.34 0.59 0.77 8.80 0.72 0.72 1.30 1.51 1.33 0.51 1.02 0.70 0.84 
               
Mean -0.05 -0.15 -0.05 0.20 0.41 -0.11 0.01 0.21 -0.07 -0.15 -0.07 0.35 -0.07 0.08 
Std. Deviation 0.38 0.37 0.42 0.37 1.90 0.35 0.37 0.51 0.66 0.99 0.33 0.51 0.40 0.43 
Std. Error 0.08 0.12 0.09 0.12 0.41 0.11 0.08 0.16 0.14 0.31 0.07 0.18 0.09 0.14 
               
D'Agostino & Pearson omnibus normality test             
Passed normality test 
(alpha=0.05)? 
Yes Yes Yes Yes No No Yes Yes Yes Yes Yes Yes Yes Yes 
 
 
 
Table 8-4 Data for plasma miRNA fold change analysis in the COPD patients and the controls  
Fold changes in plasma miRNA levels were calculated using un-logged, raw data for the COPD patients (n=33) and controls (n=12). The fold changes were then logged and the difference between the two groups 
calculated using un-paired T test (T) or Mann-Whitney as the non-parametric alternative (MW) for miR-122. It can be seen that there were no significant difference in the muscle-specific fold change in miRNA 
expression between the COPD patients and the controls.  It can be seen that there was however a difference in fold change of miR-16 between the COPD patients and controls, with a greater increase in the control 
subjects. Group median fold change values with inter-quartile ranges and mean fold change value with SD and SEM are shown in the table. 
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